

# **The cellular and molecular properties of genistein against *C. albicans* infection**

Von der Fakultät für Lebenswissenschaften

der Technischen Universität Carolo-Wilhelmina

zu Braunschweig

zur Erlangung des Grades einer

Doktorin der Naturwissenschaften

(Dr. rer. nat.)

genehmigte

D i s s e r t a t i o n

Von Shuna Cui

aus Hebei / China



1. Referentin: Professor Dr. Ursula M. Bilitewski

2. Referent: Professor Dr. André Fleißner

eingereicht am: 03.11.2010

mündliche Prüfung (Disputation) am: 06.01.2011

Druckjahr 2011



## **Vorveröffentlichungen der Dissertation**

Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für Lebenswissenschaften, vertreten durch die Mentorin der Arbeit, in folgenden Beiträgen vorab veröffentlicht:

### **Publications**

- Klippel, N., **Cui, S.**, Groebe, L., Bilitewski, U. (2010) Deletion of *Candida albicans* histidine kinase CHK1 improves recognition by phagocytes through an increased exposure of cell wall  $\beta$ -1,3-glucans. *Microbiology*, 156 (11):3432-44.
- **Cui, S.**, Jiang, JJ., Ai, H., Li, J., Bilitewski, U., Niu, JZ. (2010) Effect of genistein on the proliferation, morphology and cell cycle of macrophage RAW264.7. *Beijing Journal of Traditional Chinese Medicine*, 39 (3): 40-43.
- **Cui, S.**, Jiang, JJ., Li, Y., Bilitewski, U., Niu, JZ. (2010) Effect of genistein on the LPS induced macrophage function. *Acta Chinese Medicine and Pharmacology*, 38(2):13-16.

### **Conferences**

- **Cui, S.**, Klippel, N., Bilitewski, U. (2010) Role of *C. albicans* MAPK cascade in the interaction with macrophages, Poster, 3rd Joint conference German Society for Hygiene and Microbiology (DGHM) and Association for General and Applied Microbiology (VAAM), Hannover.
- **Cui, S.**, Klippel, N., Hassan, R., Niu, J., Bilitewski, U. (2009) Treatment of *C. albicans* with genistein enhance immune response, Poster, Annual Meeting of the German Society for Hygiene and Microbiology (DGHM), Goettingen.
- Klippel, N., **Cui, S.**, Groebe, L., Calderone, R., Bilitewski, U. (2009) Deletion of *Candida albicans* histidine kinase CHK1 improves recognition by phagocytes through an increased exposure of cell wall  $\beta$ -1, 3-glucans. Oral presentation, Annual Meeting of the German Society for Hygiene and Microbiology (DGHM), Goettingen

## ACKNOWLEDGEMENT

I would like to acknowledge many individuals who have encouraged me to achieve this goal.

First of all, I would like to express my heartiest thank towards to my supervisor, Prof. Dr. Ursula Bilitewski for first presenting me with the opportunity to pursue this degree in her laboratory, and for her mentorship and guidance throughout the completion of this dissertation. Her broad knowledge and insight were truly inspiring me. Her kind assistance and the time she dedicated to discussing the results helped me to find the right direction. The knowledge and cautious attitude towards science that I learned from her during the last three years will benefit my whole life!

My deep thanks to Prof. Dr. Andre Fleissner for kindly agreeing to act as a co-referee.

My deep thanks to Prof. Dr. Ludger Beerhues for agreeing to act as a chairman of the examiners commission.

I would like to take this opportunity to express my deep gratitude to Prof. Jianzhao Niu for her great support and encouragement.

My deepest thanks to my committee members: Dr. Eva Medina and Dr. Frank Ronald for all their valuable scientific suggestions and continuous support.

I gratefully acknowledge Dr. Lothar Groebe for his kind and continuous help for the FACS analysis; Dr. Florenz Sasse for the discussion of fluorescence microscopy results.

I am extremely grateful to my colleagues and friends, who have either contributed to this work or have offered their friendship, encouragement, and support over the years: Dr. Nina Klippel, Dr. Bianca Luederitz, Dr. Janine Wesolowski, Rabeay Hassan, Doerthe Sokolis, Anna Buschart, Fardous El-Senduny, Katja Gremmer, Daniela Evers, Karin Plank-Schumacher, Rene Wetzel, Carolin Lewark, Andrea Gottschalk, Mohammed El-Mowafy, Hani Kaba, Dr. Carolyn Lam, Dr. Bo Yu, Dr. Feng He, Dr. Jinshan Li, Xiaoli Xue, Haiya Wu, Hairong Chen, Jun Yang, and Gang Pei.

I would like to take this opportunity to express my deep gratitude to my parents and all my family members for their love, unimaginable support, and continuous encouragement during my stay in Germany.

Finally, I want to extend my sincere gratitude to the Chinese government and Helmholtz association (CSC- Helmholtz scholarship) for the financial support, and also the HZI (Braunschweig) for all the help and the possibilities during this work.

## CONTENTS

|          |   |           |
|----------|---|-----------|
| <b>1</b> | <b>ABSTRACT .....</b>   | <b>1</b>  |
| <b>2</b> | <b>INTRODUCTION .....</b>   | <b>3</b>  |
| 2.1      | Pharmacological activity of genistein .....                                       | 3         |
| 2.1.1    | Bioavailability of dietary genistein .....  | 4         |
| 2.1.2    | Genistein as a tyrosine kinase inhibitor .....                                    | 5         |
| 2.1.3    | Genistein as an antioxidant .....   | 5         |
| 2.1.4    | Genistein and immunity .....  | 5         |
| 2.1.5    | Genistein and inflammation .....  | 6         |
| 2.1.6    | Genistein and infection .....   | 7         |
| 2.1.7    | Genistein involved in signal transduction pathways.....                           | 7         |
| 2.2      | Phagocytes in the immune system.....  | 9         |
| 2.2.1    | Immune system .....   | 9         |
| 2.2.2    | Phagocytes and their functions.....   | 10        |
| 2.2.3    | Pattern recognition receptors.....  | 11        |
| 2.2.4    | Specific kinases involved in pathways activated by LPS and<br>IFN- $\gamma$ ..... | 17        |
| 2.2.5    | Phagocytosis.....   | 18        |
| 2.2.6    | Killing of phagocytosed microbes .....  | 19        |
| 2.3      | <i>Candida albicans</i> .....   | 19        |
| 2.3.1    | Background .....  | 19        |
| 2.3.2    | The MAP kinases signal transduction network in <i>C. albicans</i> ..              | 20        |
| 2.3.3    | Cell wall structure .....   | 22        |
| 2.3.4    | Respiratory chain .....   | 23        |
| 2.4      | Thesis aim and objectives.....  | 26        |
| 2.5      | Experimental design .....   | 28        |
| <b>3</b> | <b>MATERIALS AND METHODS.....</b>   | <b>29</b> |
| 3.1      | Equipment and materials .....   | 29        |
| 3.2      | Methods .....   | 31        |
| 3.2.1    | Sterile Conditions.....   | 31        |

|        |   |    |
|--------|---|----|
| 3.2.2  | Preparing PBS.....  | 31 |
| 3.2.3  | Cell number counting .....  | 31 |
| 3.2.4  | Data analysis and Programmes.....   | 32 |
| 3.3    | Cell culture.....   | 32 |
| 3.3.1  | Cell culture media and ingredients .....  | 32 |
| 3.3.2  | RAW264.7 .....  | 33 |
| 3.3.3  | RAW-Blue™.....  | 33 |
| 3.3.4  | Cultivation .....   | 33 |
| 3.3.5  | Long-term storage.....  | 34 |
| 3.3.6  | WST-1 toxicity assay .....  | 34 |
| 3.3.7  | Cell cycle analyses.....  | 35 |
| 3.3.8  | Fluorescence labelling of F-actin and cell nuclei .....                                 | 35 |
| 3.3.9  | Detection of nitric oxide by Griess reagent .....                                       | 36 |
| 3.3.10 | Cytokine determination .....  | 38 |
| 3.3.11 | Detection of NF-κB and AP-1 activation of RAW-Blue™ Cells<br>.....                      | 40 |
| 3.3.12 | RT <sup>2</sup> Profiler™ PCR Array (PAMM-018G) for Toll-like receptor<br>pathway ..... | 40 |
| 3.3.13 | Western Blot .....  | 41 |
| 3.3.14 | Receptor staining of macrophages RAW264.7.....  | 41 |
| 3.4    | Work with yeast .....   | 42 |
| 3.4.1  | Yeast strains .....   | 42 |
| 3.4.2  | Preparation of YPD and YP galactose medium .....  | 42 |
| 3.4.3  | Storage and cultivation .....   | 43 |
| 3.4.4  | Labelling yeast with fluorescence dye.....  | 43 |
| 3.4.5  | Genistein- treated <i>C. albicans</i> .....   | 44 |
| 3.4.6  | Growth curve of yeast.....  | 44 |
| 3.4.7  | Measurement of oxygen consumption.....  | 44 |
| 3.4.8  | Measurement of ROS accumulation.....  | 45 |
| 3.4.9  | Spectrophotometric assay of complex I activity with <i>C. albicans</i><br>.....         | 46 |
| 3.4.10 | Ethanol determination.....  | 46 |
| 3.4.11 | Flow cytometric analysis of cell wall glucans and mannans.....                          | 47 |



|          |   |           |
|----------|---|-----------|
| 3.4.12   | Cell surface hydrophobicity (CSH) test .....  | 48        |
| 3.5      | Infection.....  | 48        |
| 3.5.1    | Phagocytosis assay .....  | 48        |
| 3.5.2    | Cytokine detection by ELISA .....   | 49        |
| <b>4</b> | <b>RESULTS .....</b>  | <b>50</b> |
| 4.1      | Effect of genistein on the function of RAW264.7 macrophages .....   | 50        |
| 4.1.1    | Cell viability .....  | 50        |
| 4.1.2    | Cell cycle.....   | 51        |
| 4.1.3    | Morphology .....  | 53        |
| 4.1.4    | F-actin cytoskeleton .....  | 54        |
| 4.1.5    | Nitric oxide production of macrophages stimulated by LPS ....   | 55        |
| 4.1.6    | Nitric oxide production of macrophages stimulated by IFN- $\gamma$<br>and IFN- $\gamma$ + LPS .....                     | 56        |
| 4.1.7    | Cytokine production of macrophages stimulated by LPS.....   | 57        |
| 4.1.8    | Specific kinase inhibitor involved in LPS and IFN- $\gamma$ pathway.  | 58        |
| 4.1.9    | Influence of genistein on the LPS-induced MAP kinase<br>phosphorylation .....   | 60        |
| 4.1.10   | NF- $\kappa$ B and AP-1 activation detected with RAW-Blue <sup>TM</sup> Cells.  | 61        |
| 4.1.11   | Gene expression related to Toll-like receptor pathways .....  | 62        |
| 4.2      | Effects of genistein on <i>C. albicans</i> .....  | 63        |
| 4.2.1    | Genistein effects on the oxygen consumption of <i>C. albicans</i> and<br><i>S. cerevisiae</i> .....                     | 63        |
| 4.2.2    | Effect of genistein on the ROS accumulation in <i>C. albicans</i> and<br><i>S. cerevisiae</i> .....                     | 63        |
| 4.2.3    | Effect of specific respiratory chain inhibitors on oxygen<br>consumption and ROS production in <i>C. albicans</i> ..... | 64        |
| 4.2.4    | Complex I activity .....  | 67        |
| 4.2.5    | Ethanol production .....  | 68        |
| 4.2.6    | Growth of <i>C. albicans</i> .....  | 68        |
| 4.2.7    | Cell wall $\beta$ -glucans and mannans components of <i>C. albicans</i> ..  | 69        |
| 4.2.8    | Cell surface hydrophobicity of <i>C. albicans</i> .....   | 70        |
| 4.3      | Infection.....  | 71        |

|          |   |            |
|----------|---|------------|
| 4.3.1    | Receptor expression on macrophage surface related to<br><i>C. albicans</i> infections .....               | 71         |
| 4.3.2    | Phagocytosis of <i>C. albicans</i> .....  | 71         |
| 4.3.3    | Cytokine production of genistein treated macrophages with<br><i>C. albicans</i> .....                     | 72         |
| 4.3.4    | Interaction of genistein-treated <i>C. albicans</i> with RAW264.7<br>macrophage .....                     | 73         |
| 4.3.5    | Cytokine production of RAW264.7 macrophages stimulated<br>with genistein-treated <i>C. albicans</i> ..... | 74         |
| 4.4      | Interaction of <i>C. albicans</i> single gene deletion mutants with macrophages<br>.....                  | 75         |
| 4.4.1    | Phagocytosis .....  | 75         |
| 4.4.2    | Cell wall $\beta$ -glucans and mannans exposure of <i>C. albicans</i><br>mutants .....                    | 76         |
| 4.4.3    | Phagocytosis of <i>C. albicans</i> mutants by RAW264.7 macrophage<br>after genistein treatment.....       | 78         |
| <b>5</b> | <b>DISCUSSION .....</b>   | <b>80</b>  |
| 5.1      | Effects of genistein on the macrophages .....   | 80         |
| 5.2      | Genistein shows a strong anti-inflammatory effect on LPS-stimulated<br>macrophages .....                  | 81         |
| 5.3      | Genistein effects on <i>C. albicans</i> .....   | 85         |
| 5.4      | Treatment of <i>C. albicans</i> with genistein enhances the activity of murine<br>macrophages .....       | 88         |
| 5.5      | Conclusions and future directions.....  | 90         |
| <b>6</b> | <b>REFERENCE .....</b>  | <b>94</b>  |
| <b>7</b> | <b>APPENDIX.....</b>  | <b>109</b> |

## LIST OF FIGURES

|   |    |
|---|----|
| Fig. 2.1 Structure of genistein.....  | 4  |
| Fig. 2.2 Typical morphology of a monocytes and a macrophage.....  | 11 |
| Fig. 2.3 Pattern-recognition receptors on the surface of macrophage involved in <i>C. albicans</i> recognition .....                      | 12 |
| Fig. 2.4 Recognition of <i>Candida albicans</i> at the membrane level .....   | 12 |
| Fig. 2.5 TLR signalling in conventional dendritic cells, macrophages and plasmotoid dendritic cells.....                                  | 15 |
| Fig. 2.6 Scheme of kinase involved in the LPS and IFN- $\gamma$ activated macrophage signaling pathways according to the literature. .... | 18 |
| Fig. 2.7 Yeast, hyphal and pseudohyphal morphologies .....  | 20 |
| Fig. 2.8 HOG and Cek1 mitogen-activated protein kinases signalling in <i>C. albicans</i> . ....   | 21 |
| Fig. 2.9 The structure of the <i>C. albicans</i> cell wall.....   | 23 |
| Fig. 2.10 Structure of respiratory chain of <i>C. albicans</i> .....  | 24 |
| Fig. 2.11 Structure of respiratory chain of <i>S. cerevisiae</i> .....  | 25 |
| Fig. 2.12 Flowchart outlining overall design of experiments undertaken in the thesis .....  | 28 |
| Fig. 3.1 Scheme of Neubauer improved Hemocytometer .....  | 32 |
| Fig. 3.2: Principle of the toxicity tests cleavage of the tetrazolium salt WST-1 to formazan. .   | 35 |
| Fig. 3.3 Chemical reactions involved in the measurement of NO <sub>2</sub> <sup>-</sup> using the Griess Reagent. .                       | 36 |
| Fig. 3.4 Principle of a sandwich ELISA .....  | 38 |
| Fig. 3.5 Principle of the detection.....  | 46 |
| Fig. 4.1 Effects of genistein on the viability of macrophages determined by the WST-1 assay.....  | 50 |
| Fig. 4.2 The cell cycle distribution of macrophages after treatment with genistein for 24 hours .....                                     | 51 |
| Fig. 4.3 The cell cycle distribution of macrophages after treatment with genistein for 48 hours. ....                                     | 52 |

|   |    |
|---|----|
| Fig. 4.4 Morphological change of macrophages RAW264.7 after treatment with genistein  | 53 |
| Fig. 4.5 Effect of cytochalasin B and genistein on the actin cytoskeleton of macrophage RAW 264.7..   | 55 |
| Fig. 4.6 Influence of genistein on the NO production and viability of LPS stimulated RAW264.7 macrophages   | 56 |
| Fig. 4.7 Influence of genistein on the NO production of IFN- $\gamma$ and LPS+IFN- $\gamma$ stimulated RAW264.7 macrophages.                                    | 57 |
| Fig. 4.8 Genistein's dose-dependent inhibition of cytokine production in the cell culture supernatants of LPS activated macrophages                             | 58 |
| Fig. 4.9 Determination of the activation of the MAP Kinase signalling cascade in lysis of macrophages exposed to LPS and genistein for different time intervals | 60 |
| Fig. 4.10 Inhibitory effect of genistein on NF- $\kappa$ B and AP-1 activation of RAW-Blue <sup>TM</sup> cells by LPS   | 61 |
| Fig. 4.11 Hierarchical clustering of 32 induced or repressed genes.   | 62 |
| Fig. 4.12 Effect of genistein on the oxygen consumption of <i>C. albicans</i> (A) and <i>S. cerevisiae</i> (B).   | 63 |
| Fig. 4.13 Effects of genistein on the generation of endogenous ROS in <i>C. albicans</i> (A) and <i>S. cerevisiae</i> (B).                                      | 64 |
| Fig. 4.14 Effects of rotenone on the oxygen consumption of <i>C. albicans</i> and <i>S. cerevisiae</i> ...  | 65 |
| Fig. 4.15 Effects of rotenone on the generation of endogenous ROS in <i>C. albicans</i> and <i>S. cerevisiae</i> .....  | 66 |
| Fig. 4.16 Effects of antimycin A on on the oxygen consumption of <i>C. albicans</i> and <i>S. cerevisiae</i> .....  | 66 |
| Fig. 4.17 Effects of antimycin A on the generation of endogenous ROS in <i>C. albicans</i> and <i>S. cerevisiae</i> .....                                       | 67 |
| Fig. 4.18 The consuming of the DCIP color by suspensions cells of genistein and rotenone treated <i>C. albicans</i> after 20 min.                               | 68 |

|   |    |
|---|----|
| Fig. 4.19 Effects of genistein on the ethanol production of <i>C. albicans</i> after genistein treatment for 4 hours.....   | 68 |
| Fig. 4.20 Effect of genistein concentration on growth of <i>C. albicans</i> in YPgal medium .....   | 69 |
| Fig. 4.21 FACS analysis of accessible $\beta$ -1,3-glucans and mannan of genistein 100 $\mu$ M treated <i>C. albicans</i> CAF2-1 .....  | 70 |
| Fig. 4.22 Effect of genistein on the cell surface hydrophobicity of <i>C. albicans</i> .....  | 70 |
| Fig. 4.23 Receptors expression of macrophage RAW264.7 by flow cytometry. ....   | 71 |
| Fig. 4.24 Phagocytotic activity of RAW264.7 macrophage for <i>C. albicans</i> CAF2-1 after treatment with different concentration of genistein for 2-8 h (A), 24 h (B) and 48 h (C).....  | 72 |
| Fig. 4.25 TNF- $\alpha$ and IL-10 production of macrophages in response to <i>C. albicans</i> CAF2-1, influenced by genistein. ....   | 73 |
| Fig. 4.26 Phagocytosis of genistein treated <i>C. albicans</i> CAF2-1 by the macrophage cell line RAW 264.7.....  | 74 |
| Fig. 4.27 Effects of genistein treatment of <i>C. albicans</i> CAF2-1 on the production of TNF- $\alpha$ (A) and IL-10 (B) by macrophages .....   | 75 |
| Fig. 4.28 Phagocytosis of MAP kinase mutants $\Delta$ cek1, $\Delta$ mkk1 and $\Delta$ hog1 and MAPK kinase mutants $\Delta$ hst7, $\Delta$ pbs2 by RAW264.7 macrophages in comparison to the reference strain CAF2-1 and histidine kinase mutant $\Delta$ chk1. .... | 76 |
| Fig. 4.29 Overlay of $\beta$ -glucans expression of MAPK and MAPK kinase deletion mutants in comparison to <i>C. albicans</i> CAF2-1. ....  | 77 |
| Fig. 4.30 Quantitative comparison of the median fluorescence intensities of stained mutants and the reference strain CAF2-1 .....   | 78 |
| Fig. 4.31 Mannan exposure of MAPK and MAPK kinase deletion mutants in comparison to CAF2-1 and the histidine kinase mutant $\Delta$ chk.....  | 78 |
| Fig. 4.32 Phagocytosis of genistein treated mutants by RAW264.7 macrophages in comparison to the reference strain treated CAF2-1.....   | 79 |
| Fig. 5.1 Schematic illustration of the inflammation mechanism in macrophage RAW264.7 activated by LPS and/or IFN- $\gamma$ .. ....  | 85 |

## LIST OF TABLES

|   |    |
|---|----|
| Tab. 2.1 Classification, prominent food flavonoids and typical food sources.....  | 4  |
| Tab. 2.2 Anti-inflammatory of mechanism of genistein.....   | 7  |
| Tab. 2.3 Phagocytes and their function in the innate immune system.....   | 10 |
| Tab. 2.4 Description of TLRs .....  | 13 |
| Tab. 3.1 Cell culture medium and components.....  | 33 |
| Tab. 3.2 Culture volume of different tissue culture flasks.....   | 34 |
| Tab. 3.3 Specific inhibitors used in the experiment.....  | 37 |
| Tab. 3.4 Reagents from ELISA READY SET GO! Kit-systems.....   | 39 |
| Tab. 3.5 <i>C. albicans</i> strains used in this study .....  | 42 |
| Tab. 3.6 Property of the fluorescence dye.....  | 44 |
| Tab. 4.1 Effects of specific kinase inhibitors in NO production by LPS, IFN- $\gamma$ and LPS+<br>IFN- $\gamma$ stimulated RAW264.7 macrophages ..... | 59 |
| Tab. 4.2 Specific kinase inhibitors effect on the cytokine productions in the cell culture<br>supernatants of LPS-activated macrophages.....          | 59 |

## ABBREVIATIONS

---

|                   |   |
|-------------------|---|
| ADP               | Adenosindiphosphate                                       |
| AIDS              | Acquired immunodeficiency syndrome                        |
| AP-1              | Activator protein 1                                       |
| ATCC              | American Type Culture Collection                          |
| ATP               | Adenosintriphosphate                                      |
| BCA               | Bicinchoninic acid  |
| BSA               | Bovine serum albumin                                      |
| cAMP              | Cyclic adenosine monophosphate                            |
| <i>C.albicans</i> | <i>Candida albicans</i>                                   |
| CAF2-1            | <i>C.albicans</i> strain                                  |
| CARD9             | Caspase recruitment domain protein 9                      |
| DAPI              | 4',6-diamidino-2-phenylindole                             |
| DMEM              | Dulbecco's modification of Eagle's medium                 |
| DMSZ              | Deutsche Sammlung von Mikroorganismen und<br>Zellkulturen |
| DMSO              | Dimethyl sulfoxide  |
| DNA               | Deoxyribonucleic acid                                     |
| <i>E.coli</i>     | <i>Escherichia coli</i>                                   |
| EDTA              | Ethylendiamine acetic acid                                |
| Em.               | Emissions wavelength                                      |
| ERK               | Extracellular signal-regulated kinase                     |
| Ex.               | Excitation wavelength                                     |
| ELISA             | Enzyme linked immunoabsorbent assay                       |
| FACS              | Fluorescence-activated cell sorting                       |
| FBS               | Fetal bovine serum  |
| FITC              | Fluorescein isothiocyanate                                |
| FMN               | Flavin mononucleotide                                     |
| GFP               | Green fluorescent protein                                 |
| GlcNAc            | N-Acetylglucosamine                                       |
| GM-CSF            | Granulocyte colony-stimulating factor                     |
| HRP               | Horseradish peroxidase                                    |

---

---

|                |   |
|----------------|---|
| IFN- $\gamma$  | Interferon gamma                                    |
| IgG            | Immunglobulin G                                     |
| IL             | Interleukin   |
| IL-1Ra         | Interleukin 1 receptor antagonist                   |
| iNOS           | Inducible nitric oxide synthase                     |
| IRAK           | Interleukin-1 receptor-associated kinase            |
| IRF            | Interferon regulation factor                        |
| ITAM           | Immunoreceptor tyrosine-based activation-like motif |
| I $\kappa$ B   | Nuclear Factor $\kappa$ B-inhibitor protein         |
| JNK            | c-Jun N-terminal kinase                             |
| LPS            | Lipopolysaccharide                                  |
| LR             | C-type Lectin receptor                              |
| LRR            | Leucin-rich repeat                                  |
| MAL            | TIR-domain-Adapter protein                          |
| MAP            | Mitogen activated protein                           |
| MIP            | Macrophage inflammatory protein                     |
| MR             | Mannose receptor                                    |
| MKP-1          | MAP-Kinase-Phosphatase 1                            |
| MyD88          | Myeloid differentiation primary response gene 88    |
| NADPH          | Nicotinamide adenine dinucleotide phosphate         |
| NFAT           | Nuclear factor activated T-cells                    |
| NF- $\kappa$ B | Nuclear Factor kappa B                              |
| NK cells       | Natural killer cells                                |
| NOS            | Nitric oxide synthase                               |
| NO             | Nitric oxide  |
| OD             | Optical Density                                     |
| p38            | Mitogen-activated protein kinase 38                 |
| PBS            | Phosphate buffered saline                           |
| PDVF           | Polyvinylidene fluoride                             |
| Pen            | Penicillin  |
| PFA            | Paraformaldehyde                                    |
| PI3K           | Phosphatidylinositol 3-kinases                      |

---



---

|                     |   |
|---------------------|---|
| PRR                 | Pattern-recognition receptor  |
| PTK                 | Protein tyrosine kinase   |
| RAW264.7            | Macrophage cell line  |
| RIP1                | Receptor interacting protein  |
| RNS                 | Reactive nitrogen species   |
| ROS                 | Reactive oxygen species   |
| RT                  | Room temperature  |
| rpm                 | Rounds per minute   |
| <i>S.cerevisiae</i> | <i>Saccharomyces cerevisiae</i>   |
| SDS-PAGE            | Sodium dodecyl sulfate polyacrylamide gel<br>electrophoresis                            |
| Strep               | Streptomycin  |
| Syk                 | Spleen tyrosine kinase  |
| TBK1                | TANK-binding kinase   |
| T <sub>H</sub>      | T-Help cell   |
| Thr                 | Threonine   |
| TIR                 | TLR-interleukin 1 receptor  |
| TLR                 | Toll-like-Receptor  |
| TD                  | Transmembrane domain  |
| TMB                 | 3,3',5,5'-Tetramethylbenzidine  |
| TNF                 | Tumor necrose factor  |
| TRAF                | TNF Receptor Associated Factor  |
| TRAM                | TIR-domain-containing adapter-inducing<br>interferon- $\beta$ -related adaptor molecule |
| TRIF                | TIR-domain-containing adapter-inducing interferon- $\beta$                              |
| WST1                | 4-[3-(4-Jodophenyl)-2-(4-Nitrophenyl)<br>-2H-5-Tetrazolio]-1,3-Benzoldisulfonate        |
| YPD                 | Yeast extract peptone dextrose  |

---



# 1 ABSTRACT

*C. albicans* is a ubiquitous fungal organism that often colonizes the skin and the mucosal surfaces of healthy individuals, without causing disease. However, when the normal host defence mechanisms are impaired, *C. albicans* can become a pathogen. Candidaemia has an incidence of between 1.1 and 24 cases per 100,000 individuals and an associated mortality rate of more than 30%. Thus, the elucidation of the mechanisms of the interactions of *C. albicans* and the host is not only a highly relevant research topic, but also can lead to the identification of novel targets and promising compounds for treating *C. albicans* infections.

We chose as chemical compound the isoflavone genistein for our studies. Genistein is a well known natural compound which is present in soy foods and exerts many beneficial functions (anticancer, anti-inflammatory, antioxidant). However, until now little is known about the effects of genistein on *C. albicans*, the function of macrophages, and the interactions between both organisms. We used the murine macrophage cell line RAW264.7 as target cell line. We found that genistein could influence macrophage functions: at concentrations of 100 - 50  $\mu$ M, genistein reduced the cell viability to 70 % - 80 % (after 24 h) and 50 % - 60 % (after 48h), which was due to G2/M phase cell cycle arrest. Treatment of the macrophages with genistein for 24 or 48 h also led to significant morphological changes, such as elongation of the cells and development of long pseudopodia-like protrusions. By staining the F-actin cytoskeleton, we observed accumulation of actin - filaments at the edges of the cells. Phagocytosis is one of most important functions of macrophages. After treatment of the macrophages with genistein, the phagocytotic efficiency for *C. albicans* was decreased in a time- and dose-dependent manner. Moreover, the production of cytokines (TNF- $\alpha$ , IL-10) stimulated by *C. albicans* was strongly inhibited by genistein. Genistein also blocked the response of macrophages to bacterial stimulants, such as LPS, i.e. the secretion of NO, TNF- $\alpha$ , and IL-10, which is related to the inhibition of the activation of transcription factors NF- $\kappa$ B and AP-1.

Additionally, we investigated whether genistein could directly influence the pathogen, *C. albicans*. Our results showed that genistein blocked oxygen consumption of *C. albicans* and induced the production of reactive oxygen species. However, those effects were not observed in *S. cerevisiae*. *C. albicans* and *S. cerevisiae* significantly differ in the

composition of the respiratory chain, as in *S. cerevisiae* complex I is absent. From comparison with rotenone (specific complex I inhibitor) and antimycin A (specific complex III inhibitor), we concluded that complex I is the most likely target for genistein. Using DCIP as a mediator, we detected complex I reductase activity. Genistein did not act as an inhibitor of DCIP reduction by complex I as rotenone did. The results pointed out that genistein binds to complex I of *C. albicans* at a site different from that of rotenone.

Moreover, treatment of *C. albicans* with genistein enhanced the susceptibility of the pathogen for phagocytosis by the macrophages and increased the production of the cytokines IL-10 and TNF- $\alpha$ . However, genistein did not influence the structure of the cell wall glucans and mannans of *C. albicans*, which was analysed by flow cytometry; whereas the cell surface hydrophobicity, which correlates with adherence, increased.

In conclusion, genistein could influence both the functions of host macrophages and the properties of the pathogen *C. albicans*. Thus, genistein may have antimycotic effects by acting on *C. albicans* to enhance the phagocytic activity of macrophages.

## 2 INTRODUCTION

Natural products, especially isoflavones, have attracted many attentions from scientists due to their natural origins and low side effects. Isoflavones are present in food, especially in soybean and some Chinese herbs. Their beneficial health effects are well studied, in particular with respect to cancer treatment.

With the widespread use of broad-spectrum antibiotics, spread of AIDS, in particular, immunosuppressive agents in therapy cancer treatment, the incidence of *C. albicans* infections increased year by year. Candidiasis accounted for 82 % of all fungal infections. Although prevention and treatment of *C. albicans* infections has made great progress, the mortality rate is still high. Due to the commensal nature of these pathogens, prevention of the outbreak of infections by the long term use of healthy food components is one of the promising and challenging research topics. Therefore, in these studies, we focus on the influence of the food constituent genistein on the co-existence of *C. albicans* and host cells, in particular macrophages.

### 2.1 *Pharmacological activity of genistein*

Flavonoids belong to a polyphenol subclass and are widely distributed in the plant kingdom. They are chemically categorized into different subtypes based on the connection of an aromatic ring to the heterocyclic ring as well as the oxidation state and functional groups of the heterocyclic ring (Tab. 2.1) [1]. Flavonoids are found in fruits, vegetables, legumes, herbs, spices, stems, flowers, as well as tea and red wine. They are consumed regularly in many countries in a healthy diet.

Natural flavonoids and isoflavonoids are currently of great interest due to their antioxidative and anticancer properties. Genistein (4', 5, 7-trihydroxyisoflavone) (Fig. 2.1), a well studied isoflavone, is a major constituent of soyfoods and legumes such as lupin, fava beans, soybeans, kudzu, psoralea, and chickpeas. It shows a variety of biological effects, for example as a phytoestrogen or anti-cancer agent etc., but here we focus on the pharmacological activity related to microbial infections.

Tab. 2.1 Classification, prominent food flavonoids and typical food sources

| Flavonoid class | Food flavonoid   | Food source                     |
|-----------------|--|---------------------------------|
| Flavanols       | Catechin, gallocatechin, epicatechin                         | Teas, red grapes and red wine   |
| Flavanones      | Naringenin, hesperetin, eriodictyol, taxifolin               | Citrus foods                    |
| Flavones        | Apigenin, luteolin, rutin chrysin                            | Green leafy spices              |
| Isoflavones     | Daidzein, <b>genistein</b> , glycitein, biochanin A, daidzin | Soybeans, soy foods and legumes |
| Flavonols       | Kaempferol, myricetin, quercetin, isorhamnetin, tamarixetin  | Nearly ubiquitous in foods      |
| Anthocyanidins  | Cyanidin, delphinidin, pelargonidin, apigenidin              | Red, purple and blue berries    |




Fig. 2.1 Structure of genistein

### 2.1.1 Bioavailability of dietary genistein

Most flavonoids exist in plants as glycosidic conjugates, generally located in cell vacuoles. Bioavailability of these dietary components depends on relative uptake rates of conjugated and free forms, hydrolysis of glycosides by gut bacteria or gut wall enzymes, further metabolism such as glucuronides pathway within the liver, and excretion rates. The malonyl glucosides of daidzein and genistein found in soybeans are labile and are readily degraded to the non-acylated glucosides following cooking. The free aglycones, but not the glycosides, are absorbed from rat stomach. However, once in the small intestine, brush border lactase phlorizin hydrolase can effectively hydrolyze isoflavone glucosides. Nevertheless, in humans, isoflavones appear in blood plasma at a more rapid rate and at higher levels, following oral administration of aglycones as compared to glycosides. Moreover, genistein and daidzein, but not their glycosides, are readily transported across human intestinal epithelial cell monolayers [2].

### **2.1.2 *Genistein as a tyrosine kinase inhibitor***

Tyrosine kinase is an enzyme that transfers a phosphate group from high energy donor molecules such as ATP to tyrosine residues of proteins. It plays an important role in regulation signal transduction in human cells. Genistein was reported as a tyrosine kinase inhibitor by Akiyama in 1987 [3]. Genistein exerts anti-inflammatory and anti-infection effects due to this kinase inhibitory property which will be described in the related paragraph.

### **2.1.3 *Genistein as an antioxidant***

Cells and tissues in the body are continuously threatened by damage caused by free radicals and reactive oxygen species, which are produced during normal oxygen metabolism or are induced by exogenous factors [4]. The increased production of reactive oxygen species accompany most forms of tissue injury, which have been implicated in a multitude of disease states ranging from inflammatory injury to myocardial infarction and cancer [5]. Genistein has been shown to protect cells against reactive oxygen species (ROS) by scavenging free radicals and reducing the expression of stress-response related genes [6, 7]. Genistein inhibits 12-O-tetradecanoylphorbol-13-acetate-induced hydrogen peroxide production in human polymorphonuclear leukocytes and HL-60 cells [8, 9]. The antioxidant mechanism which genistein shows leads to an inhibition of the activation of NF- $\kappa$ B stimulated by oxidative stress and chemokine-8 secretion, via a decrease in either caspase-3 or protein tyrosine kinase activity [10-13]. Thus, the ability of genistein to inhibit the generation of ROS, resulting in the inhibition of NF- $\kappa$ B activation, makes it a strong candidate as an antioxidant and a powerful chemopreventive agent.

### **2.1.4 *Genistein and immunity***

The effects of genistein in immunity are well studied among the isoflavones. In some studies, ovariectomized (OVX) mice were used to avoid the effect of endogenous estrogen. The results showed that the influence of genistein on OVX mice and on the non OVX model is different. Genistein induced dose-dependent reductions in thymic weight and size in OVX mice. It decreased thymocyte numbers by up to 86 % and reduced the number of peripheral lymphocytes and antigen-specific antibody titers [14, 15]. Treatment of genistein administered mice with anti-estrogen faslodex (ICI182780) partially restored thymic weight. Therefore, the effect of genistein could partly be related to interactions with the estrogen

receptor. Non-OVX mouse, daily feeded with 4-20 mg / kg genistein showed increases of non-specific immune functions in a dose-dependent manner. Also the production of IL-4 and IFN- $\gamma$  was increased and cytotoxic T cell and NK cell activity was enhanced [16-18]. Meanwhile, *in vitro* experiments found that relatively high doses of genistein can inhibit mitogen- and alloantigen-induced lymphocyte proliferation [19].

### **2.1.5 Genistein and inflammation**

Genistein possess anti-inflammatory properties as a result of different mechanisms (Tab. 2.2). It can inhibit phospholipase A2, cyclooxygenases, and lipooxygenases resulting in the reduction of levels of pro-inflammatory mediators. *In vivo*, genistein markedly attenuates ovalbumin-induced bronchoconstriction, pulmonary eosinophilia, and airway hyper-responsiveness in a guinea pig model of asthma. This anti-inflammatory effect may be mediated by the inhibition of the tyrosine kinase signalling cascade [20]. Intraperitoneally injected genistein was shown to protect rats from the endotoxin-induced organ failure [21], and later treatment with genistein reduced the degree of inflammation and joint destruction in collagen-induced arthritic mice. These therapeutic effects were mediated by a modulation of granulocytes, monocytes, and lymphocytes [22].

*In vitro*, genistein is able to suppress NO production in LPS activated murine macrophages in a dose-dependent manner by three mechanisms: scavenging of NO radicals, inhibition of inducible nitric oxid synthase (iNOS) enzyme activity, and inhibition of iNOS gene expression [22]. Genistein was shown to inhibit TNF- $\alpha$  production in LPS-induced RAW264.7 macrophages cells [23] and to inhibit IL-1 $\beta$ , IL-6, and TNF- $\alpha$  production from LPS-stimulated human blood monocytes [24]. The inhibitory effects of genistein on IL-6 production have been shown in different cells: cultured human intestinal cells Caco2 [25], osteoblast cells [26], human gastric epithelial cells [27], or macrophages [28].



Tab. 2.2 Anti-inflammatory mechanisms of genistein [29]

| Activity                                | Mechanism                              | Effect  |
|---|--|---|
| Antioxidant activity                    | Radical scavenging                     | Lower the amounts of free   |
|   | Inhibition of ROS production           | radicals  |
|   | Inhibition of pro-oxidant enzymes      | Inhibition of lipidic peroxidation  |
| Modulation of inflammatory cells        | Modulation of enzymatic activity       | Inhibition of inflammatory cells  |
|   | Modulation of secretory processes      | activation  |
| Modulation of proinflammatory enzymes   | Inhibition of arachidonic acid enzymes | Inhibition of the production of inflammatory mediators                    |
|   | Inhibition of NO synthase              | NO, leukotrienes, prostaglandins  |
| Modulation of proinflammatory mediators | Modulation of cytokine production      | Inhibition of the inflammatory cytokines: TNF- $\alpha$ and interleukines |
|   | Modulation of signal transduction      | Inhibition of proinflammatory gene transcription                          |

### 2.1.6 *Genistein and infection*

Genistein was reported to stimulate growth of *C. albicans* by increasing the rate of germination and enhancing Hsp90 expression. These biological effects may be attributable to genistein's activity as a phytoestrogen [30]. Meanwhile, genistein strongly inhibited *C. albicans* yeast adhesion to Vitronectin and human endothelial cells by blocking the phosphorylation of endothelial cell proteins, therefore, it significantly reduced endocytosis of *C. albicans* due to inhibition of tyrosine kinase [31, 32].

### 2.1.7 *Genistein involved in signal transduction pathways*

Genistein modulates several key elements of signal transduction pathways related to cellular growth and survival. These cover the full spectrum of the intracellular signalling network.

#### 2.1.7.1 Inhibition of the activation of NF- $\kappa$ B

The transcription factor NF- $\kappa$ B plays an important role in the control of cell growth, differentiation, apoptosis, and stress-response. Under non-stimulating conditions, NF- $\kappa$ B is

sequestered in the cytoplasm through tight association with the impeding I $\kappa$ B proteins. Following stimulation, the I $\kappa$ B proteins are phosphorylated and degraded, allowing the NF- $\kappa$ B to translocate to the nucleus, bind to the NF- $\kappa$ B specific DNA binding sites or interact with other transcription factors, and thus regulate gene transcription. NF- $\kappa$ B plays a major role in pathways involved in inflammation and innate immune responses [33].

Genistein blocks the activation of NF- $\kappa$ B concomitant with degradation of I $\kappa$ B $\alpha$  in human myeloid leukaemia cells [34]. Genistein inhibits the translocation of NF- $\kappa$ B to the nucleus, preventing NF- $\kappa$ B from binding to its target DNA and thereby inhibiting the transcription of NF- $\kappa$ B downstream genes. This process ultimately inhibits cell growth and also induces apoptotic cell death. Genistein has also been found to potentiate the antitumor activity of chemotherapeutic agents through regulation of NF- $\kappa$ B [35, 36] .

#### 2.1.7.2 Regulation of Akt signalling pathway

Akt is a serine/threonine protein kinase that plays a key role in multiple cellular processes. Akt signalling is another important signal transduction pathway that plays a critical role in controlling the balance between cell survival and apoptosis [37]. Akt also regulates the NF- $\kappa$ B pathway via phosphorylation and activation of molecules in the NF- $\kappa$ B pathway [38, 39]. Genistein treatment reduces the level of the phosphorylation of the Akt protein compared to control cells, resulting in a dose-dependent induction of apoptosis of cells that display constitutively active Akt [40]. Genistein pre-treatment abrogated the activation of Akt by EGF-stimulated PC-3 prostate cancer cells [41], demonstrating that genistein inhibits the activation of Akt, which may result in the inhibition of survival signals ultimately leading to induction of apoptotic signals. Genistein exerts its inhibitory effects on NF- $\kappa$ B pathway through the Akt signalling pathway in cancer cells [25]. Genistein has been shown to exert inhibitory effect on Akt activation induced by estradiol in MCF-7 cells [42, 43]. Collectively, these results demonstrate that genistein exerts its inhibitory effect on NF- $\kappa$ B signalling through Akt pathway. Thus, abrogation of NF- $\kappa$ B and Akt signalling pathway by genistein may be one of the molecular mechanisms by which genistein inhibits inflammation and cancer cell growth, and induces apoptosis.

#### 2.1.7.3 Regulation of MAPK pathway

Mitogen-activated protein kinases (MAPK) are a family of serine/threonine kinases, which connect inflammatory and other extracellular signals to intracellular responses.

MAPK pathway consist of a module of three kinases where MAPKKK activates a MAPKK that activates a MAPK (ERK, JNK, and p38), resulting in the activation of transcription factors like AP-1. Activation of the MAPK pathways may cause the induction of phase II detoxifying enzymes and positively regulate the expression of a number of cytokines genes [44].

Genistein has been found to regulate the molecules in the MAPK pathway in different ways: Genistein is reported to inhibit TGF- $\beta$ -mediated p38 MAP kinase activation and matrix metalloproteinase type 2 [45]. In other studies, genistein has been found to be effective in preventing cytokine-induced ERK-1/2 activation and promoted apoptotic cell death [46]. Since genistein is a well known inhibitor of tyrosine kinases, it is possible that genistein inhibits tyrosine kinases upstream of p38 and subsequently inhibit the phosphorylation of tyrosine residues on p38, leading to the inactivation of MAPK pathway. On the other hand, genistein also could potentiate the phosphorylation of p38, ERK1/2 in breast cancer lines [47-49].

In summary, the modulation of a large number of signalling pathways is a distinctive property of genistein.

## **2.2 *Phagocytes in the immune system***

### **2.2.1 *Immune system***

The immune system is a remarkable versatile defence system that has evolved to protect animals from invading pathogenic microorganisms and cancer. It comprises an enormous variety of cells and molecules capable of specifically recognizing and eliminating foreign invaders [50].




The immune system has two principal components: innate and adaptive immunity, which work in concert to defend the body against infection. The innate immune system recognizes directly a wide variety of microorganisms through highly conserved receptors and essential microbial molecules, such as lipopolysaccharides present on the cell wall of gram-negative bacteria and lipoteichoic acids present in gram-positive bacteria. The cells of the innate immune system represent the first line of defence in the immunosurveillance network. In contrast to the broad reactivity of the innate immune system, the specific components of the adaptive immunity, such as lymphocytes and antibodies, recognize an antigenic challenge to the organism with a high specificity. Once the immune system has

recognized and responded to an antigen, it exhibits immunologic memory; a second encounter with the same antigen induces a faster and more efficient state of immune reactivity. Therefore, life-long immunity against many infectious agents can be acquired after an initial encounter.

### 2.2.2 Phagocytes and their functions

The most important effector cells of the innate immune system are bone marrow-derived cells that circulate in the blood and migrate into tissues [51]. These include cells of the myeloid lineage including neutrophils, mononuclear phagocytes, and dendritic cells (Tab. 2.3).

Tab. 2.3 Phagocytes and their function in the innate immune system [52]

| Cell            | Morphology  | Activated function                                     |
|-----------------|---|--|
| Macrophage      |   | Phagocytosis and activation of bactericidal mechanisms |
| Dendritic cells |  | Antigen uptake in peripheral sites                     |
| Neutrophil      |  | Phagocytosis and activation of bactericidal mechanisms |

The mononuclear phagocyte system consists of cells that have a common lineage whose primary function is phagocytosis and which play central roles in innate and adaptive immunity. Monocytes, incompletely differentiated after leaving the marrow, are the first cells that enter the blood. Once they enter tissues, these cells mature and differentiate into macrophages. Macrophages are the first phagocytes to encounter invading microorganisms (Fig. 2.2). They are dispersed throughout the body; some take up residence in particular tissues, become fixed macrophages and are named specifically according to different

tissues. For example, in the central nervous system, they are called microglial cells, in the connective tissue histiocytes, in the lung they are called alveolar macrophages and in the liver Kupffer cells. Macrophages rapidly respond to microbes and survive much longer than neutrophils at the sites of inflammation. They can undergo cell division at an inflammatory site. Therefore, macrophages are the dominant effector cells of the later stages of the innate immune response, 1 or 2 days after infection [53].




Fig. 2.2 Typical morphology of a monocyte and a macrophage. Macrophages are five to ten fold larger than monocytes and contain more organelles, especially lysosomes [50]

### 2.2.3 *Pattern recognition receptors*

Macrophages, neutrophils, and monocytes are the main cells of the host innate immune response that recognize invading pathogens. Monocytes express high levels of Toll-like receptors (TLRs) on their cell membranes, as well as moderate levels of lectin receptors (LRs). During differentiation into macrophages, they retain expression of TLRs while strongly upregulating their expression of LR [54].

Important differences in the expression of several receptors have also been reported between resident and inflammatory macrophages, as the expression of pattern recognition receptors (PRRs) can be modified by cytokines or microbial products. DCs, which are crucial for antigen processing and presentation, also express most of the PRRs that are important for the recognition of fungal pathogens. Several classes of PRRs such as dectin-1, Toll-like receptors (TLR), families of cytosolic proteins (e.g. NODs, NALPs), and retinoic

acid inducible gene (RIG)-I-like receptors (RLR) have been identified so far [55-57]. These PRRs recognize various pathogen-associated molecular patterns (PAMPs) [58] in a number of cell compartments, such as bacterial lipopolysaccharide or fungal  $\beta$ -glucans, and trigger the release of inflammatory cytokines and type I interferon for host defence [55, 59]. Here we briefly listed the receptors associated with *C. albicans* infections (Fig. 2.3-Fig. 2.4).




Fig. 2.3 Pattern-recognition receptors on the surface of macrophage involved in *C. albicans* recognition[54]. CR3: complement receptor 3; Fc $\gamma$ R: Fc $\gamma$  receptor; MR: mannose receptor; TLR: Toll-like receptor.




Fig. 2.4 Recognition of *Candida albicans* at the membrane level [54].

### 2.2.3.1 Toll-like receptors

TLRs recognize various PAMPs derived from viruses, pathogenic bacteria, pathogenic fungi, and parasitic protozoa. TLRs are expressed in distinct cellular compartments. TLR1,

TLR2, TLR4, TLR5, TLR6, and TLR11 (only expressed in mice) are expressed on the cell surface whereas TLR3, TLR7, TLR8, and TLR9 are expressed in intracellular vesicles such as the endosome and ER. The intracellular TLRs are transported to the intracellular vesicles via UNC93B1, a transmembrane protein, which is localized in the endoplasmic reticulum of the cell [60-63]. All TLRs differ from each other in ligand specificities, expression patterns, and in the target genes which they can induce [58] (Tab.2.4).

TLRs are type I integral membrane glycoproteins and have a trimodular structure. The extracellular N-terminal domain consists of approximately 16-28 leucine-rich repeats (LRRs) and each LRR consists of 20-30 amino acids with the conserved motif "LxxLxLxxN". The intracellular C-terminal domain is known as the Toll/IL-1 receptor (TIR) domain, which shows homology with that of the IL-1 receptor [58, 59, 64, 65]. This domain is required for the interaction and recruitment of various adaptor molecules to activate the downstream signalling pathway (Fig. 2.5).

Activation of signal transduction pathways downstream of TLRs leads to the induction of the expression of various genes that function in host defence, including inflammatory cytokines, chemokines, major histocompatibility complex (MHC), and co-stimulatory molecules. In this thesis, we were interested in the TLR4 signalling pathways. The TLR4 signalling pathways are categorized into MyD88 (Myeloid differentiation primary response gene 88)-dependent and TRIF (TIR-domain-containing adapter-inducing interferon- $\beta$ )-dependent pathways [67]. The MyD88-dependent pathway is utilized by all TLRs except TLR3. Stimulation with the TLR ligand recruits MyD88 and the IRAK family of protein kinases to the receptor, which leads to the activation of TRAF6. TRAF6 causes activation of TAK1 via K63-linked polyubiquitination, which results in activation of NF- $\kappa$ B and AP-1 through the IKK complex and MAP kinases, respectively (Fig. 2.5). TLR3 and TLR4 initiate a TRIF-dependent pathway to induce the expression of inflammatory cytokines and type I interferons. The TRIF-dependent pathway activates NF- $\kappa$ B via two independent pathways. The N-terminal domain of TRIF interacts with TRAF6 and activates NF- $\kappa$ B. The c-terminal domain of TRIF interacts with RIP1 and activates TAK1. The TRIF-dependent pathway also induces type I interferon through IRF3. IRF3 is phosphorylated and activated by IKK-related kinases, TBK1, and IKKi (IKK $\epsilon$ ). TRAF3 acts as a linker between TRIF and TBK1 (Fig. 2.5).

Tab. 2.4 Description of TLRs

| TLR    | Location of TLR | Ligand                                | Target pathogen  | Signalling adaptor | Transcription factor | Cytokines induced                                    |
|--------|-----------------|---------------------------------------|--|--------------------|----------------------|--|
| TLR1/2 | Cell surface    | Triacylated lipoproteins              | Bacterial and mycobacteria   | TIRAP,MyD88        | NF-κB                | Inflammatory cytokines(TNF-α, IL-6 etc)              |
| TLR2   | Cell surface    | Peptidoglycan , lipoproteins, zymosan | Gram-positive bacteria <i>S. aureus</i> , <i>S. pneumoniae</i> , yeast and other fungi | TIRAP,MyD88        | NF-κB                | Inflammatory cytokines(TNF-α, IL-6 etc)              |
| TLR3   | Endosome        | Double stranded RNA (dsRNA)           | Viruses  | TRIF               | NF-κB, IRF3,7        | Inflammatory cytokines(TNF-α, IL-6 etc), type I IFNs |
| TLR4   | Cell surface    | LPS                                   | Gram-negative bacteria,  | MyD88              | NF-κB, IRF3,7        | Inflammatory cytokines(TNF-α, IL-6 etc), type I IFNs |
| TLR5   | Cell surface    | Flagellin                             | <i>S. typhimurium</i> , <i>P. aeruginosa</i>   | MyD88              | NF-κB                | Inflammatory cytokines(TNF-α, IL-6 etc),             |
| TLR6/2 | Cell surface    | Diacylated lipoproteins, zymosan      | Mycobacteria, yeast and fungi  | TIRAP,MyD88        | NF-κB                | Inflammatory cytokines(TNF-α, IL-6 etc),             |
| TLR7/8 | Endosome        | Single-stranded RNA (ssRNA)           | Viruses, HIV, Dengue virus influenza   | MyD88              | NF-κB,IRF 7          | Inflammatory cytokines(TNF-α, IL-6 etc), type I IFNs |
| TLR9   | Endosome        | CpG DNA                               | Bacterial DNA  | MyD88              | NF-κB,IRF 7          | Inflammatory cytokines(TNF-α, IL-6 etc), type I IFNs |
| TLR10  | Unknown         | Unknown                               | Unknown  | Unknown            | Unknown              | Unknown  |
| TLR11  | Cell surface    | Profilin, uropathogenic bacteria      | <i>T. gondii</i> Uropathogenic bacteria  | MyD88              | NF-κB                | Inflammatory cytokines(TNF-α, IL-6 etc),             |





expression [75].

Dectin-1 was initially identified as a dendritic-cell-specific receptor that modulates T cell function through recognition of an unidentified ligand [68, 76]. It was subsequently reidentified as a receptor for  $\beta$ -glucans [77, 78]. Due to its  $\beta$ -glucan specificity, dectin-1 recognizes a number of fungal species, including *C. albicans*, *P. carinii*, *S. cerevisiae*, *Coccidioides immitis*, and *Aspergillus fumigatus* [78-83]. The ligation of dectin-1 also triggers intracellular signalling resulting in a variety of cellular responses, including phagocytosis. Apart from Syk-dependent signalling from dectin 1, dectin 1 also collaborates with the TLR2 receptor to stimulate the MAPK (mitogen-activated protein kinase) and NF- $\kappa$ B (nuclear factor- $\kappa$ B) pathways, with subsequent production of pro-inflammatory cytokines such as TNF (tumour necrosis factor) [78, 84].

### 2.2.3.3 Mannose receptor

The mannan receptor was the first receptor found on the surface of macrophages. It is a c-type lectin mannose receptor (MR) [85, 86], which recognizes oligosaccharides that terminate in mannose, fucose, and N-Acetylglucosamine (GlcNAc) [87]. This binding is mediated by 4 to 8 carbohydrate-recognition domains (CRDs) in the extracellular region of the receptor [88]. MR preferentially recognizes  $\alpha$ -linked oligomannoses with branched, rather than linear, structures from *C. albicans* in monocytes and macrophages [89, 90], resulting in important protective effects against *C. albicans* infections such as stimulation of cytokine production, induction of DC maturation, and T cell immunity [54].

### 2.2.3.4 Interferon gamma receptor

Interferon  $\gamma$  (IFN  $\gamma$ ) is released in an immune response by T lymphocytes and natural killer (NK) cells and plays an important role in the host defense against virus and mycobacteria [91]. The receptor for IFN  $\gamma$  is expressed on lymphoid cells, including monocytes, macrophages, T cells, B cells, NK cells, and nonlymphoid cells such as fibroblasts and endothelial cells [92]. IFN  $\gamma$  acts on macrophages to increase ability to resist the growth of intracellular pathogens by enhancing production of antimicrobial effector molecules, such as reactive oxygen species (ROS) and nitric oxide (NO) [93, 94]. The receptor complex consists of the heterodimer of two chains: IFNGR1 and IFNGR2a. Binding of IFN  $\gamma$  to the receptor activates the Jak2-Stat1 signaling pathway [95, 96]. The receptor-associated Jak1 and Jak2 tyrosine kinases phosphorylate the IFNGR-1 chain. The

tyrosine-phosphorylated receptor recruits signal transducer and activator of transcription 1 (Stat1) to the receptor, resulting in the tyrosine phosphorylation of Stat1. The phosphorylated Stat1 forms dimers and translocates to the nucleus and, after binding to a specific sequence in the promoter region of IFN- $\gamma$ -inducible genes, induces gene transcription.

#### **2.2.4      *Specific kinases involved in pathways activated by LPS and IFN- $\gamma$***

Kinases and phosphatases play an important role in signal transduction cascades activated by LPS and IFN- $\gamma$  in macrophages (Fig. 2.6). Already in 1991, LPS was reported to induce tyrosine phosphorylation of several proteins, and two of these tyrosine phosphoproteins of 41 and 44 kDa are isoforms of mitogen-activated protein (MAP) kinase [97-99]. Tyrosine kinase Jak2 was also reported to be involved in LPS-induced macrophage activation by regulating the PI3 kinase and the MAP kinase JNK which controls the expression of inflammatory factors affecting the release of IL-1 $\beta$  [100]. Meanwhile, LPS can activate the human monocyte PI3K pathway [101, 102]. The tyrosine kinase Syk plays an important role in the activation cascade in rat alveolar and peritoneal macrophages *in vitro*, and in the human THP-1 cell line [103]. Src tyrosine kinase inhibitor PP1 was found to inhibit LPS-induced macrophage activation, iNOS expression, and TNF- $\alpha$  production [104, 105].




Fig. 2.6 Scheme of kinase involved in the LPS and IFN- $\gamma$  activated macrophage signaling pathways according to the literature. Black arrows show the known connection, dash arrows mean that the mechanism is not clear yet.

### 2.2.5 Phagocytosis

Phagocytosis is the process of internalization of particles by cells: in the first step in phagocytosis, macrophages are attracted by and move toward a variety of substances generated in an immune response; this process is called chemotaxis. The next step in phagocytosis is adherence of the antigen to the macrophage cell membrane. Complex antigens, such as whole microbial cells or viral particles, tend to adhere well and are readily phagocytosed; isolated proteins and encapsulated bacteria tend to adhere poorly and are less readily phagocytosed. Adherence induces membrane protrusions in the mammalian cells called pseudopodia, which extend around the attach materials. Fusion of the pseudopodia encloses the material within a membrane-bound structure called phagosome and then enters the endocytic processing pathway. In this pathway, the phagosome moves toward the cell interior, where it fuses with a lysosome to form a phagolysosome. Lysosomes contain lysozyme and a variety of other hydrolytic enzymes that digest the ingested material. The digested contents of the phagolysosome are then eliminated in a process called exocytosis.

The macrophage membrane has receptors for certain classes of antibodies. If an antigen is coated with the appropriate antibody, the complex of antigen and antibody binds to antibody receptors on the macrophage membrane more readily than antigen alone and phagocytosis is enhanced [50].

### **2.2.6 Killing of phagocytosed microbes**

Activated macrophages kill phagocytosed microbes by the action of microbicidal molecules in phagolysosomes: activated macrophages produce several proteolytic enzymes in the phagolysosomes, which function to destroy microbes. Moreover, reactive oxygen species are produced which are highly reactive oxidizing agents that destroy microbes. In addition to reactive oxygen species, macrophages produce reactive nitrogen intermediates, mainly nitric oxide (NO), by the action of an enzyme called inducible nitric oxide synthase (iNOS). However, when macrophages are strongly activated, they can injure normal host tissues by the release of lysosomal enzymes ROS and NO. The microbicidal products of these cells do not distinguish between self tissue and microbes. As a result, if these products enter the extracellular environment, they are capable of causing host tissue injury [50].

## **2.3 *Candida albicans***

### **2.3.1 Background**

*C. albicans* is a polymorphic fungus from the Ascomycota, diverged from *S. cerevisiae* around 200 million years ago [106, 107]. *C. albicans* is able to grow in a variety of morphological forms. These range from unicellular budding yeast (Fig. 2.7 A) to hyphae (Fig. 2.7 C) [106, 108]. In between these two morphologies, the fungus can form pseudohyphae. Pseudohyphae resemble hyphae, but are morphologically different. Hyphae and pseudohyphae are both important virulence factors. Hyphae formation can be triggered by specific environmental conditions, such as temperature of 37 °C, neutral or alkaline pHs, increased CO<sub>2</sub> concentrations, or the presence of serum [107] (Fig. 2.7). *C. albicans* also expresses several other virulence factors that contribute to pathogenesis. These factors include adhesions, secreted aspartyl proteases, and phospholipases [109].



Fig. 2.7 Yeast, hyphal and pseudohyphal morphologies [107] (A) budding yeast (B) pseudohyphae (C) hyphae

*C. albicans* is a ubiquitous fungal organism that often colonizes the skin and the mucosal surfaces of healthy individuals without causing disease. However, when the normal host defence mechanisms are impaired (for example, in patients who are undergoing chemotherapy for malignancies, receiving immunosuppressants after an organ transplantation, or patients with AIDS), *C. albicans* can become a pathogen. Candidaemia has an incidence of between 1.1 and 24 cases per 100,000 individuals and an associated mortality rate of more than 30 % [110, 111].

Currently, several classes of systemic antifungal compounds are applied in the clinical practice. They target pathways related to the structure and synthesis of the fungal cell membrane or cell wall. Fluconazole and other azoles lead to the depletion of ergosterol, an essential component of the cell membrane; amphotericin B interacts with sterols in the outer cell membrane, leading to changes in permeability and leakage of cytosolic components; and echinocandins inhibit synthesis of  $\beta$ -glucans of fungal cell walls. The application of these antimycotic agents are challenged by the increasing numbers of resistant strains and severe side effects [112]. Therefore, there are desperate needs for new therapeutics addressing new targets.

### **2.3.2 The MAP kinases signal transduction network in *C. albicans***

MAP (mitogen-activated protein) kinases signal transduction pathways are widespread in eukaryotic cells to couple environmental responses to transcriptional regulation. The core structure of MAPK pathway is highly conserved, they comprise three kinases: the MAP kinase (MAPK), the MAP kinase kinase (MAPKK), and the MAP kinase kinase kinase (MAPKKK). When the MAPKKK is activated by upstream signals, it becomes phosphorylated and in turn phosphorylates the MAPKK which, in turn, does so to the MAPK. The MAPK usually transmits the signal to downstream transcription factors that generate a

specific adaptive response. These pathways have been extensively characterized in the non-pathogenic model yeast species *S.cerevisiae* and *Schizosaccharomyces pombe*. In *S. cerevisiae* they are involved in several different processes, such as adaptation to high osmolarity (HOG pathway), mating, growth, and cell integrity (PKC1-mediated pathway) (Fig. 2.8). Proteins homologous to the *S. cerevisiae* MAPK have been identified in *C. albicans* and are designated Cek1p, Hog1p, Mkc1p, Cek2p, and Csk1p, respectively.




Fig. 2.8 HOG and Cek1 mitogen-activated protein kinases signalling in *C. albicans* [113].

### 2.3.2.1 The HOG pathway

The HOG pathway in *C. albicans* is implicated in several stress resistance mechanisms (osmotic, oxidative, temperature, and antifungal drugs), such as regulation of cell wall biosynthesis (adherence to host cells), white-opaque switching, morphogenesis, and virulence of the organism [114].

In *C. albicans*, this pathway is activated by the plasma membrane protein CaSln1p, a sensor histidine kinase forming a two-component system with Ypd1p. Another two cytoplasmic histidine kinases, Chk1p [115] and CaNik1p [116], are also involved in osmosensing, morphogenesis, and cell wall biogenesis [114]. Under non-stress conditions, Sln1p phosphorylates itself, which leads to the constitutive activation of CaSln1p and Ypd1p. The phosphate is then transferred to CaSsk1p, which inhibits the activation of Ssk2p and CaSsk22p. Under hyperosmotic stress inducing conditions, the initial step of

phosphorylation in the cascade is inhibited, allowing phosphorylation of Ssk2p and CaSsk22p and hence the activation of the MAPK pathway through Pbs2p and Hog1p. Phosphorylation of Hog1p can activate the transcriptional activators Hot1p, Msn2p, Msn4p, and Skn7p, or the repressor Sko1p [117]. Deletion mutants of *CaHOG1* are sensitive to osmotic stress and resistant to compounds (nikkomycin Z, Congo red, and calcofluor white) that interfere with cell wall function. *CaHOG1* also has a repressive effect on pseudohyphal and filamentous growth. Deletion of *CaHOG1* also results in a drastic decrease in mortality in systemically infected mice, suggesting a role for this MAP kinase pathway for the virulence of *C. albicans* [118].

### 2.3.2.2 The Cek1-mediated pathway

The Cek1p MAPK pathway was first studied in 1992 by Whiteway et al. and is known in *C. albicans* for its role in growth [119], mating [120], and cell wall construction [121]. This pathway is activated by the small GTPase Cst20p, subsequently acting upon the MAPKKK Ste11p followed by Hst7p, Cek1p, and finishing with the activation of the transcription factor Cph1p (Fig. 2.8). Disruption of *CEK1* causes defects in switching from unicellular budding growth to invasive hyphal growth on certain media, such as Lee's or Spider medium. *CEK1* gene codes for a virulence determinant of *C. albicans* both in systemic murine candidiasis and localized murine candidiasis [119] [122].

### 2.3.3 Cell wall structure

The fungal cell wall is an essential organelle that maintains the viability of fungal cells. Knowledge of the structure of the cell wall is necessary to understand how it is recognized by the host immune system. Fungal cell walls combine skeletal and matrix components. The skeletal component of the cell wall of *C. albicans* is a core structure of  $\beta$ -(1,3)-glucan covalently linked to  $\beta$ -(1,6)-glucan and chitin ( $\alpha\beta$ -(1,4)-linked polymer of *N*-acetylglucosamine (GlcNAc))(Fig. 2.9). These polymers form hydrogen bonds between adjacent polysaccharide chains to form a tough three-dimensional network of microfibrils. The skeletal components of the cell wall are always found close to the cell membrane in an inner layer, although some chitin and glucan can be present throughout the whole wall. In budding yeast cells, chitin and  $\beta$ -(1,3)-glucan can become exposed at the surface of budding scar [123]. In addition to the glucan and chitin skeleton, the *C. albicans* cell wall contains a matrix that mainly comprises glycosylated proteins. The major class of cell wall



proteins are glycosylphosphatidylinositol (GPI)-anchor-dependent cell wall proteins (GPI-CWPs), which are attached through a GPI remnant to  $\beta$ -(1,3)-glucan or chitin by a highly branched  $\beta$ -(1,6)-glucan linker. The CWPs are normally highly glycosylated with mannose-containing polysaccharides (sometimes called mannan), and carbohydrates can account for up to 90% of their molecular mass. Many CWPs have a lollipop structure with a globular domain that is presented to the outside of the cell and a Ser/Thr-rich polypeptide stem-like domain that is stabilized in the cell wall by *O*-linked mannan side chains. These ether-linked *O*-mannans are relatively short linear polysaccharides that consist of one to five mannose (Man) sugars, that are almost exclusively  $\alpha$ -(1,2)-linked (Fig. 2.9). *N*-mannan consists of a core  $\text{Man}_8\text{GlcNAc}_2$  triantennary complex to which a highly branched structure is attached, comprising up to 150 mannose sugars arranged as an  $\alpha$ -(1,6)-linked backbone with side chains of  $\alpha$ -(1,2)-,  $\alpha$ -(1,3)-mannose and phosphomannan (Fig. 2.9).




Fig. 2.9 The structure of the *C. albicans* cell wall[54]. Cwp stands for cell wall protein.

### 2.3.4 Respiratory chain

Mitochondria are known as the power houses of the cell, they play very important roles in a range of processes such as ATP production, electron transport, and oxidative phosphorylation, release of caspase-activating proteins, generation of reactive oxygen species (ROS) and changes of cellular redox potentials [124]. Due to these properties, mitochondria are considered to be a potential target for antifungal agents. Compounds such as rotenone, antimycin, myxothiazols, melithiazols and cystothiazoles are known to exert

their antifungal activity by specifically inhibiting the electron transport within the respiratory chain [125, 126].

The complex structure of the respiratory chain in *C. albicans* is not yet fully elucidated. As in mammalian cells, the conventional respiratory chain of *C. albicans* comprises four large respiratory chain enzyme complexes (Fig. 2.10): NADH–ubiquinone oxidoreductase (complex I), succinate dehydrogenase (complex II), ubiquinol–cytochrome c (cytochromes bc1, complex III), and cytochrome c oxidase which is the terminal oxidase (cytochrome aa3, complex IV). In each complex, electron transport is coupled to proton translocation, with the resultant proton motive force being used for ATP synthesis. Specific inhibitors are known for each complex: rotenone inhibits complex I, TTFA inhibits complex II, antimycin A and myxothiazol inhibit complex III, and cyanide inhibits complex IV. This conventional respiratory chain provides a conserved route for passing of electrons from NADH to molecular oxygen.




Fig. 2.10 Structure of respiratory chain of *C. albicans* [127]

Additional NADH dehydrogenases (internal and external, facing the mitochondrial matrix and intermembrane space) act in parallel with complex I [128]. These dehydrogenases do not translocate protons [129] and are only partially sensitive to rotenone.

In addition, *C. albicans*, in common with many other fungal species, expresses an alternative oxidase (AOX) that branches off at the level of coenzyme Q (CoQ) in response to changing environmental conditions or cellular energy demands [130, 131]. It is induced by treatment with inhibitors of complex III and IV, such as antimycin A or cyanide [132].

Also in *S. cerevisiae*, elements of the conserved respiratory chain are present, but the complex I is absent [133]. Instead, *S. cerevisiae* has three NADH dehydrogenases associated with the inner mitochondrial membrane capable of coupling the oxidation of NADH to the reduction of CoQ [134-136] (Fig. 2.11). One internal NADH dehydrogenase (NDI) faces the matrix space and utilizes mitochondrial NADH; the other two external NADH dehydrogenases face outward and can receive electrons from cytosolic NADH (NDE<sub>1</sub> and NDE<sub>2</sub>).




Fig. 2.11 Structure of respiratory chain of *S. cerevisiae*

## 2.4 Thesis aim and objectives

The aim of the thesis is to investigate the role of genistein in *C. albicans* infections. The activity of genistein was examined using a murine macrophage cell line *in vitro*. The design of the experiments is outlined in Fig. 2.12.

Experiments were designed to investigate the following specific objectives:

- ✧ To identify potential effects of genistein on the properties of the immune cells including (i) anti-inflammatory effects of genistein and (ii) elucidation of the underlying mechanism
- ✧ To determine the molecular effects of genistein on the pathogen *C. albicans* focusing on the modulation of the function of mitochondria of *C. albicans*
- ✧ To examine the effects of genistein on the interaction of macrophages and *C. albicans*
- ✧ To examine the role of single genes on the interaction of macrophages and *C. albicans* by using deletion mutants and identify the action of genistein on the mutants.

Previous investigations have demonstrated that genistein shows a variety of biological activities. For example, genistein can function as a phytoestrogen, an antioxidant, and an inhibitor of a broad range of tyrosine kinases. Those lead to its chemoprotectant activities against different types of cancers, protection of cardiovascular disease, chronic inflammatory disorders, and antiviral properties. As *C. albicans* is an opportunistic pathogen, the immune situation plays a vital role for the protection against *C. albicans* infections. An impaired immune system increases the risks to acquire opportunistic infections and uncontrolled neoplastic tissue growth; while an over-activated immune system could lead to inflammation, allergy, and autoimmunity. Therefore, we first investigated the effects of genistein on immune cells represented by the macrophages cell line RAW264.7. We tested the effects of genistein on macrophages including effects on cell proliferation, cell morphology, cell cycle, cell skeleton structure, and anti-inflammatory effects against different stimuli from bacteria and cytokines. In order to determine the mechanisms, we utilized a reporter cell line (RAW- Blue<sup>TM</sup> cells) that was stably transfected to express a secreted embryonic alkaline phosphatase (SEAP) gene inducible by NF- $\kappa$ B and

AP-1 transcription factors. Quantitative real time PCR arrays and western blotting were used to further validate the alteration in gene expression and to investigate the phosphorylation of certain proteins (Fig. 2.12, Section 5.1 and 5.2).

The investigations of the action of genistein on *C. albicans* focused on the mitochondria function. Oxygen uptake and the measurement of reactive oxygen species production were examined and compared with the action of specific respiration chain inhibitor in both organisms *C. albicans* and *S. cerevisiae*. The metabolic activity of *C. albicans* after genistein treatment was also determined by enzymatic assay (Fig. 2.12, section 5.3).

The effects of genistein against *C. albicans* infection were determined in two ways. On one hand, genistein-pretreated macrophages were infected with *C. albicans*. On the other hand, macrophages were infected with *C. albicans* which were treated with genistein. Phagocytic efficiency and cytokine production were detected. The mechanisms were investigated in both infective conditions. Cell wall components analysis and cell surface hydrophobicity were further detected to elucidate the mechanisms.

The MAP kinase pathways are related to cell wall integrity and regarded as important virulence factors regulator for *C. albicans*. We investigated the influence of single MAP kinase pathway gene deletions of *C. albicans* on the cell wall components structure and the phagocytic efficiency by macrophages. We further investigated the genistein effects on phagocytosis of the mutants to further elucidate the activity of genistein against *C. albicans* infection (Fig. 2.12, section 5.4).

## 2.5 Experimental design




Fig. 2.12 Flowchart outlining overall design of experiments undertaken in the thesis: Words in purple color represent the methods used. Part 1 shows experiments designed for investigation the influence of pre-treated macrophage with genistein. Part 2 points out experiments designed for investigation of the influence of pre-treated *C. albicans* with genistein. Part 3 shows the interaction between genistein-treated macrophage with *C. albicans* as well as the interaction between genistein-treated *C. albicans* with macrophages

## 3 MATERIALS AND METHODS

### 3.1 *Equipment and materials*

|                           |  |
|---------------------------|--|
| Analyse balance           | PC4400, Mettler Sartorius  |
| CO <sub>2</sub> Incubator | CO <sub>2</sub> -Auto-Zero, Heraeus  |
| Bunsen burner             | Fireboy, Heraeus   |
| Steam sterilizer          | 464, Sauter GTA40, Biomedis  |
| Flow cytometry & Software | FACS Canto & FACS Diva 5.0, BD Bioscience  |
| Flow cytometry & Software | FACS Canto & FACS Diva 5.0, BD Bioscience  |
| Fluorescence microscope   | Kenyence   |
| Culture shaker            | Pilot-Shake, Kühner  |
| Magnet mixer              | MR 2002, Heidolph  |
| Multi-well-Fluorimeter    | CytoFluor <sup>®</sup> Series 4000, PerSeptive Biosystems<br>Synergy 4 <sup>®</sup> BioTek   |
| pH meter                  | pH 211 Microprocessor pH Meter, Hanna<br>Instruments   |
| Pipettes                  | Research 0.1-2.5 µl 1520615,<br>Research 2-20 µl 3478105,<br>Research 20-200 µl 3612935,<br>Research 100-1000 µl 3633985,<br>Research Multichannel 10-100 µl 3263575,<br>Research Multichannel 30-300 µl 3582685,<br>Eppendorf<br>Transferpette <sup>®</sup> -8 10-100 µl 01F72011,<br>Transferpette <sup>®</sup> -12 15-300 µl 03D5931, Brand |
| Pipettinghelper           | Easypet <sup>®</sup> 4412, Eppendorf CellMate II, Matrix   |
| Plateshaker               | Titramax 1000, Heidolph  |
| Shaker                    | Heidolph Innova 2100, New Brunswick  |

|                                    |   |
|------------------------------------|---|
|                                    | Scientific  |
| Microtiter plate reader & Software | µQuant & KCjunior Installation, BioTek Instruments  |
| Sterile bench                      | HLB 2448 & HBB2472 S, Heraeus<br>Hera Safe, Thermo Electron Corp.                                     |
| Thermomixer                        | 5437, Eppendorf   |
| Oven                               | Memmert   |
| Vortexer                           | Vortex Genie 2, Scientific Industries<br>VF2, IKA®-Labortechnik                                       |
| Water system                       | MilliQ Water Purification Systems, Millipore  |
| Water bath                         | Köttermann  |
| Hemocytometer                      | <i>Neubauer improved</i> , Assistent Germany  |
| Centrifuge                         | 5804R & 5402, Eppendorf<br>Sepatech Megafuge1.0 & Biofuge <i>fresco</i> ,<br>Heraeus                  |
| ELISA washer                       | BioTek  |
| Needles                            | TSK-SUPRA 1.1x100, Luer   |
| Combitips                          | 10 ml 1=0.2 ml 12307 & 500 µl 1=10 µl 360407,<br>Eppendorf  |
| Single-use pipette                 | Costar Stipette 5 ml 4487, 10 ml 4488 & 25 ml<br>4489, Corning  |
| Cryovials                          | Nalgene® Cryoware™ 5000-0020, Nalge Nunc<br>Int.  |
| Multi-well-culture plate           | 4 Well Nunclon Surface 176740, Nunc<br>96 Well Tissue Culture Plate Flat Bottom<br>353916, BD Falcon  |
| Pipette Tips                       | epT.I.P.S. Standard 2-200 µl 0030000.870,<br>epT.I.P.S. Standard 50-1000 µl 0030000.919,<br>Eppendorf |



|                    |  |
|--------------------|--|
| Reaction tube      | Safe-Lock Tubes 1.5ml 0030120.86, Eppendorf  |
| Resevior           | 60 ml solution volume with cover, Eppendorf  |
| Cell culture flask | Corning® Flask 0.2 µM Vent Cap Angled Neck:<br>175 cm <sup>2</sup> 431080 & 75 cm <sup>2</sup> 430641, Corning<br>Tissue Culture Flask 25 cm <sup>2</sup> PS red filter cap<br>690175, Greiner Bio-one |
| Cell scraper       | 23 cm 179693 & 32 cm 179707, Nalge Nunc  |
| Centrifuge tubes   | 15 ml volume AN77.1 Roth<br>50 ml volume 430291 & 430921, Corning  |
| Oxoplate®          | Presens, Regensburg  |

## 3.2 Methods

### 3.2.1 Sterile Conditions

All work with yeasts and phagocytic cells were conducted under sterile conditions. Glassware (shaker flask, glass pipettes, etc.) were sterilized at 180 °C for six hours. Solutions, media and plastic materials (eg. pipette tips) were steam sterilized at 121 °C for 20 min; alternatively, solutions that were not suitable for steam sterilization were sterilized with a filter pore size of 0.2 microns (Millipore). All ready to use media and materials were purchased sterile from manufacturer.

### 3.2.2 Preparing PBS

The buffered, isotonic saline PBS (phosphate buffered saline) from tablets of Invitrogen (18912-014), was prepared according to manufacturers instructions: one pill (5 g) is solved in 500 ml MilliQ-water, and adjusted to pH=7.4 with hydrochloric acid (HCl).

### 3.2.3 Cell number counting

The determination of the number of yeast and macrophages cells was carried out by using a Neubauer improved Hemocytometer (Fig. 3.1). It consists of nine large squares, each with an area of 1 mm<sup>2</sup>. Largest square in the center is divided into 5 × 5 small squares (each 0.04 mm<sup>2</sup>), which in turn consists of 4 × 4 midget squares (each 0.0025 mm<sup>2</sup>). The chamber depth is 0.1 mm. For the cell counting, the chamber was filled with 10 µl well mixed cell suspension and the cells were

counted under the microscope. The macrophages were counted within the four corner squares (big red square); cells which were located on the outer boundary lines were not been included. Subsequently, cell number was divided by four in order to obtain the mean value for each corner squares. The volume per corner square of a chamber is 0.1  $\mu\text{l}$ , so this average was multiplied by  $1 \times 10^4$  in order to determine the number of cells per milliliter. For the determination of the concentration of yeast, cells were counted for five small squares (small red square) within the central large squares. The amount corresponded to the number of cells per 0.02  $\mu\text{l}$  cell suspension, so this number was multiplied by  $5 \times 10^4$  to identify the yeast concentration per milliliter. To avoid too high cell density, the counting was carried out by dilution of the cell suspensions in PBS and the dilution factor was included in the calculation of cell number.




Fig. 3.1 Scheme of Neubauer improved Hemocytometer [137]

### 3.2.4 Data analysis and Programmes

The text, graphics and tables of this work were created with the programmes Microsoft® office 2007 (Microsoft Corp.) and OriginPro70 (Origin Lab Corp.). Significance of the data was evaluated using the student's t-test.

## 3.3 Cell culture

### 3.3.1 Cell culture media and ingredients

In Tab. 3.1, the cell culture medium and ingredients are listed. The DME medium was stored at 4 °C. 5 ml Pen-Strep solution and 50 ml FBS were added to 500 ml of DME medium before use. For RAW-Blue<sup>TM</sup> cells, 200  $\mu\text{g/ml}$  Zeocin<sup>TM</sup> was additionally added to the prepared DMEM,

FBS was previously heat treated at 55 °C for 30 min. The media were warmed in a water bath at 37 °C before use. The freezing medium was purchased and stored in 5 ml aliquots at -20 °C.

Tab. 3.1 Cell culture medium and components

|  | Company    | Article number |
|--|------------|----------------|
| DMEM<br>( <i>Dulbecco's modification of Eagle's medium</i> ) | Lonza      | BE12-741F      |
| Frozen medium (with DMSO)                                    | Invitrogen | 12648-010      |
| FBS ( <i>fetal bovine serum</i> )                            | Lonza      | 14-801F        |
| 100x Pen-Strep ( <i>Penicillin-Streptomycin</i> )            | Sigma      | P0781          |
| Zeocin <sup>TM</sup>   | Invivogen  | ant-zn-5b      |

### 3.3.2 RAW264.7

RAW264.7 cells are murine macrophages [138]. The cell line was purchased from the American Type Culture Collection (ATCC; TIB-71) and was cultivated immediately as indicated by ATCC after delivery.

### 3.3.3 RAW-Blue<sup>TM</sup>

RAW-Blue<sup>TM</sup> cells (InvivoGen; #raw-sp), derived from murine macrophages, are designed for the study of pattern recognition receptors (PRRs). They express a large repertoire of different classes of PRRs, such as the Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs).

They stably express a secreted embryonic alkaline phosphatase (SEAP) gene inducible by NF-κB and AP-1 transcription factors. RAW-Blue<sup>TM</sup> cells are resistant to the selection marker Zeocin<sup>TM</sup>. Upon TLR, RLR or NOD stimulation, RAW-Blue<sup>TM</sup> cells activate NF-κB and/or AP-1 leading to the secretion of SEAP which is easily detectable and measurable when using QUANTI-Blue<sup>TM</sup> as substrate.

### 3.3.4 Cultivation

The adherent RAW264.7 cells were grown in tissue culture flasks at 37 °C and 10 % CO<sub>2</sub>. The volume of DMEM was different by the size of the culture flask (Tab. 3.2). After reaching a confluence of approximately 80 %, the cells were harvested and passaged by scraping with a cell scraper and mixing the cells by repeated pipetting up and down with a glass pipette. Finally, an

aliquot (5-10 %) of the culture volume was transferred into a new culture flask and again grown to confluence.

The cultivation of RAW-Blue™ cells is done in the same way as RAW264.7 cells.

Tab. 3.2 Culture volume of different tissue culture flasks

| Surface of the bottle [cm <sup>2</sup> ] | Volume [ml] |
|--|-------------|
| 25                                       | 10          |
| 75                                       | 30          |
| 175                                      | 50          |

### 3.3.5 Long-term storage

80 % of confluent cells in a 25 cm<sup>2</sup> culture flask were washed with 10 ml PBS, scraped, transferred into a 15 ml centrifuge tube and harvested by centrifugation (3000 rpm, 5 min, 4 °C). Subsequently, the supernatant was decanted; the cell pellet was resuspended in 1 ml of ice cold freezing medium and transferred into cryogenic vials. The cells were stored for 24 hours at -80 °C before they are permanently stored in liquid nitrogen at -196 °C. To reactivate, the cells were thawed as quickly as possible at 37 °C, and transferred into a 25 cm<sup>2</sup> culture flask with 10 ml DMEM medium to dilute the DMSO in the freezing medium. Once the cells had attached the bottom, the medium was changed to the complete removal of DMSO and the cells were cultured as described in (3.3.2).

### 3.3.6 WST-1 toxicity assay

The determination of cell vitality after a compound treatment was conducted using a tetrazolium salt, which is a redox indicator. In metabolically active cells, the tetrazolium ion is reduced by the dehydrogenases of the respiratory chain to formazan (Fig. 3.2). The formation of formazan results in a color change and can be detected and quantified by measuring the absorbance at the respective wavelength. In our work, the water soluble tetrasolium salt WST-1 (4-[3-(4-Jodophenyl)-2-(4-nitrophenyl)-2H-5-Tetrazolio]-1.3-Benzoldisulfonate) from Roche Diagnostics (11644807001), was used. The reduction of WST-1 results in a water-soluble yellow product, which can be quantified at the wavelength of 450 nm.

100 µl of RAW264.7 cells were seeded into 96-well cell culture plates at  $2 \times 10^6$  cells / mL,  $1 \times 10^6$  cells / ml and  $5 \times 10^5$  cells / ml in DMEM containing various concentrations of genistein

(Sigma: G6649). The cells were incubated for 2 h, 24 h and 48 h under normal cell culture condition. Subsequently, 10  $\mu$ l WST-1 per well were added and the plate was placed on a plate shaker for 1 min to ensure optimal mixing. After 30 min incubation at 37 °C and 10 % CO<sub>2</sub>, the plate was analysed in a microtiter plate reader. For data analysis the mean value and standard deviation were determined from 8 replicates.




Fig. 3.2: Principle of the toxicity tests cleavage of the tetrazolium salt WST-1 to formazan. (EC = electron coupling reagent RS = mitochondrial succinate-tetrazolium-reductase system) (Invitrogen)

### 3.3.7 Cell cycle analyses

The distribution of cells at the different stages in the cell cycle was estimated by flow cytometric DNA analysis. Propidium iodide is a fluorescence dye which can bind directly to the DNA in the nucleus, hence the measurement of the fluorescence provides a measure of the amount of dye taken up by the cell and indirectly the amount of DNA content. Cells were harvested and counted when the cells are up to approximately 80 % of confluence,  $5 \times 10^5$  cells / ml were incubated for 24 h and 48 h with or without various concentrations of genistein. Cells from the different conditions were harvested and washed in the cold phosphate-buffered saline (PBS) pH=7.4, fixed in 70 % cold ethanol and stored at 4 °C until processing. The fixed cells were washed with cold PBS twice, then treated with flurochrome DNA staining solution (0.5 ml) containing propidium iodide (Sigma: P4170) (20  $\mu$ g / ml) and RNase A (1 mg / ml) (Carl-Roth: 2326466) for 1 hour, than the stained cells were analyzed by flow cytometry. The percentage of cells in each cell cycle phase was calculated by using Flowjo 7.5 software, 10000 cells per sample were be evaluated in each case.

### 3.3.8 Fluorescence labelling of F-actin and cell nuclei

The RAW264.7 cells were cultured and harvested and the concentration of cells was determined by counting. Subsequently, RAW264.7 cells suspension was prepared with  $1 \times 10^5$  ml

in DMEM with 2 nM cytochalasin B (Sigma: C6762), 0.1 % DMSO (Biozol: EMR385250) and genistein 25 and 12.5  $\mu$ M. 500  $\mu$ l of the respective suspension were seeded into 4 well plates and cultured for 48 hours under standard conditions. Then, the supernatant was removed and the cells were washed twice with 750  $\mu$ l PBS. After washing, the cells were fixed by addition of 750  $\mu$ l 3.7 % paraformaldehyde (PFA) for 15 min at room temperature. They were then again washed twice with PBS to remove the PFA and the cells were incubated with 750  $\mu$ l 0.1 % Triton X in PBS for 5 min to permeabilize. After permeabilization, cells were washed twice with PBS and finally, 500  $\mu$ l Alexa Fluor<sup>®</sup> 488-phalloidin (2 U/ml in PBS containing 10% FBS, Invitrogen: 12379) was added for 1 hour at 37 °C in 10 % CO<sub>2</sub>. Since phalloidin specifically binds the F-actin, the actin filaments of the cells were fluorescently labeled. Then the cells were washed twice with PBS to remove unbound dye and stored in 500  $\mu$ l PBS. 1 $\mu$ g/ml of DAPI (Invitrogen: P36931) was added into the wells, It can bind to the nuclei of the cells. Specimens were examined using fluorescence microscope.

### 3.3.9 Detection of nitric oxide by Griess reagent

Nitric oxide (NO) is an important physiological messenger and effector molecule in many biological systems, including immunological, neuronal and cardiovascular tissues( this depends more to the introduction) The indirect evidence of the release of nitric oxide (NO) by RAW264.7 cells was carried out by Griess reaction [139]. NO, the unstable radical in aqueous solution, reacts with oxygen to form nitrite (NO<sub>2</sub><sup>-</sup>) and a smaller amount of nitrate (NO<sub>3</sub><sup>-</sup>) [140]. The detection is based on the chemical reaction (Griess-reaction) shown in Fig. 3.3, which uses sulfanilamide and N-1-naphthylethylenediamine dihydrochloride (NED) under acidic (phosphoric acid) conditions. The product of this reaction can be detected at 540 nm using a photometer.




Fig. 3.3 Chemical reactions involved in the measurement of NO<sub>2</sub><sup>-</sup> using the Griess Reagent (Roche).

### 3.3.9.1 Sample preparation

RAW264.7 cells were grown up to a confluence of approximately 80 % in standard conditions of cultivation and counted. 100  $\mu$ l of  $1 \times 10^6$  / ml cells suspension in DMEM were seeded into the wells of a 96-well plate, so that there were  $1 \times 10^5$  cells per well. The cells were pretreated with different concentrations of genistein (0-100  $\mu$ M) or other inhibitors (Tab. 3.3) for 1 hour and then stimulated with LPS (100 ng / ml) for another 20 hours. Finally, 50  $\mu$ l supernatant per well were transferred by a pipette to a reduced volume 96 well microtiter plate and then used for all other experiments. Cell viability was detected by WST-1 in parallel following the protocol described in 3.3.6.

Tab. 3.3 Specific inhibitors used in the experiment

| Inhibitor        | Target      | Company                             | Solvent | Stock concentration | Working concentration |
|------------------|-------------|-------------------------------------|---------|---------------------|-----------------------|
| AG490            | Jak2 (PTK)  | Biaffin( PKI-AG490-010)             | DMSO    | 34 mM               | 0.16-340 $\mu$ M      |
| PP2              | Src (PTK)   | Biaffin(PKI-PP2-001)                | DMSO    | 3.3 mM              | 0.4-33.3 $\mu$ M      |
| Syk inhibitor    | Syk (PTK)   | Calbiochem (574712)                 | DMSO    | 14 mM               | 1.6-14 $\mu$ M        |
| PD98059          | MEK1/2      | Biaffin (PKI-PD98059)               | DMSO    | 18 mM               | 6.7-180 $\mu$ M       |
| SB203580         | P38MAPK     | Biaffin (PKI-SB203-001)             | DMSO    | 4 mM                | 2.2-20 $\mu$ M        |
| U1026            | MEK1/2      | Cell signalling (9903)              | DMSO    | 10 mM               | 10 $\mu$ M            |
| LY294002×HCL     | PI3-Kinase  | Sigma (L9908)                       | DMSO    | 2 mM                | 0.27-22.2 $\mu$ M     |
| Wortmanin        | PI3-Kinase  | Sigma (W1628)                       | DMSO    | 233 $\mu$ M         | 0.013-23.3 $\mu$ M    |
| Akt1/2 inhibitor | Akt1/2      | Sigma (A6730)                       | DMSO    | 9 mM                | 0.4-33.4 $\mu$ M      |
| Bpv(phen)        | Phosphatase | ALEXIS<br>Biochemicals(ALX-270-204) | Water   | 14 mM               | 1.6-14 $\mu$ M        |

### 3.3.9.2 Detection of nitrite in cell culture

A standard method for detection of sodium nitrite ( $\text{NaNO}_2$ ) was used. Griess reagent was prepared by 1:1 mixing sulfanilamide (1 % in 5 %  $\text{H}_3\text{PO}_4$ ) and N-(1 naphthyl) ethylenediamid (0.1 % dissolved in 5 %  $\text{H}_3\text{PO}_4$ ). Samples prepared in 3.3.9.1 were mixed with 50  $\mu$ l of the Griess reagent for 10min at room temperature. The calibration was made by dilution of  $\text{NaNO}_2$  (100 mM  $\text{NaNO}_2$  in  $\text{H}_2\text{O}$ ) to a concentration range from 0 to 100  $\mu$ M by DMEM, 50  $\mu$ l of this solution were mixed with 50  $\mu$ l of the reagent, the samples were measured at 540 nm. For data analysis, a linear regression equation was calculated according to the values of the standard series. With this linear regression equation the nitrite concentration in the cell culture suspension was determined.

### 3.3.10 Cytokine determination

#### 3.3.10.1 Principle of the ELISA method

The cytokine production by LPS stimulated macrophages was detected by Enzyme linked immunosorbent assay (ELISA) [141]. The principle of the method is shown below:




Fig. 3.4 Principle of a sandwich ELISA (1) The ELISA plate is coated with a capture antibody (red); (2) Sample is added, and the respective antigen present binds to capture antibody (green); (3) Biotin-conjugated secondary detection antibody (blue/orange) is added, and binds to the antigen captured by the first antibody; (4) Streptavidin-HRP is added and binds to the biotin conjugated detection antibody (dark blue); (5) Coloured product (light blue) is formed in proportion to the amount of antigen present in the sample; The reaction is terminated by addition of acid and absorbance is measured at 450 nm.

#### 3.3.10.2 Sample preparation

RAW264.7 cells were grown up to a confluence of approximately 80% in standard conditions of cultivation and counted. For TNF- $\alpha$ , 100  $\mu$ l of  $1 \times 10^5$  / ml cells suspended in DMEM were seeded into the wells of a 96-well plate. For IL-6 and IL-10, 100  $\mu$ l of  $5 \times 10^5$  / ml cells suspended in DMEM were seeded into the plate. The cells were pretreated with different concentrations of genistein or other inhibitors (Tab. 3.3) for 1 hour and then stimulated with 10  $\mu$ l (1  $\mu$ g / ml) LPS. The incubation time differed according to the interesting cytokines. For TNF- $\alpha$  determination the concentrations were detected after a incubation time of 1 and a half hour, IL-6 were determined after 5 hours and IL-10 concentrations were determined after 6 hours. Finally, the supernatant was collected and stored at -20 °C. Cell viability was detected by WST-1 in parallel following the protocol described in 3.3.6.



## 3.3.10.3 ELISA-protocol

Tab. 3.4 Reagents from ELISA READY SET GO! Kit-systems

|                            |  |
|----------------------------|--|
| <b>Coating buffer</b>      | PBS-powder dissolved in 1L MillQ H <sub>2</sub> O; 00-0044-59  |
| <b>Coating antibody</b>    | 250 times concentrated, diluted in coating buffer<br>IL-10-Coating: anti-Mouse-IL-10; 88-7104-CP<br>IL-6-Coating: anti-Mouse-IL-6; 88-7064-CP<br>TNF $\alpha$ -Coating: anti-Mouse-TNF $\alpha$ ; 88-7324-CP                     |
| <b>Block buffer</b>        | 5 times concentrated in MillQ. H <sub>2</sub> O; 00-4202-AD2   |
| <b>Detections antibody</b> | 250 times concentrated, diluted in block buffer, biotin-coupled<br>IL-10-Detection: anti-Mouse-IL-10; 88-7104-DT<br>IL-6-Detection: anti-Mouse-IL-6; 88-7064-DT<br>TNF $\alpha$ -Detection: anti-Mouse-TNF $\alpha$ ; 88-7324-DT |
| <b>Avidin-HRP</b>          | 250 times concentrated, diluted in block buffer; 00-4100-EN2   |
| <b>Substrate</b>           | TMB solution, ready to use; 00-4201-SB   |
| <b>Standard</b>            | Recombinant mouse cytokine 1 $\mu$ g/ ml, dilution series in DMEM<br>IL-10; 88-7104-ST<br>IL-6; 88-7064-ST<br>TNF $\alpha$ ; 88-7324-ST  |

The reagents used in the assay are listed in Tab. 3.4, the protocol is described as below:

A reduced volume 96 well plate was filled with capture antibody in coating buffer (50  $\mu$ l / well) and incubated over night at 4 °C. On the next day, the antibody solution was removed and the plate was washed with 150  $\mu$ l wash buffer (PBS with 0.05 % Tween 20) at least 5 times. To increase the effectiveness of the washes, the plate was blotted on absorbent paper to remove any residual buffer. Then the wells were blocked with 1X assay diluents, incubated at room temperature for 1 hour, washed and 50  $\mu$ l / well of samples were added. Standard serial dilutions were added to the appropriate wells for 2 hours, after washing, 50  $\mu$ l / well of detection antibody diluted in 1X assay diluents were added for 1 hour. The plate was washed and then 50  $\mu$ l / well of AvidinHRP\* for 30 minutes were added. This was repeated for a total of 7 washes; then 100  $\mu$ l / well of substrate solution to each well were added for 15 minutes. Finally, 50  $\mu$ l of 2 M sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) were added to each well to stop the enzymatic reaction. The plate was measured plate at 450 nm.

For data analysis, a linear regression equation was calculated according to the values of the standard series. The cytokine concentration in the cell culture suspension was calculated by the linear regression equation. Data were represented as means  $\pm$  the standard deviation.

### **3.3.11 Detection of NF- $\kappa$ B and AP-1 activation of RAW-Blue<sup>TM</sup> Cells**

The RAW-Blue<sup>TM</sup> cells were harvested and counted when the cells were grown up to a confluence of approximately 80 % in standard conditions of cultivation. 180  $\mu$ l of  $5 \times 10^5$  / ml of RAW-Blue<sup>TM</sup> cells were seeded in 96 well plates and treated with genistein (0-100  $\mu$ M) 1 hour before stimulation with 10  $\mu$ l of LPS (1  $\mu$ g / ml), incubated in normal culture condition for 20 h. 40  $\mu$ l of induced RAW-Blue<sup>TM</sup> cells supernatant were taken into a flat bottom 96 well plate, 160  $\mu$ L of resuspended QUANT-Blue<sup>TM</sup> (#rep-qbl) was added, SEAP levels were determined at OD 620nm.

### **3.3.12 RT<sup>2</sup> Profiler<sup>TM</sup> PCR Array (PAMM-018G) for Toll-like receptor pathway**

RAW264.7 macrophages were grown up to a confluence of approximately 80 % in standard conditions of cultivation and counted. The cells were seeded in 25 cm<sup>2</sup> flask with the  $2 \times 10^5$  / ml and cultivated overnight. On the next day, the cells were incubated with or without genistein 50  $\mu$ M for 1 hour before stimulation with LPS (final concentration 100 ng / ml) for 6 h. Total RNA was prepared from cells using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was reconstituted in RNase free water; concentration and purity were determined using UV spectrophotometry. RNA integrity was verified by gel electrophoresis.

A total of 0.5  $\mu$ g RNA was used with RT<sup>2</sup>First Strand kit (C-03) (Superarray, Fredrick, MD) with the addition of 2  $\mu$ l of 2GE (5x gDNA elimination buffer). The RNA was incubated at 42°C for 5 minutes and placed on ice of 1 minute. RT cocktail of 4  $\mu$ l of BC3 (5x RT buffer 3), 1  $\mu$ l of P2 (primer & external control mix), 2  $\mu$ l RE3 (RT enzyme mix) and 3  $\mu$ l of RNase free water was added to each sample. The mixture was carefully pipetted and incubated at 42°C for 15 minutes and then heated at 95 °C for 5 minutes and placed on ice. 91  $\mu$ l of double distilled water was added to each 20  $\mu$ l of cDNA synthesis reaction. PCR was performed using 10  $\mu$ l of the following mixture: 2000  $\mu$ l of 2x SuperArray RT<sup>2</sup> qPCR Master Mix, 102  $\mu$ l diluted first strand cDNA synthesis reaction and 1898  $\mu$ l of double distilled water in the wells of a 384-well microtiter plate. The amplification process included 1 cycle for 10 mins at 95°C, 40 cycles for 15 secs at 95°C, followed by 40 cycles for 1 min at 60°C.

Thermal cycling and fluorescence detection were performed using LightCycler 480 (Roche). The signals of the target cDNAs were normalized by comparison with the housekeeping genes (GAPDH, Actin, GUSB, HPRT1, HSP90, reverse transcription control, and positive PCR control) supplied within the 384-well microtiter plate. Final calculations were made using a web-based PCR Array Data Analysis tool (Superarray, Fredrick, MD).

### **3.3.13 Western Blot**

RAW264.7 macrophage cells were grown up to a confluence of approximately 80 % in standard conditions of cultivation and counted. The cells were pretreated with or without DMSO (as control), 100  $\mu$ M genistein, 100  $\mu$ M PD98059, 12  $\mu$ M SB203580 or 10  $\mu$ M U1026 for 1 hour and then stimulated with LPS (100 ng / ml) in the presence of the inhibitors for 15 and 30 min. Cells were washed with ice-cold PBS and scrapped. The whole cell lysates were prepared in ice-cold lysis buffer (50 mM Tris/HCl pH 7.5; 150 mM NaCl; 2 mM EDTA; 1 % Triton; 0.5 % Nonidet p-40 (Sigma); 100  $\times$  phosphatase and protease inhibitor cocktail set I (Roche, Calbiochem)). Lysates were clarified by centrifugation. Proteins were quantified by BCA assay and 30  $\mu$ g protein/lane resolved by electrophoresis on 10-12 % SDS-PAGE. Resolved proteins were transferred onto PVDF membrane (Biorad, USA) by semi-dry transfer in blot buffer (Tris 50 mM, Glycine 40 mM, 0.01 % SDS, and 4 % methanol) at 250 mA for 1 hour using the Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Biorad, USA). Membranes were probed with primary antibody followed by HRP conjugated secondary antibody and detection by ECL chemi-illuminescence (RPN2132, Amersham, GE healthcare, USA). All primary antibodies were purchased from cell signal. Phospho-ERK1/2 pathway sample kit (9911), phospho-p38 MAPK (Thr180/Tyr182) (3D7) (9215) and P38 MAP kinase alpha (L53F8) mouse mAb (9228) were used at concentrations of 1:1000. Secondary antibodies were used at dilutions of 1:6666.

### **3.3.14 Receptor staining of macrophages RAW264.7**

RAW264.7 macrophage cells were grown up to a confluence of approximately 80% in standard conditions of cultivation and counted. 1 ml of  $10^6$  cells / ml were washed with PBS containing 2 % FBS. The surface dectin-1 or TLR2 receptor expressions were detected respectively using TLR2 mAb (SC-52736, Santa Cruz Biotechnology, USA) or recombinant mouse Dectin-1/CLECA7 mAb (1756-DC-050, R&D Systems, USA). The cells were incubated for 1 hour with 200  $\mu$ l of the antibody solution which was prepared by a 1 / 50 dilution of the delivered antibody. For detection of the primary antibody, cells were washed 3 times in PBS

containing 2 % FBS and incubated for 45 min with the Alexa Fluor 488-labeled anti-mouse antibody from goat as secondary antibody diluted 1 / 250. As negative control yeast cells were incubated only with the secondary antibody. All reactions were performed at room temperature. After washing, cells were fixed in 0.4 % formalin and analyzed by flow cytometry.

Flow cytometry was performed with an FACS Canto equipped with an argon ion laser with an excitation power of 20 mW at 488 nm. Forward and side light scatter were analyzed on linear scales, while fluorescence intensity was determined on logarithmic scales. Analysis gates were set around debris and intact cells on a forward and side light scatter dot plot. The fluorescence histograms of 10,000 cells were generated using gated data. Data analysis was performed using Flowjo 7.5.

### 3.4 Work with yeast

#### 3.4.1 Yeast strains

All the *C. albicans* strains used in the experiment are listed in Tab.3.5. These were provided by R. Calderone (Georgetown University, USA) and Jesus Pla (Universidad Complutense de Madrid, Spain). In addition, the *S. cerevisiae* strain BY4741 was established in Euroscarf (Johann Wolfgang Goethe-University, Frankfurt am Main).

Tab. 3.5 *C. albicans* strains used in this study

| Strains       | Synonym  | Genotype   | Reference |
|---------------|----------|--|-----------|
| CAF2-1        |          | $\Delta ura3::imm434/URA3$   | [142]     |
| $\Delta chk1$ | CHK21    | $\Delta ura3::imm434/\Delta ura3::imm434$<br>$\Delta cahl1::hisG/\Delta cahl1::hisG-URA3-hisG$ | [115]     |
| $\Delta cek1$ | CK43B-16 | $ura3/ura3\Delta cek1::hisG/\Delta cek1::hisG-URA3-hisG$                                       | [143]     |
| $\Delta mck1$ | CM1613   | $\Delta mck1::hisG/\Delta mck1::hisG-URA3-hisG$  | [143]     |
| $\Delta hst7$ | CDH12    | $ura3/ura3\Delta hst7::hisG/\Delta hst7::hisG$   | [144]     |
| $\Delta pbs2$ | BRD3     | $\Delta pbs2::cat/\Delta pbs2::cat-URA3-cat$   | [117]     |
| $\Delta hog1$ | CNC13    | $hog1::hisG/hog1::hisG-URA3-hisG$<br>$\Delta his1::hisG/\Delta his1::hisG$                     | [145]     |

#### 3.4.2 Preparation of YPD and YP galactose medium

YPD medium (yeast extract peptone dextrose) is a complex culture medium from yeast

extract, peptone and glucose which was used for the cultivation of yeasts. The YPD medium was purchased from Sigma (Y1375) and according to the manufacturer's specifications 50 g of powder were dissolved in 1L MilliQ water. The sterilization of the medium was done as described in 2.3.1.

YP galactose medium is a complex culture medium from yeast extract 10 g, peptone 20 g and galactose 20 g dissolved in 1L MilliQ water. The sterilization of the medium was done as described in 3.2.1

### **3.4.3 Storage and cultivation**

1 ml yeast suspension from the stationary growth phase was stored in cryogenic tubes with YPD medium at -80 °C. For using, a tube was thawed at room temperature and cultivated overnight in an Erlenmeyer flask (100 ml) volume of 20 ml YPD medium at 30 °C with shaking (160 rpm). The next day, the yeast cells were used for an experiment or frozen for new storage.

### **3.4.4 Labelling yeast with fluorescence dye**

The fluorescent labelling of yeast cells was carried out by the coupling of the fluorescein derivative fluorescein isothiocyanate (FITC) to amino groups of cell wall components of yeast. Yeasts were cultured in YPD medium as described in 3.4.3 and the cell number was determined (3.2.3). Subsequently,  $1 \times 10^8$  yeast cells were transferred into a 1.5 ml reaction tube filled with PBS to 1 ml, harvested by centrifugation ( $16\,000 \times g$ , 5 min, 24 °C). The supernatant was discarded and the pellet was resuspended in 1 ml PBS. This washing step was repeated twice before the yeasts were added in 1 ml of a dye solution of the dye (Tab. 3.6) and incubated overnight at 4 °C. The next day, the yeasts were washed three times with 1 ml of PBS, either used immediately or stored until use at -20 °C.

Tab. 3.6 Property of the fluorescence dye

|                            | <b>FITC</b>                                      |
|----------------------------|--|
| <b>Company</b>             | Sigma  |
| <b>Article number</b>      | F7250  |
| <b>Coupling group</b>      | Isothiocyanate                                   |
| <b>Excitationmax.</b>      | 495 nm   |
| <b>Emissionsmax</b>        | 519 nm   |
| <b>Storage</b>             | 100 mg/ml in DMSO,<br>-20 °C                     |
| <b>Final concentration</b> | 1.25 mM (500 µg/ml)                              |
| <b>Stain buffer</b>        | 0.1 mM NaHCO <sub>3</sub> + 0.5%<br>DMSO, pH 9.0 |

### 3.4.5 *Genistein- treated C. albicans*

From the overnight cultures of yeast, the concentration of yeast suspension was determined. The yeasts were diluted into OD=0.2 in 20 ml YPD. After 2 hours preculture, the yeasts were diluted into OD=0.1 and different concentration of genistein were added for another 24 hours. The yeasts were then prepared for further experiments.

### 3.4.6 *Growth curve of yeast*

The investigation of the growth of yeast was based on the measurement of optical density (OD) of yeast suspensions using a multi-well photometer. The yeasts from an overnight culture were transferred (180 µl / well) into a column in a 96-well culture plate and measured at 620 nm. This preculture was diluted to an optical density (620 nm) of 0.2, for 2 h growth and started with OD=0.1 for working culture with or without genistein 100 µM treatment in YP galactose medium and determined the OD hourly by the microtiter plate reader µQuant.

### 3.4.7 *Measurement of oxygen consumption*

The test organisms *S. cerevisiae* BY4741 and *C. albicans* CAF2-1 were grown in YPD medium overnight at 30 °C on a shaker. The culture was diluted into OD=0.2 in 20 ml YP galactose. After 2-3 hours preculture, this culture was then diluted to an optical density (620 nm) of 0.15 (for *S. cerevisiae*) and 0.05 (for *C. albicans*) determined by the microtiter plate reader

μQuant.

Oxygen consumption was measured by a fluorometric assay as previously described [146]. Round-bottomed OxoPlates<sup>®</sup> (PreSens, Regensburg, Germany) were used instead of the clear polystyrene microtiter plates. In a 96 well round-bottomed OxoPlates<sup>®</sup> (PreSens, Regensburg, Germany) (Greiner, Recklinghausen, Germany), compounds were serially diluted by a factor of 3. In the first column 30 μl of the working solution was added to 60 μl YP galactose medium; the other columns contained 60 μl medium to which 30 μl was added from the preceding column. By this procedure not only the compounds were serially diluted but also the amount of solvent, which was still 33% in the first column at this stage. Finally, for inoculation 120 μl of the diluted cell suspension was added. For *C. albicans*, all experiments were started with OD=0.05; for *S. cerevisiae*, OD started with 0.15. The plates were then incubated at 30 °C and 650 rpm using the Heidolph instruments Titramax 1000 shaker.

The determination was done as described by the manufacturer i.e. fluorescence of the indicator and the reference dye was determined with a fluorescence microtiter plate reader (Cytofluor, Reader Series 4000, PerSeptive Biosystems) from the bottom using the excitation wavelength  $\lambda_{\text{ex}}$  530 nm and the emission wavelength  $\lambda_{\text{em}}$  620 nm for the indicator and  $\lambda_{\text{ex}}$  530 nm /  $\lambda_{\text{em}}$  590 nm for the reference dye. Calibration was done with water saturated with air (100%) and with an aqueous Na<sub>2</sub>SO<sub>3</sub> solution 1 g / 100 ml (0%) according to the supplier's protocol.

### 3.4.8 Measurement of ROS accumulation

Endogenous amounts of ROS in yeasts were measured by a fluorometric assay using H<sub>2</sub>DCFDA, SE (Invitrogen, catalog number D-2935) as a ROS indicator as previously described [147]. The succinimidyl ester of 2', 7'-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA), is a chemically reduced and acetylated form of the highly fluorescent dye 2',7'-dichlorofluorescein (DCF) (Fig. 3.5).

Logarithmically growing *C. albicans* cells were suspended in sterile water to OD=0.5. Then H<sub>2</sub>DCFDA, SE was added from a stock solution of 2 mg/ml in DMSO to a final concentration of 40 μg/ml. After 30 min of incubation at 30 °C, the cells were collected by centrifugation and resuspended in sterile water. Then 120 μl of this mixture were added to a dilution series of genistein, rotenone and antimycin in a 96 well microtiter plate. The development of fluorescence was monitored after 2 hours at 30 °C at  $\lambda_{\text{ex}}$ =485 nm and  $\lambda_{\text{em}}$ =535 nm through the bottom of the plates by a fluorescence multi-well plate reader.




Fig. 3.5 Principle of the detection: Nonfluorescent 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H<sub>2</sub>DCFDA) permeates live cells and is deacetylated by nonspecific intracellular esterases. In the presence of ROS, which are produced throughout the cell, particularly during oxidative stress, the reduced fluorescein compound is oxidized and emits bright green fluorescence.

### 3.4.9 Spectrophotometric assay of complex I activity with *C. albicans*

From overnight cultures of *C. albicans*, precultures were prepared by diluting the overnight culture to an optical density (OD at 620nm) of 0.2 determined with the  $\mu$ Quant microtiter plate reader by taking 180  $\mu$ l cell suspensions from overnight culture. This culture was allowed to grow for 2-3 hours until the exponential growth phase was reached. Then working cultures were prepared by diluting the pre-culture to OD<sub>620nm</sub> = 0.1, and adding of 12.3  $\mu$ l of either DMSO or genistein and rotenone from the 200 mM stock solution, so that the final concentration of genistein was 123  $\mu$ M, the final concentration of rotenone was 63.3  $\mu$ M. The samples were taken after 3 hours by centrifugation. OD was measured in parallel. The supernant was discarded and the pellet was washed carefully with PBS at pH=7 for 2 times. The pellet was then suspended in 1 ml PBS.

To assay the redox activity of the complex I within the microorganisms, in the normal 96 well plate 20  $\mu$ l from the yeast suspension were added in the first 3 wells of the plate and then 160  $\mu$ l of DCIP (dichlorophenolindophenol) (D1878, Sigma) with 40  $\mu$ M in PBS at pH 7 was added. Measurement of the change in the DCIP color at different times was carried out at 600 nm with the microtiter plate reader  $\mu$ Quant.

### 3.4.10 Ethanol determination

From overnight cultures of *C. albicans* and *S. cerevisiae* precultures were prepared by diluting the overnight culture to an optical density (OD at 620nm) of 0.2 determined with the  $\mu$ Quant microtiter plate reader, using 180  $\mu$ l cell suspensions in 20 mL YPD. This culture was allowed to grow for 2-3 hours until the exponential growth phase was reached. Then working cultures were prepared by diluting the pre-culture to OD<sub>620</sub> = 0.1 and 10  $\mu$ l of either DMSO or



genistein from the 200 mM stock solution were added so that the final concentration of genistein was 100  $\mu$ M. For ethanol determination 200  $\mu$ L were taken as sample from the culture every hour and immediately centrifuged at 14,000 rpm and 4 °C for 10 minutes. The supernatants were stored in liquid nitrogen until ethanol was determined.

Ethanol was determined as described previously [148]: All solutions of the enzyme mix were prepared in 100 mM NaPP buffer, or which 4.46 g were solved in 100 ml water. The pH was adjusted with phosphoric acid. The enzyme mix comprised alcohol dehydrogenase (ADH; 288 U / mg; Fluka; stock solution: 3 U /  $\mu$ l NaPP, pH 7.5) and NAD<sup>+</sup> (Biomol; stock solution: 11 Mm in NaPP, pH 8.5). For the preparation of the enzyme mix, 33  $\mu$ l ADH were added to 5 ml NAD<sup>+</sup> solution. Ethanol standards (50 mM) were prepared in YPD. In each well, 5  $\mu$ l of the sample or the standard solution was placed, and the reaction was started by the addition of 45  $\mu$ l of the enzyme mix. After incubation at room temperature for 30 min, the absorbance at 340 nm was determined with the microtiter plate reader ( $\mu$ Quant, Biotek). Four aliquots of each sample were analyzed.

### **3.4.11 Flow cytometric analysis of cell wall glucans and mannans**

#### **3.4.11.1 $\beta$ -(1,3)-glucans analysis**

The accessibility of  $\beta$ -1, 3-glucans on the yeast cell wall was investigated by flow cytometry. The methods were performed according to Jouault et al [149].  $\beta$ -1, 3-glucans were stained by a monoclonal antibody: 1 ml of 10<sup>6</sup> cells / ml were washed with PBS containing 2 % FBS and then incubated for 1 hour with 200  $\mu$ l of the antibody solution which was prepared by an 1 / 150 dilution of the delivered antibody. For detection of the primary antibody, cells were washed 3 times in PBS containing 2 % FBS and incubated for 45 min with the Alexa Fluor 488-labeled anti-mouse antibody from goat as secondary antibody diluted 1 / 250. As negative control yeast cells were incubated only with the secondary antibody. All reactions were performed at room temperature. After washing, cells were fixed in 0.4 % formalin and analyzed by flow cytometry.

Flow cytometry was performed with an FACS Canto equipped with an argon ion laser with an excitation power of 20 mW at 488 nm. Forward and side light scatter were analyzed on linear scales, while fluorescence intensity was determined on logarithmic scales. Analysis gates were set around debris and intact cells on a forward and side light scatter dot plot. The fluorescence histograms of 10,000 cells were generated using gated data. Data analysis was performed using Flowjo 7.5.

### 3.4.11.2 Mannan analysis

The accessibility of mannan on the yeast cell wall was investigated by flow cytometry. Staining of the yeasts with FITC-labeled concanavalin A, which binds to carbohydrates, were performed according to Tkacz et al [150]. Yeast from an overnight culture was adjusted to a final optical density of 0.1 at 620 nm in 0.5 ml. The cells were washed twice with 0.9 % NaCl and collected by centrifugation and resuspended in 0.5 ml of the FITC-concanavalin A (stock solution with 1 mg/ml) diluted 1: 50 with 0.9 % NaCl. After 30min at room temperature, the cells were again collected by centrifugation and washed twice with 1 ml 0.9 % NaCl. All reactions were performed at room temperature. After washing, cells were fixed in 0.4 % formalin and analyzed by flow cytometry.

Flow cytometry was performed with an FACS Canto equipped with an argon ion laser with an excitation power of 20 mW at 488 nm. Forward and side light scatter were analyzed on linear scales, while fluorescence intensity was determined on logarithmic scales. Analysis gates were set around debris and intact cells on a forward and side light scatter dot plot. The fluorescence histograms of 10,000 cells were generated using gated data. Data analysis was performed using Flowjo 7.5 software.

### 3.4.12 Cell surface hydrophobicity (CSH) test

CSH was measured by the biphasic separation method (Microbial Adhesion To Hydrocarbons) as described previously [151]. For each strain tested, 1.5 ml of yeast suspension ( $OD_0=1$ ) was placed into a clean glass tube and overlaid with 1 ml hexadecane (Sigma-Aldrich : 52210). The samples were vortexed for 2 min and settled down for 10 min, the phases were allowed to separate. The  $OD_{620nm}$  was measured for the aqueous phase. Genistein treated yeasts were prepared as shown in (0).

The Hydrophobicity was determined with the help of the following formula:

$$\text{Hydrophobicity index} = (OD_0 - OD_{620nm} \text{ after hexadecane overlay}) / OD_0 \times 100 .$$

## 3.5 Infection

### 3.5.1 Phagocytosis assay

Phagocytosis of *C. albicans* by macrophages was conducted using a fluorimetric phagocytosis test. It was quantified as described [152].  $100 \mu\text{l}$  of  $2 \times 10^6$  macrophages/ml were seeded in each well of 96 well microtiter plates followed by incubation for 2 hours to let the cells

adhere to the plates. Macrophages were pre-incubated for 2 hour with the test compounds, before FITC-stained *C. albicans* was added. The ratio of macrophages: yeast was 1 : 2. For 24 hours genistein treatment  $1 \times 10^6$  macrophages / ml were used. For 48hours genistein treatment of macrophages the cell concentration was  $0.5 \times 10^6$  macrophages / ml. In this way, there are enough cells for the phagocytosis assay. Phagocytosis was allowed to proceed at 37 °C in 10 % CO<sub>2</sub> for different periods of time. The medium was removed and 100 µl trypan blue (Fluka, 250 µl / ml in PBS) were added to quench the fluorescence of yeasts which were not internalized. After an incubation of 1 min at room temperature, the trypan blue solution was removed. The number of internalized yeasts was estimated from fluorescence measurements ( $\lambda_{\text{Ex}}=480$  nm and  $\lambda_{\text{Em}}=520$  nm) through the bottom of the plates by a fluorescence multi-well plate reader.

### 3.5.2 Cytokine detection by ELISA

#### 3.5.2.1 Samples preparation

The cells were harvested and counted under normal culture condition. 100 µl of  $3 \times 10^5$  macrophages / ml were seeded in each well of 96 well microtiter plates and allowed to adhere for 2 hours.  $1 \times 10^8$  *C. albicans* / ml were harvested from culture with or without genistein by centrifugation (13,000 rpm, 5 min, 24 °C), and washed twice with 1 ml PBS. They were suspended in DMEM cell culture medium. The supernatant was removed from the cell culture and 100 µl of the yeast suspension were added. When macrophages were treated with genistein, the compound was added 1 hour before the yeast was added. The ratio of macrophages: yeast was 1:10 in all experiments. TNF- $\alpha$  concentrations were determined after yeast-macrophage incubation time of 1 hour, IL-10 concentrations were determined after 5 hours. The supernatant was collected by centrifugation (3000 rpm 5 min 4 °C). These samples were analyzed either immediately by ELISA or stored in -80°C. The detection was done as described in (0).

## 4 RESULTS

### 4.1 Effect of genistein on the function of RAW264.7 macrophages

#### 4.1.1 Cell viability

Genistein is known to inhibit cell proliferation of human breast cancer cells (MCF-7), human ovarian cancer cells (HeLa), and human prostate cancer cells (PC3) [153-155]. We tested the influence of genistein concentrations and incubation times on the viability of the macrophages by the WST-1 assay.

The results showed that genistein has an inhibitory effect on the cell viability in a time- and dose-dependent manner (Fig. 4.1). When the macrophages were treated with genistein for the short time of only 2 h, none of the genistein concentrations led to decreased signals. However, when the incubation time was extended to 24 and 48 hours, genistein concentrations of 100 - 50  $\mu$ M reduced the cell viability to 70 % - 80 % and 50 % - 60 % after 24 and 48 hours treatment ( $P < 0.01$ ), respectively. With lower genistein concentrations, no influence on the cell viability was observed.




Fig. 4.1 Effects of genistein on the viability of macrophages determined by the WST-1 assay. Data are given with respect to the solvent control (100 %) and are the average of three independent experiments.

\*\* :  $p < 0.01$  compared with solvent control.

### 4.1.2 Cell cycle

Genistein was described to arrest the cell cycle of human gastric cancer cells (HGC-27) and human breast adeno-carcinoma cells (MCF-7), as well as neuronal cells at the G2/M phase [156-159]. To elucidate whether the reduction of signals in the WST-1 test was due to a decreased proliferation rate, which could be caused by a cell cycle arrest, the influence of genistein on the cell cycle of macrophages was investigated by flow cytometry.




Fig. 4.2 The cell cycle distribution of macrophages after treatment with genistein for 24 hours. The cell cycle distribution was determined by flow cytometry after PI staining. All experiments were performed in duplicate and gave similar results.

As shown in Fig. 4.2, genistein treatment induced a significant accumulation of cells in the G2/M phase of the cell cycle in a concentration- and time-dependent manner, with a parallel depletion of the percentage of cells in G0/G1. When the macrophages were treated with genistein for 24 hours, the percentage of cells in S phase was between 20 - 30%, independent on the

genistein concentration. However, the number of cells in the G2/M phase increased significantly from 8.5% to 27.3% and 18.6%, for 100 and 50  $\mu$ M genistein, respectively. The numbers in the G0/G1 phase decreased from 61.6 % to 36.9 % and 49.1 % respectively.

The effect was more striking when the incubation time was extended to 48 hours, which also influenced the amount of cells in the S phase (Fig. 4.3): the amount of cells in the S phase increased from 15.8 % to 29.7 % and 19.5 %, respectively. The percentage of cells in the G2 / M phase increased from 11.4 % to 51.9 % and 30 %, respectively, whereas the percentage in the G0 / G1 phase decreased only slightly for 50  $\mu$ M genistein from 67.2 % to 51.8 % but significantly to 9.2 %, when 100  $\mu$ M genistein was used. Lower concentrations of genistein had no obvious effect on the cell cycle of the cells.




Fig. 4.3 The cell cycle distribution of macrophages after treatment with genistein for 48 hours. The cell cycle distribution was determined by flow cytometry after PI staining. All experiments were performed in duplicate and gave similar results.

### 4.1.3 Morphology

Microscopic observations revealed that genistein influenced the morphology of the RAW264.7 macrophages. Thus, pictures were taken with an inverted contrast microscope after treatment of the cells with genistein for 2, 24, and 48 hour. Aberrations in cellular morphology were observed in a time- and dose-dependent manner (Fig. 4.4). After 2 hours of treatment, the cells were round and well attached to the bottom of the plates. The different concentrations of genistein exerted no effects on the morphology. After 24h, the cells were confluent and round in the control culture; whereas, in the genistein-treated culture, the cells were well attached, but the cell size increased and showed irregular shapes such as diamond shapes or pseudopodia-like protrusions. After 48h, these morphological changes became even more obvious.




Fig. 4.4 Morphological change of macrophages RAW264.7 after treatment with genistein. Different concentrations of genistein were incubated for 2 h (Top), 24h (Middle) and 48h (Bottom); (A) Control, (B) 12.5 $\mu$ M, (C) 25 $\mu$ M. The pictures were taken under the inverted contrast microscope. They are representatives of three independent experiments which were repeated on different days.

#### **4.1.4 *F-actin cytoskeleton***

The cytoskeleton of cells consists of highly dynamic actin polymer structures that play a critical role to maintain cellular morphology. As genistein significantly altered the morphology of macrophage cells (Fig. 4.4), we examine the effects of genistein on the cytoskeleton network in RAW264.7 macrophages.

Cytochalasin B is a well known cytoskeleton inhibitor, which blocks actin polymerization by preventing the binding of monomeric G-actin to the growing (+) end of actin filaments (F-actin) [160]. Cytochalasin B also inhibits cell division by destruction of the contractile ring [161]. As it is shown in Fig. 4.5, there is clear difference between cytochalasin B-treated (Fig. 4.5 B) and untreated (Fig. 4.5 A) cells. Cytochalasin B-treated cells were round and had three nuclei, and the filament structures were not visible; whereas the untreated cells were round and the actin filaments were clearly discernible at the edges of the cells. After genistein treatment of the macrophages, changes of the F-actin structure were obviously induced: (i) the cell size increased and the cells had two nuclei, a long pseudopodia-like protrusion was formed after treatment with 100  $\mu$ M genistein; (ii) lobopodia-like protrusions were formed after treatment with 50  $\mu$ M genistein; (iii) whereas macrophage treated with 25  $\mu$ M genistein showed a typical spindle morphology, the actin was clearly stained at the edges of the cells and had long pseudopodia-like protrusions. Macrophage treated with 12.5  $\mu$ M genistein showed similar effect.






Fig. 4.5 Effect of cytochalasin B and genistein on the actin cytoskeleton of macrophage RAW 264.7. The cells were incubated with cytochalasin B 2 nM (B) and genistein (C – F) for 48 hours, the actin filaments were stained with Alex488-phalloidin (Green fluorescence) and the cell nuclei were stained with DAPI (Blue Fluorescence), the pictures are the overlay of both fluorescence channels. (A) DMSO; (B) Cytochalasin B 2nM; (C) Genistein 100 $\mu$ M; (D) Genistein 50 $\mu$ M ; (E) Genistein 25 $\mu$ M; (F) Genistein 12.5  $\mu$ M.

#### 4.1.5 Nitric oxide production of macrophages stimulated by LPS

One of the major functions of macrophages is the production of signalling compounds and of reactive oxygen and nitrogen (nitric oxide, NO) species to kill foreign material. Thus, the effects of genistein on NO synthesis in RAW264.7 macrophages were investigated. The macrophages were stimulated with LPS and genistein for 20h. The NO production was determined via the nitrite concentrations in the culture medium using the Griess reaction. As shown in Fig. 4.6, cells treated with LPS for 20 h produced high amounts of nitrite ( $32 \pm 4$   $\mu$ M), which were 10-fold higher than the basal production of the unstimulated cells ( $3 \pm 1$   $\mu$ M). A

marked reduction of nitrite production was observed after genistein treatment (12.5 - 100  $\mu$ M). Cell viability of the macrophages stimulated with LPS and genistein was analyzed with the WST-1 assay to exclude the possibility that the inhibitory effect of genistein was due to cytotoxic effects (Fig. 4.6). The viability of all cultures was not affected by any of the treatments and generally was > 90%. This result indicated that the inhibition of nitrite production by genistein was not due to cell death.




Fig. 4.6 Influence of genistein on the NO production and viability of LPS stimulated RAW264.7 macrophages. Left Y-axis: nitrite concentrations in the cell culture supernatants of LPS treated macrophages in the presence or absence of different concentrations of genistein. Results are expressed as means  $\pm$  SD; n=8. Right Y-axis: Cell viability of LPS treated macrophages in the presence and absence of genistein. The cell viability of the solvent control (0  $\mu$ M genistein) was 100 %. Results are expressed as mean  $\pm$  SD; n=8. \*\*: p<0.01 compared with control.

#### 4.1.6 Nitric oxide production of macrophages stimulated by IFN- $\gamma$ and IFN- $\gamma$ + LPS

IFN- $\gamma$  exhibits a wide spectrum of biological activities, for example antiviral immunomodulatory effect. Not only the endotoxin LPS but also cytokines, such as IFN- $\gamma$ , stimulate macrophages to produce NO. A combination of IFN- $\gamma$  plus LPS is usually used to achieve the maximal induction of NO in macrophages. Therefore, we determined the genistein effect on the macrophages stimulated with (i) IFN- $\gamma$  and (ii) IFN- $\gamma$  plus LPS for 20 h. As shown in Fig. 4.7, genistein led to a dose-dependent inhibition of nitrite accumulation by IFN- $\gamma$  alone and in combination with LPS. Cells treated with IFN- $\gamma$  / IFN- $\gamma$ + LPS for 20 h produced a high level of nitrite ( $30 \pm 2$   $\mu$ M,  $52 \pm 2$   $\mu$ M), which was significantly higher than the basal production of

the unstimulated cells (0  $\mu\text{M}$ ). A marked reduction of nitrite production was observed after genistein treatment (4 - 111  $\mu\text{M}$  genistein for IFN- $\gamma$ , 37 - 111  $\mu\text{M}$  genistein for IFN- $\gamma$  + LPS).





Fig. 4.7 Influence of genistein on the NO production of IFN- $\gamma$  and LPS+IFN- $\gamma$  stimulated RAW264.7 macrophages. Nitrite concentrations in the cell culture supernatants of IFN- $\gamma$  and LPS+IFN- $\gamma$  treated macrophages in the presence or absence of different concentrations of genistein. Results are expressed as mean  $\pm$  SD; n=8.

\*\* :  $p < 0.01$  compared with control.

#### 4.1.7 Cytokine production of macrophages stimulated by LPS

The effects of genistein on the production of the cytokines TNF- $\alpha$ , IL-6, and IL-10 by RAW264.7 macrophages were investigated. As shown in Fig. 4.8, genistein showed a dose-dependent inhibition of the cytokine accumulation in the supernatants of the LPS activated macrophages. After 1.5 h of stimulation, LPS-treated cells produced a high level of TNF- $\alpha$  ( $1100 \pm 50$  pg/ml), which were 5-fold higher than the basal production ( $200 \pm 20$  pg/ml). This LPS-induced TNF- $\alpha$  production could be significantly reduced by incubation with the highest genistein concentration of 100  $\mu\text{M}$ . After 5 hour of stimulation, the induction of IL-6 secretion by LPS could also be detected ( $390 \pm 26$  pg/ml in comparison to 0 pg/ml of untreated cells). Even the lowest concentration of genistein (3.7  $\mu\text{M}$ ) resulted in a significant reduction of the IL-6 production. After 6 hours, high levels of IL-10 ( $5190 \pm 260$  pg/ml) were measured (unstimulated cells:  $1130 \pm 503$  pg/ml), which were reduced by elevated genistein concentrations of 33-100  $\mu\text{M}$ .

Cell viability of the macrophages stimulated with LPS and genistein for 6 hours was analyzed to exclude the possibility that the inhibitory effect of genistein was due to cytotoxicity. The viability of all cultures was not affected by any of the treatments and generally was > 80%. This result indicated that the inhibition of nitrite production by genistein was not due to cell death.



#### 4.1.8 Specific kinase inhibitor involved in LPS and IFN-γ pathway

##### 4.1.8.1 NO production

Genistein inhibits the NO production induced by LPS and IFN-γ as well as by the combination of LPS + IFN-γ. Genistein is, in addition, a well known tyrosine kinase inhibitor. Therefore, we examined which tyrosine kinases and downstream kinases are involved in this process. We found that tyrosine kinases Syk, Jak2, Src, PI3Kinase, and Akt kinase are involved in the LPS-induced NO production in a concentration-dependent manner; whereas, tyrosine kinases (Syk and Jak2, but not Src), PI3 kinase, and Akt kinase are involved in the IFN-γ-induced NO production in a concentration-dependent manner (Tab.4.1).

Tab. 4.1 Effects of specific kinase inhibitors in NO production by LPS, IFN- $\gamma$  and LPS+ IFN- $\gamma$  stimulated RAW264.7 macrophages.

| Target kinase | Inhibitor        | LPS               | IFN- $\gamma$    | LPS+ IFN- $\gamma$ |
|---------------|------------------|-------------------|------------------|--------------------|
| Jak2          | AG490            | 0.16-340 $\mu$ M  | 4.2-340 $\mu$ M  | 12.6-340 $\mu$ M   |
| Src           | PP2              | 3.7-11.1 $\mu$ M  | ----             | 11.1 $\mu$ M       |
| Syk           | Syk inhibitor    | 4.7-14 $\mu$ M    | 4.7-14 $\mu$ M   | 4.7-14 $\mu$ M     |
| MEK1/2        | PD98059          | ----              | ----             | ----               |
| P38           | SB203580         | 26.7 $\mu$ M      | ----             | ----               |
| PI3K          | LY294002         | 0.82-22.2 $\mu$ M | 7.4-22.2 $\mu$ M | 7.4-22.2 $\mu$ M   |
| PI3K          | Wortmanin        | 2.6-7.8 $\mu$ M   | 2.6-7.8 $\mu$ M  | 2.6-7.8 $\mu$ M    |
| AKT           | Akt1/2 inhibitor | 0.13-33.3 $\mu$ M | 33.3 $\mu$ M     | 11.1-33.3 $\mu$ M  |
| PTP           | Bpv(phen)        | ----              | ----             | ----               |

#### 4.1.8.2 Cytokine production

As shown in Tab.4.2, specific kinase inhibitors showed a dose-dependent inhibition of the cytokine (TNF- $\alpha$ , IL-6, and IL-10) accumulation in the supernatants of LPS-activated macrophages. Tyrosine kinases (Syk, Jak2, and Src), MAP kinase, PI3 kinase, Akt kinase, and protein phosphotyrosine phosphatase (PTP) are involved in the production of cytokine IL-6, IL-10, and TNF- $\alpha$ .

Tab. 4.2 Specific kinase inhibitors effect on the cytokine productions in the cell culture supernatants of LPS-activated macrophages. TNF- $\alpha$  was detected after 1.5 hours, IL-6 after 5 hours, and IL-10 after 6 hours.

| Target kinase | Inhibitor        | IL-6              | IL-10             | TNF- $\alpha$     |
|---------------|------------------|-------------------|-------------------|-------------------|
| Jak2          | AG490            | 12-37 $\mu$ M     | 12-37 $\mu$ M     | 12-37 $\mu$ M     |
| Src           | PP2              | 0.4-11.1 $\mu$ M  | 0.4-11.1 $\mu$ M  | 1.2-33 $\mu$ M    |
| Syk           | Syk inhibitor    | 1.6-14 $\mu$ M    | 1.6-14 $\mu$ M    | 1.6-14 $\mu$ M    |
| MEK1/2        | PD98059          | 180 $\mu$ M       | 6.7-180 $\mu$ M   | 6.7-180 $\mu$ M   |
| P38           | SB203580         | 2.2-20 $\mu$ M    | 2.2-20 $\mu$ M    | 2.2-20 $\mu$ M    |
| PI3K          | LY294002         | 0.27-22.2 $\mu$ M | 0.27-22.2 $\mu$ M | 0.27-22.2 $\mu$ M |
| PI3K          | Wortmanin        | 0.013-7.8 $\mu$ M | 0.013-7.8 $\mu$ M | 1.3-7.8 $\mu$ M   |
| AKT           | Akt1/2 inhibitor | 0.4-33.3 $\mu$ M  | 0.4-33.3 $\mu$ M  | 0.4-33.3 $\mu$ M  |
| PTP           | Bpv(phen)        | 1.6-14 $\mu$ M    | 1.6-14 $\mu$ M    | 4.7-14 $\mu$ M    |

Note: The concentration ranges, shown in the Tab.4.1 and Tab.4.2, led to a strong inhibition of NO and cytokine production to less than 70 % compared with solvent control, but had no influence of the cell viability.

### 4.1.9 Influence of genistein on the LPS-induced MAP kinase phosphorylation

MAP kinase pathways are involved in the LPS-induced macrophage activation [162]. To further delineate and confirm the signalling process involving MAP kinases in the regulation of LPS-induced activation of macrophages by genistein, we evaluated the induction of their phosphorylation by performing western blot analysis.




Fig. 4.9 Determination of the activation of the MAP Kinase signalling cascade in lysis of macrophages exposed to LPS and genistein for different time intervals. Macrophages were pretreated with different inhibitors for 1 hour and then stimulated with LPS in the presence of inhibitors for 15 min and 30 min. Western blot analysis of p-Raf, p-MEK1/2, p-ERK1/2, p-p90rsk, p-p38, and p38.

As shown in Fig. 4.9, phosphorylation of Raf, MEK1/2, and ERK1/2 after LPS treatment was detectable after 15 minutes post-stimulation and sustained until 30 minutes. Phosphorylation of p38 after LPS treatment is not as obvious as p-ERK1/2. However, genistein together with LPS showed a strong phosphorylation of ERK1/2, the downstream protein p90rsk, as well as p38. Using specific kinase inhibitors as control, the results showed that the specific MEK1/2 kinase inhibitors U1026 and PD98059 significantly inhibited the phosphorylation of MEK1/2 and

ERK1/2, and slightly increased p38 phosphorylation; while the specific kinase inhibitor for p38 (SB203580) inhibited the phosphorylation of p38 and increases MEK/ERK1/2 phosphorylation.

#### 4.1.10 *NF- $\kappa$ B and AP-1 activation detected with RAW-Blue™ Cells*

RAW-Blue™ cells are derived from RAW264.7 macrophages. They are stably transfected to express a secreted embryonic alkaline phosphatase (SEAP) gene inducible by NF- $\kappa$ B and AP-1 transcription factors, so that the gene product SEAP is detectable in the supernatant upon TLR, RLR, or NOD stimulation. LPS is a standard stimulus for the TLR-4 receptor pathway. Thus, RAW-Blue™ macrophages were treated with LPS and genistein for 20h and the activity of SEAP was detected. LPS showed a strong activation of NF- $\kappa$ B and AP-1 as shown in Fig. 4.10. Genistein caused a dose-dependent inhibitory effect on the activation of NF- $\kappa$ B and AP-1. A strong inhibition of NF- $\kappa$ B and AP-1 activation was observed for the highest genistein concentration of 100  $\mu$ M ( $p < 0.01$ ); whereas, at lower concentrations effects were less pronounced (33  $\mu$ M genistein inhibitory effect with  $p < 0.05$ ). The cell viability result shows that the inhibitory effect is not due to toxicity effects.




Fig. 4.10 Inhibitory effect of genistein on NF- $\kappa$ B and AP-1 activation of RAW-Blue™ cells by LPS. Right Y-axis: Cell viability of LPS treated RAW-Blue™ cells in the presence and absence of genistein. The cell viability of the solvent control (0  $\mu$ M genistein) was 100 %. Results are expressed as means  $\pm$  SD;  $n=4$ . \*\*:  $p < 0.01$  compared with control; \*:  $p < 0.05$  compared with control.

#### 4.1.11 Gene expression related to Toll-like receptor pathways

In order to confirm the genistein effect on the macrophages in the transcriptional level, we used a Toll-like receptor pathway PCR array to analyze the expression of related genes after treatments with (i) LPS and (ii) LPS together with genistein. A significant number of genes were differentially regulated compared to control cells (Fig. 4.11) (Appendix). Genistein alone could up-regulate the genes CD80, MEKK1, c-fos, Rela, and Ticam2. LPS could up-regulate 20 genes including (a) cytokines IFN- $\beta$ , IL-10, IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$ , Csf2, and Csf3; (b) chemokines Ccl2 and Cxcl10; (c) cyclooxygenase 2 (COX-2); (d) transcription factor NF- $\kappa$ B1; and (e) I $\kappa$ B- $\alpha$ . Whereas genistein shows a strong inhibition of the expression of these genes. Moreover, genistein treatment in LPS-stimulated macrophages could up-regulate the transcription factor I $\kappa$ B- $\beta$  and c-Rel.




Fig. 4.11 Hierarchical clustering of 32 induced or repressed genes. Genes passing appropriate filter criteria were subjected to a hierarchical clustering. The homology tree plot is shown on the left side. 1: Genistein-treated (50 $\mu$ M) macrophages RAW 264.7; 2: LPS -treated (100 ng/ml) macrophages RAW 264.7; 3 means LPS+ Genistein treated macrophages RAW 264.7.



## 4.2 Effects of genistein on *C. albicans*

### 4.2.1 Genistein effects on the oxygen consumption of *C. albicans* and *S. cerevisiae*

In order to investigate the action of genistein on the mitochondrial function of *C. albicans* and *S. cerevisiae*, the rates of oxygen consumption in the presence of genistein (123-1.5  $\mu\text{M}$ ) were determined. For *C. albicans*, an inhibitory effect of genistein on oxygen consumption was observed (Fig. 4.12 A) after 10 min. Within the applied genistein concentration range from 1.5 to 123  $\mu\text{M}$ , an influence of genistein concentration was observed. All cultures containing genistein showed higher oxygen concentrations, i.e. the respiratory rate was lower, than in cultures without genistein. However, for *S. cerevisiae*, no significant effect of genistein on oxygen consumption could be detected, even at the highest concentration of 123  $\mu\text{M}$  (Fig. 4.12).




Fig. 4.12 Effect of genistein on the oxygen consumption of *C. albicans* (A) and *S. cerevisiae* (B). Oxygen consumption was measured in the OxoPlates<sup>®</sup> at the indicated times. The results represent two independent experiments.

### 4.2.2 Effect of genistein on the ROS accumulation in *C. albicans* and *S. cerevisiae*

Interference with the electron transport chain could lead to incomplete reduction of electron carriers, such as ubiquinones, which can induce the formation of reactive oxygen species (ROS) due to the subsequently incomplete reduction of oxygen. The fluorescent probe H<sub>2</sub>DCFDA, is suitable for measurement of ROS formation in yeast cells [163], and was used to monitor ROS formation in *C. albicans* and *S. cerevisiae*. Genistein caused an increase in the fluorescence

intensity of *C. albicans* as shown in Fig. 4.13. After 2 h of incubation with genistein, the increased ROS generation was seen. At a concentration of 41  $\mu\text{M}$ , 13.8  $\mu\text{M}$ , and 4.6  $\mu\text{M}$  of genistein the increase was 1.26, 1.41, and 1.26 times compared with the control ( $p < 0.01$ ), respectively. These data indicated that genistein induced ROS accumulation in *C. albicans*.

On the other hand, genistein had no influence on ROS production of *S. cerevisiae* as shown in Fig. 4.13. After 2 h of incubation with genistein, no increase of ROS generation was observed. These data indicated that genistein did not induce ROS accumulation in *S. cerevisiae*.




Fig. 4.13 Effects of genistein on the generation of endogenous ROS in *C. albicans* (A) and *S. cerevisiae* (B). Data represents the percentage of solvent control.

### 4.2.3 Effect of specific respiratory chain inhibitors on oxygen consumption and ROS production in *C. albicans*

#### 4.2.3.1 Effect of rotenone on the oxygen consumption of *C. albicans* and *S. cerevisiae*

In the respiratory chain of *S. cerevisiae*, the classical complex I for NADH oxidation is missing [133]. Instead, it has two groups of rotenone-insensitive NADH dehydrogenases called NDI and NDE, which are NADH dehydrogenases placed at the inner (NDI) and at the external (NDE) side of the mitochondrial membrane. As the respiratory chain of *C. albicans* contains complex I, we speculated that this part of the respiratory chain may be the site of action of genistein. Thus, we used the specific complex I inhibitor rotenone to test its effects on oxygen consumption.

The rates of oxygen consumption in the presence of rotenone (34.8–3.9  $\mu\text{M}$ ) were determined. For *C. albicans*, a slightly inhibitory effect of rotenone on oxygen consumption was observed

( Fig. 4.14 A). However, for *S. cerevisiae*, no effect of rotenone on oxygen consumption was observed ( Fig. 4.14 B).




Fig. 4.14 Effects of rotenone on the oxygen consumption of *C. albicans* and *S. cerevisiae*. Oxygen consumption was measured in the OxoPlates® at the indicated times (A) *C. albicans* (B) *S. cerevisiae*

#### 4.2.3.2 Effect of rotenone on the ROS accumulation in *C. albicans* and *S. cerevisiae*

Rotenone also caused an increase in the fluorescence intensity of *C. albicans* as shown in Fig. 4.15. After 2 h of incubation with rotenone, an increased ROS generation was seen for concentrations exceeding 10  $\mu\text{M}$ . These data indicated that the specific complex I inhibitor rotenone induced ROS accumulation in *C. albicans* as well.

On the other hand, rotenone had no influence on ROS production of *S. cerevisiae* after 2 h of incubation with rotenone, suggesting that rotenone did not induce ROS accumulation in *S. cerevisiae*.




Fig. 4.15 Effects of rotenone on the generation of endogenous ROS in *C. albicans* and *S. cerevisiae*. Data represents the percentage of solvent control.

#### 4.2.3.3 Effect of antimycin A on the oxygen consumption of *C. albicans* and *S. cerevisiae*

Antimycin A is a specific inhibitor of the complex III of the respiratory chain for both *C. albicans* and *S. cerevisiae*. The rates of oxygen consumption in the presence of antimycin A (16.4-0.6 μM) were determined. For *C. albicans*, a strong inhibitory effect of antimycin A on the oxygen consumption was already observed (Fig. 4.16 A) after 10 min. Moreover, for *S. cerevisiae*, antimycin A also showed a striking inhibition of oxygen consumption in the concentration range 16.4-0.6 μM (Fig. 4.16 B).




Fig. 4.16 Effects of antimycin A on the oxygen consumption of *C. albicans* and *S. cerevisiae*. Oxygen consumption was measured in the OxoPlates® at the indicated times (A) *C. albicans* (B) *S. cerevisiae*.

#### 4.2.3.4 Effect of antimycin A on the ROS accumulation in *C. albicans* and *S. cerevisiae*

Both *C. albicans* and *S. cerevisiae* showed a significant increase in ROS production when treated with antimycin A, as shown in Fig. 4.17. For *C. albicans*, at a concentration of 16.4  $\mu\text{M}$ , 5.4  $\mu\text{M}$ , 1.8  $\mu\text{M}$ , and 0.6  $\mu\text{M}$  of antimycin A, the increase was 2.05, 1.93, 1.84, and 1.85 times respectively compared with the control ( $p < 0.01$ ). On the other hand, antimycin A had a strong influence on ROS production of *S. cerevisiae* as it is shown in Fig. 4.17 B, which shows an increase of 1.68, 1.64, 1.62, and 1.60 times respectively compared with the control ( $p < 0.01$ ).




Fig. 4.17 Effects of antimycin A on the generation of endogenous ROS in *C. albicans* and *S. cerevisiae*. Data represent the percentage compared to solvent control.

#### 4.2.4 Complex I activity

Dichlorophenolindophenol (DCIP) is used as artificial electron acceptor for complex I reductase activity. The oxidized form of blue DCIP can be reduced and turned into a colorless reduced form in the presence of *C. albicans* cells. Rotenone is an inhibitor of complex I, and thus inhibits the catalysed oxidation of NADH by DCIP. Fig. 4.18 shows DCIP reduction by the suspension of *C. albicans*. There is no difference between genistein-treated *C. albicans* and the control. However, rotenone strongly blocked the DCIP reduction. Thus, genistein shows a behavior different from rotenone.




Fig. 4.18 The consuming of the DCIP color by suspensions cells of genistein (123  $\mu$ M) and rotenone (63.3  $\mu$ M) treated *C. albicans* after 20 min.

#### 4.2.5 Ethanol production

As inhibition of the respiratory chain results in the redirection of metabolic pathways in favour of fermentative reactions, we detect ethanol in the culture supernatants (Fig. 4.19). The results showed that genistein (100  $\mu$ M) led to a significant increase in ethanol productivities after treatment of *C. albicans* for 4 hours.




Fig. 4.19 Effects of genistein on the ethanol production of *C. albicans* after genistein treatment for 4 hours. The results represent at least two independent experiments.

#### 4.2.6 Growth of *C. albicans*

Rotenone is a specific complex I inhibitor, which does not prevent *C. albicans* proliferation [198]. According to the literature, we tested whether genistein could influence the growth of *C. albicans*. Growth was followed via the determination of the turbidity at OD 620nm. As shown in Fig. 4.20, genistein (123  $\mu$ M) had no effect on the growth rate of *C. albicans* from 0 - 5 hour

growth compared with DMSO control.




Fig. 4.20 Effect of genistein on growth of *C. albicans* in YPgal medium. The results represent at least two independent experiments.

#### 4.2.7 Cell wall $\beta$ -glucans and mannans components of *C. albicans*

$\beta$ -1,3-glucans are reported to be essential for the recognition of *C. albicans* by the macrophage receptor dectin-1, the main receptor for phagocytosis of *C. albicans*. Therefore, we investigated whether genistein changed the cell wall structure and enhanced the accessibility of  $\beta$ -1,3-glucans on the surface of *C. albicans*. As shown in Fig. 4.21, treatment of *C. albicans* with genistein (100  $\mu$ M) did not lead to an increase of the accessibility of  $\beta$ -1,3-glucans compared with DMSO control.

Mannan is another important cell wall constituent of *C. albicans*, which plays a role in the interaction between pathogen and host. So, we investigated whether genistein could influence the accessibility of mannans on the surface of *C. albicans*. As shown in Fig. 4.21, treatment of *C. albicans* with genistein (100  $\mu$ M) did not lead to any influence of the accessibility of mannan compared with DMSO control.




Fig. 4.21 FACS analysis of accessible  $\beta$ -1,3-glucans and mannan of genistein 100  $\mu$ M treated *C. albicans* CAF2-1. The results presented are representative of three independent experiments.

#### 4.2.8 Cell surface hydrophobicity of *C. albicans*

Cell surface hydrophobicity (CSH) was associated with an increased virulence of *C. albicans* due to stronger adherence to substrates [164, 165]. Therefore, we investigated the influence of genistein on the CSH of *C. albicans*. Hydrophobic and hydrophilic cells were separated using the biphasic separation method. As shown in Fig. 4.22, genistein (100  $\mu$ M) treatment led to a 5 % increase of the cell surface hydrophobicity of *C. albicans* compared with the solvent control ( $p < 0.01$ ).




Fig. 4.22 Effect of genistein on the cell surface hydrophobicity of *C. albicans*. Results presented are representative of three independent experiments.



### 4.3 Infection

#### 4.3.1 Receptor expression on macrophage surface related to *C. albicans* infections

Macrophages express high levels of Toll-like receptors (TLRs) on their cell membranes, as well as lectin receptors. Among them, Toll-like receptor 2 and dectin-1 receptor are important for recognition of *C. albicans* infections. The expression of the receptors may differ with different macrophage cell lines. Therefore, it is necessary to confirm the presence of receptors in the macrophage cell line RAW264.7. As shown in Fig. 4.23, macrophages RAW264.7 expressed high levels of TLR-2 and dectin-1 compared with the control which was only stained with the secondary antibody.




Fig. 4.23 Receptors expression of macrophage RAW264.7 by flow cytometry. The overlay of control: staining with only secondary antibody (grey area) and the first antibody staining (white area).

#### 4.3.2 Phagocytosis of *C. albicans*

Genistein was reported to be a tyrosine kinase inhibitor with a rather broad specificity so that a number of signal transduction cascades could be influenced. Interactions of the pathogen *C. albicans* with host cells frequently lead to internalization of the yeast by processes such as endocytosis and phagocytosis. Endocytosis is of major relevance for non-phagocytotic host cells, such as vascular endothelial cells; whereas phagocytosis is an important function of macrophages. Both processes involve the phosphorylation of tyrosine residues and it was reported that endocytosis of *C. albicans* was significantly reduced by pretreatment of endothelial cells with genistein (100  $\mu$ M) [32]. As phosphorylation of tyrosine residues are also downstream reactions of pathogen recognition by phagocytosis receptors [166], we investigated the influence of genistein on the phagocytosis of *C. albicans* by macrophages. As shown in Fig. 4.24, treatment of the macrophages with genistein reduced the phagocytosis efficiency in a time- and

dose-dependent manner. Pre-treatment of the macrophages with genistein for 2-8 hours did not influence the phagocytotic effect. However, when the pre-incubation time was extended to 24 hours, phagocytosis of *C. albicans* was decreased to 50% of the control by 25  $\mu$ M genistein; and to about 80 - 90 % by 12.5  $\mu$ M genistein, with a slight recovery after prolonged phagocytosis times (60 min). After 48 hours, the effects were even more pronounced, as the higher concentration (25  $\mu$ M) led to the strong inhibition to 40%, and the lower concentration (12.5  $\mu$ M) to less than 70%. The inhibition effect was observed throughout the whole observation period.




Fig. 4.24 Phagocytotic activity of RAW264.7 macrophage for *C. albicans* CAF2-1 after treatment with different concentration of genistein for 2-8 h (A), 24 h (B), and 48 h (C). The yeast cells were fluorescently labeled and the amount of internalized yeasts was determined after the indicated times (30 min, 45 min, and 60 min) by a multiwell - fluorimeter. White bars are 25  $\mu$ M genistein; grey bars are 12.5  $\mu$ M genistein. Data are given with respect to the solvent control and are the results of three independent experiments.

### 4.3.3 Cytokine production of genistein treated macrophages with *C. albicans*

We had observed that genistein reduced the cytokine production of LPS stimulated macrophages (4.1.7). As LPS mainly activates signal transduction cascades downstream of TLR4, whereas *C. albicans* also interacts with TLR2 and dectin-1, the influence of genistein on cytokine production by macrophages, which were stimulated with *C. albicans*, was also tested.

Macrophages were treated with genistein 1 hour before *C. albicans* was added. The supernatant was discarded after genistein treatment and the yeast suspension without genistein supplement was added, so that genistein could not influence *C. albicans*. As shown in Fig. 4.25, genistein led to a pronounced inhibition of TNF- $\alpha$  and IL-10 production after 1.5 and 5 hours infection times.




Fig. 4.25 TNF- $\alpha$  and IL-10 production of macrophages in response to *C. albicans* CAF2-1, influenced by genistein. The results represent two independent experiments, and data are the mean  $\pm$  S.D. of at least 4 single values of each experiment.

\*\* $p < 0.01$  compared with DMSO control.

#### 4.3.4 Interaction of genistein-treated *C. albicans* with RAW264.7 macrophage

Genistein influenced the respiratory activity of *C. albicans*, the endogenous ROS accumulation, and cell surface hydrophobicity (4.2). As cell surface hydrophobicity may influence also the interactions to host cells, we tested whether genistein treatment of *C. albicans* could influence the degree of internalization by macrophages. The effect of genistein treatment of *C. albicans* on the time course of phagocytosis is shown in Fig. 4.26. Already at the earliest time point of 15 minutes incubation time of *C. albicans* with macrophages, the level of phagocytosis was significantly enhanced and this effect lasted during the whole experimental period of 60 minutes.




Fig. 4.26 . Phagocytosis of genistein treated *C. albicans* CAF2-1 by the macrophage cell line RAW 264.7. Data represent the mean  $\pm$  S.D. for at least 6 single values in each experiment, each experiment was repeated 3 times. \*\*:  $p < 0.01$ ; \*:  $p < 0.05$  comparison with DMSO control.

#### 4.3.5 Cytokine production of RAW264.7 macrophages stimulated with genistein-treated *C. albicans*

As we had observed an enhanced phagocytosis of genistein-treated *C. albicans*, we evaluated whether genistein treatment also influenced cytokine production. In Fig. 4.27, data are shown for the production of TNF- $\alpha$  and IL-10. Contrary to the results obtained, when macrophages were treated with genistein, the pre-incubation of *C. albicans* with genistein led to a significant enhancement of TNF- $\alpha$  concentrations and also to an increase of IL-10 concentrations ( $p < 0.01$ ).




Fig. 4.27 Effects of genistein treatment of *C. albicans* CAF2-1 on the production of TNF- $\alpha$  (A) and IL-10 (B) by macrophages; the results represent two independent experiments, the data for each experiment are the mean of at least 4 single values of each experiment. \*\*:  $p < 0.01$  comparison with DMSO control.

## 4.4 Interaction of *C. albicans* single gene deletion mutants with macrophages

### 4.4.1 Phagocytosis

As we had observed that treatment of *C. albicans* with genistein influenced the interaction to RAW264.7 macrophages, we used single gene deletion mutants of *C. albicans* to identify fungal pathways which are involved in this interaction. MAP kinase pathways and the histidine kinase Chk1p are involved in the cell wall structure of *C. albicans* [167, 168]. Therefore, we investigate whether there is any relation between MAP kinase pathways and histidine kinases, which may be the sensor proteins of the MAP kinases cascades. The MAP kinase mutants ( $\Delta cek1$ ,  $\Delta mkc1$ , and  $\Delta hog1$ ) and MAPK kinase mutants ( $\Delta hst7$  and  $\Delta pbs2$ ) were used together with the histidine kinase mutant  $\Delta chk1$  and the reference strain CAF2-1 in the phagocytosis assay.




Fig. 4.28 Phagocytosis of MAP kinase mutants (*Δcek1*, *Δmkc1*, and *Δhog1*) and MAPK kinase mutants (*Δhst7* and *Δpbs2*) by RAW264.7 macrophages in comparison to the reference strain CAF2-1 and histidine kinase mutant *Δchk1*. The phagocytosis time was one hour. The figure shown above is the mean  $\pm$  standard deviation of three independent experiments. \*\*:  $p < 0.01$ ; \*:  $p < 0.05$  comparison with CAF2-1.

Among the mutants, the MAP kinase mutant *Δhog1* showed only a small increase in phagocytosis efficiency compared with the reference strain (CAF 2-1). The mutant *Δpbs2* showed another slight increase which was to be regarded as significant. In contrast, the other MAP kinase mutants, *Δcek1* and *Δmkc1*, and the respective MAPK kinase mutant *Δhst7* were internalized significantly better by the RAW264.7 cells than the reference strain CAF2-1 (Fig. 4.28). Thus, effects from these strains were investigated further.

#### 4.4.2 Cell wall $\beta$ -glucans and mannans exposure of *C. albicans* mutants

$\beta$ -1,3-glucans are reported to be essential for the recognition of *C. albicans* by the macrophage receptor dectin-1, the main receptor for phagocytosis of *C. albicans*. A previous study had shown that cell wall mannans of *CHK1*-deficient *C. albicans* were significantly truncated [169]. As in *C. albicans* the inner  $\beta$ -glucan layer of the fungal cell wall is known to be shielded by these mannan chains [54, 170], these shorter mannans could lead to an increased exposure of the  $\beta$ -glucans for immune recognition. Thus, the accessibility of  $\beta$ -1,3-glucans and mannans of MAPK and MAPK kinase mutants was evaluated in comparison to *Δchk1* and the parental strain CAF2-1. Antibody-staining of the  $\beta$ -1,3 -glucans of CAF2-1 resulted in only poor fluorescence intensities of about 500 RFU (Fig. 4.30), whereas the MAPK and MAPK kinase

mutants as well as  $\Delta chk1$  were efficiently stained and achieved high median fluorescence intensities indicating a high amount of accessible  $\beta$ -1,3-glucans compared with CAF2-1 (Fig. 4.29). In addition, it has to be noted that background fluorescence observed from negative controls was similar for all mutants.

The cell wall mannans were stained with FITC-labeled concanavalin A and analysed by flow cytometry. The exposure of mannans of  $\Delta chk1$  was reduced to 60% of the level of CAF2-1. The decrease observed with  $\Delta hog1$  was not significant.  $\Delta pbs2$  still had 75% of the signal of CAF2-1, whereas all the other MAPK and MAPK kinase mutants showed mannan exposure levels of 60-70% of CAF2-1.




Fig. 4.29 Overlay of  $\beta$ -glucans expression of MAPK and MAPK kinase deletion mutants in comparison to *C. albicans* CAF2-1. Fluorescence intensity of antibody-labeled yeasts was detected via flow cytometry. The overlay of CAF2-1 (white area) and the respective mutants is shown (grey area). The mutants which have a higher exposure of glucans are highlighted in red.




Fig. 4.30 Quantitative comparison of the median fluorescence intensities of stained mutants and the reference strain CAF2-1. Representative data of three independent experiments are shown.




Fig. 4.31 Mannan exposure of MAPK and MAPK kinase deletion mutants in comparison to CAF2-1 and the histidine kinase mutant  $\Delta chk$ . (A) Yeast cells of the *C. albicans* mutant strains were stained with FITC labelled Concanavalin A. Fluorescence intensity of labeled yeasts was detected via flow cytometry. Quantitative comparison of the median fluorescence intensities of stained mutants and the reference strain CAF2-1. (B) Percentage of median fluorescence intensities of CAF2-1. Representative data of three independent experiments are shown.

#### 4.4.3 Phagocytosis of *C. albicans* mutants by RAW264.7 macrophage after genistein treatment

MAP kinase pathways are used by eukaryotic cells to response to changes in the external environment. Although there are several differences between mammalian cells and lower eukaryotic cells regarding the complexity and functionality of the elements involved, the core structure of the MAP kinase cascade is highly conserved [171]. As genistein could activate the



MAPK kinase signalling cascade by phosphorylation of MAP kinase p38 and ERK1/2 in mammalian cells, we utilized genistein-treated MAP kinase deletion mutants with genistein to detect whether genistein could target on the MAPK kinase pathways in *C. albicans*. We analyzed the phagocytic efficiency of macrophages for genistein treated *C. albicans* mutants. The result showed that the phagocytosis efficiency for  $\Delta cek1$  and  $\Delta hog1$  was not affected by genistein treatment, suggesting that the genistein effect of the wild type could be related to the pathways.




Fig. 4.32 Phagocytosis of genistein treated mutants by RAW264.7 macrophages in comparison to the reference strain treated CAF2-1. The phagocytosis time was 45 minutes. The figure shown above is the mean  $\pm$  standard deviation of 4 repeated values.

## 5 DISCUSSION

### 5.1 *Effects of genistein on the macrophages*

Genistein, an isoflavone, has been shown to inhibit the proliferation of several types of cancer cells. However, currently little is known about its effect on macrophages. Our experiments focused on the effects of genistein on the murine macrophage cell line RAW264.7. Different concentrations of genistein were used to examine the effects of genistein on macrophage proliferation, cell cycle, cell morphology and F-actin cytoskeleton structure.

In this study, the WST-1 method was used to detect cell proliferation. The WST-1 method is easier and more sensitive compared with the conventional MTT method. In metabolically active cells, the colorless tetrazolium salt is reduced by dehydrogenases to a yellow water-soluble formazan. This color change can be detected by a spectrophotometer at the wavelength of 450 nm. The results showed that genistein had an inhibitory effect on the cell viability in a time- and dose-dependent manner (4.1.1). When the macrophages were treated with genistein for the short time of only 2 h, none of the genistein concentrations led to decreased signals. However, when the incubation time was extended to 24 and 48 hours, genistein concentrations in the range of 50-100  $\mu$ M reduced the cell viability. But no influence on the cell viability was observed with lower genistein concentrations (12.5, 25  $\mu$ M). Meanwhile, genistein arrested the macrophages at the G2/M phase of the cell cycle in a concentration- and time-dependent manner. When the macrophages were treated with genistein for 24 hours, the number of cells in the G2/M phase significantly increased when the concentration was 100 or 50  $\mu$ M, respectively. The effect was more striking when the incubation time was extended to 48 hours. Lower concentrations (25 and 12.5  $\mu$ M) of genistein had no obvious effect on the cell cycle, suggesting that the reduction of cell viability was due to reduced cell proliferation, which was due to cell cycle arrest (4.1.2).

Genistein treatment also altered the morphology of RAW264.7 cells via influencing the actin cytoskeleton structure (4.1.3-4.1.4). An inverted contrast microscope was used to observe the cells treated with genistein for 2, 24, and 48 hours. Aberrations in cellular morphology were observed and the morphological changes were time- and dose-dependent. The different concentrations of genistein exerted no effects on the morphology after 2 hours of treatment. After 24h, genistein-treated cells were well attached, but the cell size increased and showed irregular shapes such as diamond shapes or pseudopodia-like protrusions. After 48h, these morphological

changes became even more obvious. The morphology change is consistent with the results from cell proliferation and cell cycle.

As the morphology of cells is at least partly determined by the cytoskeleton, we investigated the structure of the actin filaments in cells, which were treated with genistein. We could clearly observe the elongated actin filaments leading to the above mentioned protrusions, and the spindle morphology with actin filaments at the edge of the cells. The effect of genistein occurred after a longer treatment time than effects of cytochalasin B (an actin polymerization inhibitor), which exerts its effect already after 2 hours [152]. Therefore, we speculated that the genistein effect could be a secondary effect, such as the result of inhibition of different tyrosine kinases in actin signal transduction pathways, which subsequently may result in changes in cytoskeleton dynamics. The results also showed that genistein caused the changes via different mechanism than the cytoskeleton inhibitor cytochalasin B. The results laid a basis for further investigations, especially on the phagocytic function of macrophages for *C. albicans*.

Genistein has been reported to suppress tumor cell growth, an effect which is mediated by different types of cell cycle arrest in the G2/M phase in the several tumor cell lines. Examples of such tumor cells include hepatoma cells, breast cancer cells, neoplastic human mammary epithelial cells, lung cancer cells, gastric cancer cells, and prostate cancer cells [156, 172-176]. Recent studies have shown that genistein can block the human epithelial cell line A549 cells in G2/M phase, alter their morphology, and depolymerise interphase microtubules [177]. MAP kinase pathways were shown to be implicated in G2/M phase regulation and genistein may exert its influence on the cell cycle via activation and inhibition of distinct MAP kinase pathways [47-49]. Our results showed for the first time that genistein inhibited the proliferation of macrophages via arrests of cells in the G2/M phase in high concentrations. But whether genistein could activate the p-ERK1/2 and p-p38 of macrophage needs to be further investigated.

In conclusion, our comprehensive results clearly showed that only extended incubation of macrophages with genistein affected proliferation, cell cycle, cell morphology, and cytoskeleton structure. The results provided a basis for further studies of genistein on macrophage functions.

## **5.2 Genistein shows a strong anti-inflammatory effect on LPS-stimulated macrophages**

Genistein has a variety of pharmacological effects, such as anti-cancer, anti-inflammatory, immune modulatory, and cardiovascular protection effects. Excessive secretions of inflammatory

factors can cause severe disease such as septic shock. Effective regulation of pro-inflammatory cytokine secretion has a potential clinical application as it will effectively control the inflammatory response, but could also lower the infectivity of some opportunistic pathogens such as *C. albicans* and *Aspergillus fumigatus*. However, the anti-inflammatory effects of genistein in particular on activated macrophages RAW264.7 had not been investigated in depth. Therefore, we studied effects of genistein on the response of macrophages to LPS, IFN- $\gamma$ , and IFN- $\gamma$  + LPS. A possible mechanism of genistein especially on LPS-activated macrophages is discussed.

LPS is a membrane component of gram-negative bacteria, acts as an endotoxin and elicits strong immune responses in animals. It activates macrophages via the Toll-like receptor 4 signal transduction pathway to activate nuclear transcription factors NF- $\kappa$ B and AP-1, leading to a release of inflammatory mediators like NO, TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IL-10. Thus, in the laboratory, LPS mimics the inflammation state in the body. Genistein could strongly inhibit LPS-induced NO and secretion of inflammatory cytokines TNF- $\alpha$ , IL-6, and IL-10 in the RAW264.7 macrophages in a dose-dependent manner. It has been reported that pre-treatment with genistein before intraperitoneal injection of LPS in a murine inflammation model significantly lowered the serum levels of TNF- $\alpha$  *in vivo* [178]. Moreover, genistein significantly inhibited cytokine-induced increases of TNF- $\alpha$ , interleukin-1 $\beta$ , IL-8 mRNA, and protein expression of inflammatory mediators in human brain microvascular endothelial cells [179]. Our results confirmed that genistein has a potential anti-inflammatory effect.

IFN- $\gamma$  is a cytokine that is critical for innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. IFN- $\gamma$  not only inhibits viral replication but also shows immunostimulatory and immunomodulatory effects [180]. Aberrant IFN- $\gamma$  expression is associated with a number of autoinflammatory and autoimmune diseases. IFN- $\gamma$  activates the Jak-STAT pathway in macrophages and induces production of NO and cytokines. Genistein strongly abrogated both IFN- $\gamma$ -induced and LPS-induced release of NO in a similar way. The effect of the genistein on the IFN- $\gamma$  pathway is currently not well understood. Our results showed for the first time that genistein also influences the IFN- $\gamma$ -activated Jak2-STAT signalling transduction pathways.

Tyrosine phosphorylation is one of the earliest events to occur in response to an immune challenge, but the role of specific tyrosine kinases in inflammatory cytokine production has been difficult to ascribe due to conflicting literature. As genistein is a broad range tyrosine kinase inhibitor, we additionally applied specific tyrosine kinase inhibitors (Jak2, Syk, and Src inhibitors), MAP kinase inhibitors (SB203580, PD98059), inhibitors of down-stream kinases (PI3

kinase and Akt kinase inhibitors), and a protein phosphotyrosine phosphatase inhibitor (Bpv (phen)). We found that both tyrosine kinases Jak2 and Syk are essential for NO production as a response to LPS and IFN- $\gamma$  activation. Until now, only Jak2 is known to be involved in the IFN- $\gamma$  signaling pathway, our results now showed the decisive role of tyrosine kinase Syk. However, we did not find an essential role for the MAP kinase ERK and the protein phosphotyrosine phosphatase in both the LPS and the IFN- $\gamma$  pathway, and p38 was required only for LPS stimulated NO production. The results do not correlate with another report, in which an regulating role of the ERK pathway in the IFN- $\gamma$ -induced macrophage NO production and an enhancement by phosphatase inhibition was observed [181]. However, all kinases and phosphatases were involved in TNF- $\alpha$ , IL-6, and IL-10 production in a dose-dependent manner. The results suggest that the different kinases and the phosphatase functions in a dose-dependent manner. As tyrosine phosphorylation is one of the rapid responses to the stimulus, after a long time period stimulation like in the NO assay, the effect of some kinases could be compensated by the cross talk with other pathways. From these results, we concluded that the MAP kinases, ERK1/2, and p38 are involved in the short time response of LPS activation for cytokine production; whereas, tyrosine kinases are involved in both processes. This could explain the inhibitory effect of genistein, a broad spectrum tyrosine kinase inhibitor, on NO and cytokines production independent of the stimulus.

To further delineate and confirm the signalling processes involving MAP kinases in the regulation of LPS-induced activation of macrophages by genistein, we evaluated the induction of their phosphorylation by western blot analysis (4.1.9). LPS led to the phosphorylation of Raf, MEK1/2, and ERK1/2 already after 15 min post-stimulation and it sustained till 30 minutes. Phosphorylation of p38 was also observed, but it was not as obvious as p-ERK1/2. The results also proved that both p38 and p44/42 mitogen-activated protein kinases are involved in LPS activation of RAW264.7, which is also partly confirmed in the literature [162]. Addition of genistein further increased the phosphorylation of ERK1/2, of its downstream protein p90rsk and of p38. These results differed from the ones observed by Chu [182], who showed that LPS activation of MAPK was significantly depressed by genistein, SB 203580, and PD 98058 in the human monocytic THP-1 cells. The discrepancy between our results and those reported previously could be due to the different cell lines, the pre-treatment time for inhibitors, and the stimulation times for LPS. Meanwhile, genistein has been reported to selectively potentiate arsenic trioxide-induced apoptosis in human leukaemia cells via activation of p38 mitogen-activated protein kinase [48]. Our results were the first to suggest that genistein activated

p-p38 and p-ERK1/2 in LPS-stimulated macrophages, but the clear mechanism still requires further investigation.

At the transcriptional level, the NF- $\kappa$ B and AP-1 transcription factors play a key role in the regulation of inflammation and therefore, in the generation and release of NO and cytokines like TNF- $\alpha$ , IL-6, and IL-10. NF- $\kappa$ B plays important roles in the control of cell growth, differentiation, apoptosis, and stress-response. Whereas, NF- $\kappa$ B activation is part of the TLR4 signalling pathway, and the activation of AP-1 is related to the MAPK signal transduction pathway. To further elucidate the anti inflammatory role of genistein, we first used the RAW-Blue<sup>TM</sup> cells to detect the effect of genistein on both the nuclear transcription factor NF- $\kappa$ B and AP-1 (4.1.10). RAW-Blue<sup>TM</sup> cells could stably express the secreted embryonic alkaline phosphatase (SEAP) gene, which is induced by activation of either the NF- $\kappa$ B or the AP-1 transcription factor. The results showed that genistein significantly reduced the expression of the reporter protein and thus inhibited simultaneously NF- $\kappa$ B and AP-1 in a dose-dependent manner.

In order to study genistein effects on the macrophages at the transcriptional level, we used a Toll like receptor pathway PCR array to investigate expression of related genes after different treatments (4.1.11). Cells treated with (i) LPS and (ii) LPS together with genistein demonstrated significant number of genes to be differentially regulated compared to control cells. Genistein alone could up-regulate the gene CD80, MEKK1, c-fos, Rel $\alpha$ , and Ticam2. LPS could up-regulate 20 genes including (a) cytokines IFN- $\beta$ , IL-10, IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$ , Csf2, and Csf3; (b) chemokines Ccl2 and Cxcl10; (c) transcription factor NF- $\kappa$ B1; (d) I $\kappa$ B- $\alpha$ ; and (e) cyclooxygenase 2 (COX-2). The presence of genistein led to a strong inhibition of the expression of these genes and upregulated the transcription factors I $\kappa$ B- $\beta$  and c-Rel, a subunit of NF- $\kappa$ B. Genistein has been shown to inhibit the COX-2 production in LPS-stimulated chondrocytes [183]. The results correlate to the data obtained from IL-10, IL-6, and TNF- $\alpha$  protein secretion.

The results also showed that genistein alone could activate MEKK1 and c-Fos gene expressions. Members of the Fos family dimerise with c-jun to form the AP-1 transcription factor. In the previous results, we found genistein could inhibit the activation of transcription factor NF- $\kappa$ B and AP-1 in the RAW-Blue<sup>TM</sup> reporter cell line. This results confirmed the knowledge that genistein could inhibit the expression of NF- $\kappa$ B1 and I $\kappa$ B- $\alpha$  at the transcriptional level. Additionally, these results provide additional evidence for the results from western blot that genistein could activate MAP kinase cascade.

In conclusion, genistein showed a strong anti-inflammatory effect in RAW264.7 macrophages: it inhibited the secretion of NO and reduced the secretion of inflammatory

cytokines such as TNF- $\alpha$ , IL-6, and IL-10 via its effects on the transcription of these proteins. Moreover, genistein could strongly regulate the gene expression of cytokines, such as IL-1 $\alpha$ , IL-1 $\beta$ , IFN- $\beta$ , Csf-2, and Csf-3, and of chemokines, such as Ccl2 and Cxcl10. The effects of genistein could partly be due to tyrosine kinase inhibition of JAK2, Syk, Src and their downstream kinase PI3K-AKT pathway leading to the inhibition of the activation of the transcription factors NF- $\kappa$ B and AP-1. The results of this study provided more evidence for investigation of the mechanism of anti-inflammatory effects of genistein.




Fig. 5.1 Schematic illustration of the inflammation mechanism in macrophage RAW264.7 activated by LPS and/or IFN- $\gamma$ . The kinases which are potentially targeted by genistein based on our results are highlighted by a red rectangle.

### 5.3 Genistein effects on *C. albicans*

Mitochondria are known as the power houses of the cell, they play very important roles in a range of processes such as ATP production, electron transport, and oxidative phosphorylation, release of caspase-activating proteins, generation of reactive oxygen species (ROS) and changes of cellular redox potentials [124]. Due to these properties, mitochondria are considered to be a potential target for antifungal agents. Compounds such as rotenone, antimycin, myxothiazols, melithiazols and cystothiazoles are known to exert their antifungal activity by specifically inhibiting the electron transport within the respiratory chain [125, 126]. In plants, flavonoids are also responsible for defense against infections. Flavonoids, such as hispidulin, resveratrol, eupafolin, genistein, and flavone, target on the respiratory chain of mammalian cells [184-188].

However, the function of flavonoids, on *C. albicans* is still unknown. Therefore, it is interesting to investigate genistein effects on *C. albicans* especially on mitochondria.

Genistein showed an inhibitory effect of oxygen consumption and induced ROS production in *C. albicans* but not in *S. cerevisiae*, suggesting electron transport chain could be the target of genistein. Rotenone, a specific complex I inhibitor, also showed an inhibitory effect of oxygen consumption and an increased ROS production only in *C. albicans*. *S. cerevisiae* lacks the classical complex I and thus is resistant to rotenone, whereas, *C. albicans* has NADH dehydrogenases and complex I.

Antimycin A is a specific complex III inhibitor, which strongly blocked oxygen consumption and significantly increased ROS production both in *C. albicans* and *S. cerevisiae*, suggesting that inhibition of complex III is prominent for oxygen consumption and ROS production for both *C. albicans* and *S. cerevisiae*. This result also indicated that genistein did not target on the complex III.


In contrast to *S. cerevisiae*, *C. albicans* expresses an alternative oxidase (AOX) that act downstream from coenzyme Q. It is induced by inhibitors of complex III and IV, such as antimycin A or cyanide [132]. This alternative oxidase is related to cyanide resistant respiration, which accepts electrons from the ubiquinone pool of the main cytochrome pathway and reduces oxygen to water [132]. There are also reports that reactive oxygen species (ROS), such as superoxide radical anions and  $H_2O_2$  induce the expression of AOX in *Hansenula anomala* and *Petunia hybrid*, suggesting that the cyanide-resistant respiration may be part of defence system against oxidative stress, minimizing the generation of ROS in mitochondria [189, 190]. Since we observed an increase in the level of ROS, we excluded the possibility that genistein could target on the alternative oxidase. Thus, we assumed that complex I is the most likely target of genistein.

Complex I is a very large enzyme at the entry point of the mitochondrial electron transport chain [191, 192]. It has a complex structure and a number of redox centers involved in the electron transfer from NADH to a lipid soluble electron carrier, ubiquinone or Coenzyme Q (CoQ). The redox reactions are performed by one non-covalently bound FMN, at least six iron-sulfur clusters, and at least two distinct protein-bound species of quinone [193]. The FMN is considered to be the direct electron acceptor of NADH and subsequently electrons are transferred to the iron-sulphur clusters. N-2 iron-sulphur center is the direct electron donor to endogenous ubiquinone. Complex I is also considered to be one of the main sites of reactive oxygen species (ROS) production. Electrons leaked at complex I can reduce oxygen and give rise to the superoxide anion. N-2 iron-sulphur cluster was reported to be the site of the electron leak, but



N-2-ubisemiquinone region, ubisemiquinone, FMN and iron-sulphur cluster N1a have also been proposed as electron donors to oxygen [192].

As the mechanism of superoxide production by complex I is not yet clear due to a lack of knowledge about the exact sequence of the electron carriers and on the coupling of the electron transfer to proton translocation [192], the mechanism of action of genistein cannot be precisely defined. But we propose that genistein could act as a prooxidant by its direct reaction with the iron of complex I of the respiratory chain and O<sub>2</sub>. Cao et al. have proposed a reaction sequence for ROS production where the first step requires the oxidized state of the involved transition metal, which is reduced by the reaction with genistein [194]. The generation of the hydrogen peroxide can be assumed by the following reaction sequence [186, 194].



**GEN-OH is the reduced form of genistein, GEN=O is the oxidized form and Fe<sup>3+/2+</sup> is part of an Fe-S cluster belonging to the involved respiratory chain complex.**

We further tested whether genistein influenced the complex I reductase activity. We used DCIP as an electron mediator, DCIP is a hydrophilic electron acceptor widely used to test complex I reductase activity. It is reported that only 20-30% of this activity is sensitive to rotenone [192]. The results showed that genistein and rotenone affect DCIP reduction in a different way. Rotenone prevented this reduction, while genistein has no effect. This suggests genistein did not target the rotenone sensitive NADH dehydrogenase. Genistein was reported to inhibit the activity of complex I in bovine heart electron transport particles but was considered to be less active than rotenoid compounds [195].

As glucose was the carbon source in the cultivations, the main pathway for the carbon metabolism was glycolysis. In aerobic organism *C. albicans*, respiration is the main pathway for energy generation [146]. The glucose will convert to pyruvate together with the production of adenosine triphosphate (ATP) and NADH. NADH oxidation in the respiratory chain leads to electron transfer from NADH finally to oxygen and production ATP. Inhibitors of respiratory chain redirect pathways to fermentation and thus enhance the ethanol and glycerol production [148]. Thus, inhibition of the respiratory chain by genistein should influence the ethanol production. We confirmed that genistein indeed slightly induced ethanol production at the highest

concentration of 100  $\mu$ M.

In conclusion, our results showed that genistein targeted on the respiratory chain of *C. albicans*. We propose that genistein is oxidized by a redox reaction with iron-sulfur clusters and thus blocks electron transport and consequently oxygen consumption and induces ROS production. Our results also confirmed that growth rates of yeasts are not necessarily correlated to respiration rates. The parallel analysis of effects on growth rate and on the oxygen consumption rate improves the reliability of the detection of potential inhibitors and gives additional hints on the mode of action of compounds [146].

## **5.4 Treatment of *C. albicans* with genistein enhances the activity of murine macrophages**

Anti-inflammatory properties of genistein have been investigated. Up to now, most experiments are focused on the pre-treatment of different cells of the immune system with genistein and on studying the resulting influences on the functions of the immune system. For example, macrophages [196-200], neutrophils [201-206] and monocytes [207] were treated with genistein prior to stimulation with LPS or infection by different pathogens such as *E. coli* [208], *Legionella pneumophila* [207], and *Cryptosporidium parvum* [209]. Usually inhibitory effects on the functions of the immune cells were observed, which could be explained mainly by the inhibition of tyrosine kinases by genistein. In our study, the effect of genistein on the interaction between *C. albicans* and macrophages was evaluated, particularly, the effects of genistein on phagocytosis of *C. albicans* by macrophages considering two different aspects: genistein acts either (i) on the host or (ii) on the pathogen. The results showed that genistein could act on both the yeast and the macrophages.

According to previous reports, tyrosine residues in host cell proteins became phosphorylated when host cells interact with *C. albicans* [31, 32]. As the endocytotic internalization of *C. albicans* by endothelial cells was one of the affected processes [37], we investigated whether incubation of macrophages with genistein also influenced internalization of *C. albicans* by these cells, which is mainly due to phagocytosis. We did not observe short-term effects, but extension of the incubation time to 24 or 48 hours significantly reduced the phagocytotic activity without influencing the cell viability [210]. This observation correlates to the changes in cell morphology and in the structure of the actin cytoskeleton, which were also observed only after 48 hours of incubation. Previously, it was shown that any interference with the dynamics of the actin

cytoskeleton leads to a reduction of the phagocytotic efficiency of macrophages for *C. albicans* [211]. Thus, the inhibition of phagocytosis after extended genistein incubation time may be due to secondary effects of genistein on the cytoskeleton.

However, inhibition of the secretion of the cytokines TNF- $\alpha$  and IL-10 occurred after a pre-incubation time of only 1 hour, which indicates direct effects on signal transduction cascades. Similar effects of genistein on TNF- $\alpha$  and IL-10 production were observed when macrophages were treated with LPS. Moreover, dectin-1 together with Toll-like receptor 2 (TLR2) are involved in cytokine production resulting from the presence of *C. albicans* [84], and the corresponding signalling cascades comprise of several tyrosine kinases. FACS analysis showed that dectin-1 and TLR2 receptors are expressed on the surface of RAW264.7 macrophages. The inhibitory effects of genistein on the production of these cytokines are probably due to the tyrosine kinase inhibitory property of genistein.

Further, we investigated whether treatment of *C. albicans* with genistein influenced the interaction to host cells. We cultivated *C. albicans* in the presence of genistein overnight to allow not only immediate effects, but also secondary effects such as the cell wall composition, which is the primary point of interaction to host cells. Contrary to the results obtained when macrophages were treated with genistein, we observed an enhanced level of phagocytosis and also a stimulated production of the cytokines TNF- $\alpha$  and IL-10. It was reported that released TNF- $\alpha$  can have a positive feedback on phagocytosis at early stages of infection [212]. Therefore, the increased secretion of TNF- $\alpha$  may be the reason for the enhanced phagocytosis of *C. albicans*.

Moreover, the increased cell surface hydrophobicity resulting from genistein treatment of *C. albicans* points to influences on the cell wall composition. These may affect its interaction with macrophages via either specific receptor-ligand interactions or changes in physicochemical properties, since cell surface hydrophobicity of *C. albicans* cells affects adherence of *C. albicans* to host tissues [213]. However, genistein treatment of *C. albicans* did not influence  $\beta$ -1, 3-glucan exposure so that specific dectin-1 activation cannot be considered to be the reason for the positive effects on the macrophage functions. The respective mechanisms are yet unknown and their elucidation is a topic for further studies.

MAPK kinase cascades are involved in several stress resistance mechanisms: regulation of cell wall biosynthesis, morphogenesis, and virulence [118, 121, 167]. In particular, CEK1-mediated mitogen-activated protein kinase pathway controls *C. albicans*  $\beta$ -glucan exposure and modulates immune responses [214]. Our results showed that the MAPK mutants have a high phagocytotic uptake efficiency compared with the parental strains CAF2-1, which is

related to higher  $\beta$ -glucans exposure. Cek1p, Mkc1p, Hst7p, and Pbs2p are reported to regulate the virulence of *C. albicans* in *in vivo* experiments [167]. We used genistein to pre-treat the mutants  $\Delta hog1$  and  $\Delta cek1$ , then infected the macrophages. The results showed no influence of genistein on the phagocytosis of the mutants compared with solvent control, suggesting that these pathways are involved in the genistein effect on phagocytosis.

In conclusion, we studied the effects of genistein on the interaction of *C. albicans* with macrophages, using primarily phagocytosis and cytokine production as indicators. Genistein exerted dose- and time-dependent inhibitory effects when macrophages were pre-treated with genistein. However, genistein also showed the ability to modify the cell surface of *C. albicans* so that the cell surface became more hydrophobic and enhanced the activity of murine macrophages.

Thus, our studies point to new pharmacological activities of genistein and alternative strategies for immunostimulation in host-pathogen systems by treating the immune cells as well as the pathogen.

## 5.5 Conclusions and future directions

Flavonoids belong to a class of phytochemicals with remarkable chemical and biological properties. Since ancient times, humans have exploited the therapeutic properties of medicinal plants, many of which have been found to have flavonoids as their primary active constituent. Isoflavones are a subclass of flavonoids which is found mainly in soybeans, which are mostly consumed in Asian countries like China and Japan in the regular diet. The target compound genistein is one of the most important isoflavones. Research on the health benefits of genistein over the last century has elucidated the effects as antioxidant, anti-inflammatory, anti-microbial, cardioprotective, and anti-cancer compound.

Fungal infections are a severe medical issue in particular for patients with a compromised immune system. *C. albicans* infections have risen steadily over the past three decades. Approximately 70% of women experience vaginal infections and 20% of them suffer from recurrent infections. In those latter recurrent infections, about half of the patients have four or more episodes per year [215].

The immune system has two principal components: innate and adaptive immunity, which work together to protect the body against infections. The cells of the innate immune system represent the first line of defense in the immunosurveillance network; they directly recognize a wide variety of microorganisms through highly conserved receptors and essential microbial

molecules. Meanwhile, the immune system carries out its important defensive function in intimate and coordinated interactions with the nervous and endocrine systems. Compromised immune system increases risks of opportunistic infections and uncontrolled neoplastic tissue growth, while an over-activated immune system could also lead to inflammation, allergy, and autoimmunity.

Currently, several classes of systemic antifungal compounds are applied in clinical therapy. The application of these antimycotic agents is challenged by the increasing numbers of resistant strains and by severe side effects. Drug resistant strains cause tremendous economic damage and life-threatening diseases in both immunocompromised and immunocompetent individuals.

Thus, there is an increasing need to develop new agents, which utilize new targets against fungal human pathogens, reduce the risk of resistance development and maintain an efficient and equilibrated immune system.

The research undertaken in this thesis was designed to:

- ✧ Identify potent effects of genistein on the properties of the immune cells including anti-inflammatory effects of genistein against stimuli from bacteria and cytokines and elucidate the underlying mechanisms
- ✧ Determine the molecular effects of genistein on the pathogen *C. albicans* focusing on the modulation of the mitochondria function of *C. albicans*
- ✧ Examine the effects of genistein on the interaction of macrophages and *C. albicans*
- ✧ Examine the role of single gene deletions on the interaction of macrophage and *C. albicans* and on the activity of genistein

The elucidation of the mechanisms of action of genistein against *C. albicans* infection listed above is a challenging task. A multitude of chemical and biological properties of genistein may together collaborate in the anti-inflammatory and anti-fungal effects. The findings outlined in this thesis provide the basis for piecing together a mechanism explaining the properties of genistein against *C. albicans* infection.

We have demonstrated that genistein induces a cell cycle arrest in G2/M phase and influences cell proliferation in high concentration (50-100  $\mu$ M) with long time incubation (24-48 h). Treatment of the macrophages with genistein for 24 or 48 h also led to significant morphological changes, such as elongation of the cells and development of long pseudopodia-like protrusions. By staining the F-actin cytoskeleton, we observed the accumulation of actin-filaments at the edges of the cells.

Genistein influences the function of macrophage challenged by different stimuli such as LPS

and cytokines like IFN- $\gamma$ . It showed a strong anti-inflammatory effect, while the precise mechanism underlying this inhibition still remains to be further determined. Possible mechanisms include: (i) inhibition of the secretion of NO; (ii) reduction in the secretion of inflammatory cytokines TNF- $\alpha$ , IL-6, and IL-10 protein levels via influencing of their transcription; and (iii) strong regulation of the expression of (a) cytokines IFN- $\beta$ , IL-10, IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$ , Csf2, and Csf3; (b) chemokines Ccl2 and Cxcl10; (c) transcription factor NF- $\kappa$ B1; (d) I $\kappa$ B- $\alpha$ ; and (e) cyclooxygenase 2 (COX-2). It could be due to tyrosine kinase inhibition of Jak2, Syk, and Src and their downstream kinase PI3k-Akt pathway, which leads to the inhibition of the transcription factors NF- $\kappa$ B and AP-1.

Additionally, we investigated whether genistein directly influences the pathogen *C. albicans*. Our results showed that genistein blocked oxygen consumption of *C. albicans* and induced the production of reactive oxygen species which means that genistein could influence the function of mitochondria of *C. albicans*. The respiratory chain structure of *C. albicans* is more complex and flexible than that of mammalian cells. It is not yet fully elucidated. Therefore, this brings a challenge to the work. The site of action by genistein in complex I and the question of whether genistein induces AOX expression are still to be investigated.

We further studied the effect of genistein on the interaction of *C. albicans* with macrophages, using primarily phagocytosis and cytokine production as indicators. After treatment of the macrophages with genistein, the phagocytotic efficiency for *C. albicans* was decreased in a time- and dose-dependent manner. Moreover, the production of cytokines (TNF- $\alpha$  and IL-10) stimulated by *C. albicans* was strongly inhibited by genistein. The inhibition of phagocytosis after extended genistein incubation may be due to indirect effects on the cytoskeleton. On the other hand, treatment of *C. albicans* with genistein enhanced the susceptibility of the pathogen for phagocytosis by the macrophages and increased the production of the cytokines IL-10 and TNF- $\alpha$ . However, genistein did not influence the layered structure of the cell wall but *C. albicans* became more hydrophobic.

All investigations in this study were performed as *in vitro* experiments. It is reported that genistein also shows protection of the acute lung injury *in vivo*. However, little is known about the function of genistein in more complex systems. And the effect of genistein on *C. albicans* infection should be extended to *in vivo* experiments. Moreover, the mode of action of genistein on *C. albicans* still needs to be further investigated by microarray and protein analysis. Moreover, whether there is a direct link between the inhibition of respiration and the modulation of inflammatory responses to *C. albicans* by macrophage or not still needs to be further studied.

The advantage of genistein is that it shows not only anti-fungal but also strong anti-inflammatory effects. It can target pathogens and modulate the immune condition of the body. Our studies pointed to new pharmacological activities of genistein and alternative strategies for immunostimulation in host-pathogen systems by treatment of the pathogens instead of the immune cells. As a future research direction, it will be interesting to modify the structure of genistein by altering its functional groups to enhance the antifungal effect and then further identify the medical potential of the new compounds.

## 6 REFERENCE

- [1] Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. *The Journal of nutrition* 2003;133:324S-54S.
- [2] Steensma A, Faassen-Peters MA, Noteborn HP, Rietjens IM. Bioavailability of genistein and its glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. *Journal of agricultural and food chemistry* 2006;54:8006-12.
- [3] Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. *The Journal of biological chemistry* 1987;262:5592-5.
- [4] Nishikawa M. Reactive oxygen species in tumor metastasis. *Cancer letters* 2008;266:53-9.
- [5] Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. *Critical reviews in food science and nutrition* 2004;44:275-95.
- [6] Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. *Free radical research* 1997;26:63-70.
- [7] Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. *Journal of the National Cancer Institute* 1998;90:381-8.
- [8] Wei H, Wei L, Frenkel K, Bowen R, Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. *Nutrition and cancer* 1993;20:1-12.
- [9] Rotondo S, Krauze-Brzosko K, Manarini S, Martelli N, Pecce R, Evangelista V, et al. Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake. *The British journal of nutrition* 2008;99:240-7.
- [10] Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. *Free radical biology & medicine* 2001;30:1293-302.
- [11] Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate cancer cells. *Nutrition and cancer* 1999;35:167-74.
- [12] Choi C, Cho H, Park J, Cho C, Song Y. Suppressive effects of genistein on oxidative stress and NFkappaB activation in RAW 264.7 macrophages. *Bioscience, biotechnology, and biochemistry* 2003;67:1916-22.
- [13] Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, et al. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. *The American journal of pathology* 1999;155:473-81.
- [14] Yellayi S, Naaz A, Szewczykowski MA, Sato T, Woods JA, Chang J, et al. The phytoestrogen genistein induces thymic and immune changes: a human health concern?



Proceedings of the National Academy of Sciences of the United States of America 2002;99:7616-21.

[15] Yellayi S, Zakroczymski MA, Selvaraj V, Valli VE, Ghanta V, Helferich WG, et al. The phytoestrogen genistein suppresses cell-mediated immunity in mice. *The Journal of endocrinology* 2003;176:267-74.

[16] Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S. Genistein enhances antigen-specific cytokine production in female DO11.10 transgenic mice. *Journal of nutritional science and vitaminology* 2006;52:327-32.

[17] Guo TL, McCay JA, Zhang LX, Brown RD, You L, Karrow NA, et al. Genistein modulates immune responses and increases host resistance to B16F10 tumor in adult female B6C3F1 mice. *The Journal of nutrition* 2001;131:3251-8.

[18] Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S. Genistein suppresses development of spontaneous atopic-like dermatitis in NC/Nga mice. *Journal of nutritional science and vitaminology* 2006;52:293-6.

[19] Rapaport FT, Terashima T, Tsukuda K, Kono K, Takayama T, Malinowski K. Suppression of lectin, alloantigen, and xenoantigen-induced T-cell proliferation by Genistein. *Transplantation proceedings* 1997;29:1261-4.

[20] Duan W, Kuo IC, Selvarajan S, Chua KY, Bay BH, Wong WS. Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. *American journal of respiratory and critical care medicine* 2003;167:185-92.

[21] Ruetten H, Thiemermann C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. *British journal of pharmacology* 1997;122:59-70.

[22] Sheu F, Lai HH, Yen GC. Suppression effect of soy isoflavones on nitric oxide production in RAW 264.7 macrophages. *Journal of agricultural and food chemistry* 2001;49:1767-72.

[23] Cho JY, Kim PS, Park J, Yoo ES, Baik KU, Kim YK, et al. Inhibitor of tumor necrosis factor- $\alpha$  production in lipopolysaccharide-stimulated RAW264.7 cells from *Amorpha fruticosa*. *Journal of ethnopharmacology* 2000;70:127-33.

[24] Geng Y, Zhang B, Lotz M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. *J Immunol* 1993;151:6692-700.

[25] Paradkar PN, Blum PS, Berhow MA, Baumann H, Kuo SM. Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. *Cancer letters* 2004;215:21-8.

[26] Chen XW, Garner SC, Anderson JJ. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. *Biochemical and biophysical research communications* 2002;295:417-22.

[27] Ding SZ, Cho CH, Lam SK. Regulation of interleukin 6 production in a human gastric epithelial cell line MKN-28. *Cytokine* 2000;12:1129-35.

[28] Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T,

Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. *The Journal of pharmacology and experimental therapeutics* 2001;296:181-7.

[29] Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA, Martinez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. *Inflamm Res* 2009;58:537-52.

[30] Yazdanyar A, Essmann M, Larsen B. Genistein effects on growth and cell cycle of *Candida albicans*. *Journal of biomedical science* 2001;8:153-9.

[31] Santoni G, Lucciarini R, Amantini C, Jacobelli J, Spreghini E, Ballarini P, et al. *Candida albicans* expresses a focal adhesion kinase-like protein that undergoes increased tyrosine phosphorylation upon yeast cell adhesion to vitronectin and the EA.hy 926 human endothelial cell line. *Infection and immunity* 2002;70:3804-15.

[32] Belanger PH, Johnston DA, Fratti RA, Zhang M, Filler SG. Endocytosis of *Candida albicans* by vascular endothelial cells is associated with tyrosine phosphorylation of specific host cell proteins. *Cellular microbiology* 2002;4:805-12.

[33] Pereira SG, Oakley F. Nuclear factor-kappaB1: regulation and function. *The international journal of biochemistry & cell biology* 2008;40:1425-30.

[34] Natarajan K, Manna SK, Chaturvedi MM, Aggarwal BB. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. *Archives of biochemistry and biophysics* 1998;352:59-70.

[35] Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. *Cancer research* 2006;66:4816-25.

[36] Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. *Cancer* 2006;106:1260-8.

[37] Tanaka T, Kohno H, Tanino M, Yanaida Y. Inhibitory effects of estrogenic compounds, 4-nonylphenol and genistein, on 7,12-dimethylbenz[a]anthracene-induced ovarian carcinogenesis in rats. *Ecotoxicology and environmental safety* 2002;52:38-45.

[38] Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature* 1999;401:82-5.

[39] Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. *Nature* 1999;401:86-90.

[40] Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. *International journal of cancer* 2007;120:906-17.

[41] Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. *Clin Cancer Res* 2002;8:2369-77.

[42] Stoica GE, Franke TF, Wellstein A, Czubyko F, List HJ, Reiter R, et al.

Estradiol rapidly activates Akt via the ErbB2 signaling pathway. *Molecular endocrinology* (Baltimore, Md 2003;17:818-30.

[43] Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, et al. Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. *Oncogene* 2003;22:2073-87.

[44] Treisman R. Regulation of transcription by MAP kinase cascades. *Current opinion in cell biology* 1996;8:205-15.

[45] Huang X, Chen S, Xu L, Liu Y, Deb DK, Plataniias LC, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. *Cancer research* 2005;65:3470-8.

[46] Liu H, Du J, Hu C, Qi H, Wang X, Wang S, et al. Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells. *The Journal of nutritional biochemistry* 2009.

[47] Frey RS, Singletary KW. Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. *The Journal of nutrition* 2003;133:226-31.

[48] Sanchez Y, Amran D, Fernandez C, de Blas E, Aller P. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). *International journal of cancer* 2008;123:1205-14.

[49] Li Z, Li J, Mo B, Hu C, Liu H, Qi H, et al. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. *Cell biology and toxicology* 2008;24:401-9.

[50] A.Goldsby R, Kindt TJ, Osborne BA, Kuby J. *Immunology*. 2003.

[51] K.Abbas A, H.Lichtman A, Pillai S. *Cellular and molecular immunology*, 2007.

[52] Janeway CA, Travers P, Walpot M, Shlomchik MJ. *Immunobiology*: Garland Science Publishing, 2005.

[53] Silbernagel S, Despopulos A. *Taschenatlas der Physiologie*. Stuttgart - New York: Georg Thieme Verlag, 2003.

[54] Netea MG, Brown GD, Kullberg BJ, Gow NA. An integrated model of the recognition of *Candida albicans* by the innate immune system. *Nat Rev Microbiol* 2008;6:67-78.

[55] Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol* 2001;2:675-80.

[56] Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. *Nature reviews* 2003;3:371-82.

[57] Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. *Nat Rev Mol Cell Biol* 2003;4:95-104.

[58] Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.

[59] Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive

immune response. *Curr Opin Immunol* 1997;9:4-9.

[60] Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. *Proceedings of the National Academy of Sciences of the United States of America* 2004;101:3516-21.

[61] Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature* 2008;452:234-8.

[62] Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. *Nature* 2008;456:658-62.

[63] Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. *The Journal of cell biology* 2007;177:265-75.

[64] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006;124:783-801.

[65] Beutler BA. TLRs and innate immunity. *Blood* 2009;113:1399-407.

[66] Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. *Biochemical and biophysical research communications* 2009;388:621-5.

[67] Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. *The Biochemical journal* 2009;420:1-16.

[68] Ariizumi K, Shen GL, Shikano S, Xu S, Ritter R, 3rd, Kumamoto T, et al. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. *The Journal of biological chemistry* 2000;275:20157-67.

[69] Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, et al. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. *Immunity* 2005;22:507-17.

[70] Gow NA, Netea MG, Munro CA, Ferwerda G, Bates S, Mora-Montes HM, et al. Immune recognition of *Candida albicans* beta-glucan by dectin-1. *J Infect Dis* 2007;196:1565-71.

[71] Heinsbroek SE, Taylor PR, Rosas M, Willment JA, Williams DL, Gordon S, et al. Expression of functionally different dectin-1 isoforms by murine macrophages. *J Immunol* 2006;176:5513-8.

[72] Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L, Gordon S, et al. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. *J Immunol* 2002;169:3876-82.

[73] Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. *The Journal of allergy and clinical immunology* 2006;118:837-43.

[74] Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, et al. The human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. *European journal of immunology* 2005;35:1539-47.

[75] Willment JA, Lin HH, Reid DM, Taylor PR, Williams DL, Wong SY, et al.

Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. *J Immunol* 2003;171:4569-73.

[76] Grunebach F, Weck MM, Reichert J, Brossart P. Molecular and functional characterization of human Dectin-1. *Experimental hematology* 2002;30:1309-15.

[77] Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. *Nature* 2001;413:36-7.

[78] Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of beta-glucans. *J Exp Med* 2003;197:1119-24.

[79] Gersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and TLRs permit macrophages to distinguish between different *Aspergillus fumigatus* cellular states. *J Immunol* 2006;176:3717-24.

[80] Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. *Nat Immunol* 2007;8:31-8.

[81] Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, et al. Dectin-1 is required for host defense against *Pneumocystis carinii* but not against *Candida albicans*. *Nat Immunol* 2007;8:39-46.

[82] Steele C, Marrero L, Swain S, Harmsen AG, Zheng M, Brown GD, et al. Alveolar macrophage-mediated killing of *Pneumocystis carinii* f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. *The Journal of experimental medicine* 2003;198:1677-88.

[83] Viriyakosol S, Fierer J, Brown GD, Kirkland TN. Innate immunity to the pathogenic fungus *Coccidioides posadasii* is dependent on Toll-like receptor 2 and Dectin-1. *Infection and immunity* 2005;73:1553-60.

[84] Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. *J Exp Med* 2003;197:1107-17.

[85] Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. *Proceedings of the National Academy of Sciences of the United States of America* 1986;83:2501-5.

[86] Stephenson JD, Shepherd VL. Purification of the human alveolar macrophage mannose receptor. *Biochemical and biophysical research communications* 1987;148:883-9.

[87] Stahl PD, Rodman JS, Miller MJ, Schlesinger PH. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. *Proceedings of the National Academy of Sciences of the United States of America* 1978;75:1399-403.

[88] Linehan SA, Martinez-Pomares L, Gordon S. Macrophage lectins in host defence. *Microbes and infection / Institut Pasteur* 2000;2:279-88.

[89] Kery V, Krepinsky JJ, Warren CD, Capek P, Stahl PD. Ligand recognition by purified human mannose receptor. *Archives of biochemistry and biophysics*

1992;298:49-55.

[90] Netea MG, Gow NA, Munro CA, Bates S, Collins C, Ferwerda G, et al. Immune sensing of *Candida albicans* requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. *The Journal of clinical investigation* 2006;116:1642-50.

[91] Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. *Annual review of immunology* 1997;15:749-95.

[92] Valente G, Ozmen L, Novelli F, Geuna M, Palestro G, Forni G, et al. Distribution of interferon-gamma receptor in human tissues. *European journal of immunology* 1992;22:2403-12.

[93] Kaufmann SH. Immunity to intracellular bacteria. *Annual review of immunology* 1993;11:129-63.

[94] MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. *Annual review of immunology* 1997;15:323-50.

[95] Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science (New York, NY)* 1994;264:1415-21.

[96] Schindler C, Shuai K, Prezioso VR, Darnell JE, Jr. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. *Science (New York, NY)* 1992;257:809-13.

[97] Weinstein SL, Sanghera JS, Lemke K, DeFranco AL, Pelech SL. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. *The Journal of biological chemistry* 1992;267:14955-62.

[98] Weinstein SL, Gold MR, DeFranco AL. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. *Proceedings of the National Academy of Sciences of the United States of America* 1991;88:4148-52.

[99] Weinstein SL, June CH, DeFranco AL. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. *J Immunol* 1993;151:3829-38.

[100] Okugawa S, Ota Y, Kitazawa T, Nakayama K, Yanagimoto S, Tsukada K, et al. Janus kinase 2 is involved in lipopolysaccharide-induced activation of macrophages. *American journal of physiology* 2003;285:C399-408.

[101] Herrera-Velit P, Reiner NE. Bacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. *J Immunol* 1996;156:1157-65.

[102] Herrera-Velit P, Knutson KL, Reiner NE. Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes. *The Journal of biological chemistry* 1997;272:16445-52.

[103] Ulanova M, Asfaha S, Stenton G, Lint A, Gilbertson D, Schreiber A, et al. Involvement of Syk protein tyrosine kinase in LPS-induced responses in macrophages. *Journal of endotoxin research* 2007;13:117-25.

[104] Orlicek SL, Meals E, English BK. Differential effects of tyrosine kinase

inhibitors on tumor necrosis factor and nitric oxide production by murine macrophages. *The Journal of infectious diseases* 1996;174:638-42.

[105] Orlicek SL, Hanke JH, English BK. The src family-selective tyrosine kinase inhibitor PP1 blocks LPS and IFN-gamma-mediated TNF and iNOS production in murine macrophages. *Shock* (Augusta, Ga 1999;12:350-4.

[106] Berman J, Sudbery PE. *Candida Albicans*: a molecular revolution built on lessons from budding yeast. *Nat Rev Genet* 2002;3:918-30.

[107] Sudbery P, Gow N, Berman J. The distinct morphogenic states of *Candida albicans*. *Trends in microbiology* 2004;12:317-24.

[108] Odds FC. Morphogenesis in *Candida albicans*. *Critical reviews in microbiology* 1985;12:45-93.

[109] Calderone RA, Fonzi WA. Virulence factors of *Candida albicans*. *Trends in microbiology* 2001;9:327-35.

[110] Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. *The Pediatric infectious disease journal* 2003;22:686-91.

[111] Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis* 2003;37:1172-7.

[112] Kruppa M, Goins T, Cutler JE, Lowman D, Williams D, Chauhan N, et al. The role of the *Candida albicans* histidine kinase [CHK1) gene in the regulation of cell wall mannan and glucan biosynthesis. *FEMS yeast research* 2003;3:289-99.

[113] Rebecca A. Hall FC, Fritz A. Muehlschlegel. *Molecular Networks in the Fungal Pathogen Candida albicans*, 2009.

[114] Kruppa M, Calderone R. Two-component signal transduction in human fungal pathogens. *FEMS yeast research* 2006;6:149-59.

[115] Calera JA, Calderone R. Histidine kinase, two-component signal transduction proteins of *Candida albicans* and the pathogenesis of candidosis. *Mycoses* 1999;42 Suppl 2:49-53.

[116] Nagahashi S, Mio T, Ono N, Yamada-Okabe T, Arisawa M, Bussey H, et al. Isolation of CaSLN1 and CaNIK1, the genes for osmosensing histidine kinase homologues, from the pathogenic fungus *Candida albicans*. *Microbiology (Reading, England)* 1998;144 ( Pt 2):425-32.

[117] Arana DM, Nombela C, Alonso-Monge R, Pla J. The Pbs2 MAP kinase kinase is essential for the oxidative-stress response in the fungal pathogen *Candida albicans*. *Microbiology (Reading, England)* 2005;151:1033-49.

[118] Alonso-Monge R, Navarro-Garcia F, Molero G, Diez-Orejas R, Gustin M, Pla J, et al. Role of the mitogen-activated protein kinase Hog1p in morphogenesis and virulence of *Candida albicans*. *Journal of bacteriology* 1999;181:3058-68.

[119] Csank C, Schroppel K, Leberer E, Harcus D, Mohamed O, Meloche S, et al. Roles of the *Candida albicans* mitogen-activated protein kinase homolog, Cek1p, in

hyphal development and systemic candidiasis. *Infection and immunity* 1998;66:2713-21.

[120] Chen J, Chen J, Lane S, Liu H. A conserved mitogen-activated protein kinase pathway is required for mating in *Candida albicans*. *Molecular microbiology* 2002;46:1335-44.

[121] Eisman B, Alonso-Monge R, Roman E, Arana D, Nombela C, Pla J. The Cek1 and Hog1 mitogen-activated protein kinases play complementary roles in cell wall biogenesis and chlamyospore formation in the fungal pathogen *Candida albicans*. *Eukaryotic cell* 2006;5:347-58.

[122] Guhad FA, Jensen HE, Aalbaek B, Csank C, Mohamed O, Marcus D, et al. Mitogen-activated protein kinase-defective *Candida albicans* is avirulent in a novel model of localized murine candidiasis. *FEMS microbiology letters* 1998;166:135-9.

[123] Gantner BN, Simmons RM, Underhill DM. Dectin-1 mediates macrophage recognition of *Candida albicans* yeast but not filaments. *Embo J* 2005;24:1277-86.

[124] Green DR, Reed JC. Mitochondria and apoptosis. *Science (New York, NY)* 1998;281:1309-12.

[125] Clough JM. The strobilurins, oudemansins, and myxothiazols, fungicidal derivatives of beta-methoxyacrylic acid. *Natural product reports* 1993;10:565-74.

[126] Clough JM, Dube H, Martin BJ, Pattenden G, Reddy KS, Waldron IR. Total synthesis of myxothiazols, novel bis-thiazole beta-methoxyacrylate-based anti-fungal compounds from myxobacteria. *Organic & biomolecular chemistry* 2006;4:2906-11.

[127] Ruy F, Vercesi AE, Kowaltowski AJ. Inhibition of specific electron transport pathways leads to oxidative stress and decreased *Candida albicans* proliferation. *Journal of bioenergetics and biomembranes* 2006;38:129-35.

[128] Guerin M, Camougrand N, Caubet R, Zniber S, Velours G, Manon S, et al. The second respiratory chain of *Candida parapsilosis*: a comprehensive study. *Biochimie* 1989;71:887-902.

[129] Moller IM, Rasmusson AG, Fredlund KM. NAD(P)H-ubiquinone oxidoreductases in plant mitochondria. *Journal of bioenergetics and biomembranes* 1993;25:377-84.

[130] Siedow JN, Umbach AL. The mitochondrial cyanide-resistant oxidase: structural conservation amid regulatory diversity. *Biochimica et biophysica acta* 2000;1459:432-9.

[131] Joseph-Horne T, Hollomon DW, Wood PM. Fungal respiration: a fusion of standard and alternative components. *Biochimica et biophysica acta* 2001;1504:179-95.

[132] Huh WK, Kang SO. Characterization of the gene family encoding alternative oxidase from *Candida albicans*. *The Biochemical journal* 2001;356:595-604.

[133] Balcavage WX, Mattoon JR. Properties of *Saccharomyces cerevisiae* mitochondria prepared by a mechanical method. *Biochimica et biophysica acta* 1968;153:521-30.

[134] Bakker BM, Overkamp KM, van Maris AJ, Kotter P, Luttik MA, van Dijken JP, et al. Stoichiometry and compartmentation of NADH metabolism in *Saccharomyces cerevisiae*. *FEMS microbiology reviews* 2001;25:15-37.



- [135] Luttik MA, Overkamp KM, Kotter P, de Vries S, van Dijken JP, Pronk JT. The *Saccharomyces cerevisiae* NDE1 and NDE2 genes encode separate mitochondrial NADH dehydrogenases catalyzing the oxidation of cytosolic NADH. *The Journal of biological chemistry* 1998;273:24529-34.
- [136] Small WC, McAlister-Henn L. Identification of a cytosolically directed NADH dehydrogenase in mitochondria of *Saccharomyces cerevisiae*. *Journal of bacteriology* 1998;180:4051-5.
- [137] Alcibiades. Schematic draft of a Neubauer improved counting chamber for cells. 2006.
- [138] Raschke W, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. *Cell* 1978;15:261-7.
- [139] Griess JP. Bemerkungen zu der Abhandlung der HH. Weselky und Benedikt "Ueber einige Azoverbindungen". *Berichte der Deutschen chemischen Gesellschaft* 1879;12:426-8.
- [140] Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. *Proceedings of the National Academy of Sciences of the United States of America* 1993;90:8103-7.
- [141] Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. *Immunochemistry* 1971;8:871-4.
- [142] Fonzi WA, Irwin MY. Isogenic strain construction and gene mapping in *Candida albicans*. *Genetics* 1993;134:717-28.
- [143] Navarro-Garcia F, Sanchez M, Pla J, Nombela C. Functional characterization of the MKC1 gene of *Candida albicans*, which encodes a mitogen-activated protein kinase homolog related to cell integrity. *Mol Cell Biol* 1995;15:2197-206.
- [144] Leberer E, Harcus D, Broadbent ID, Clark KL, Dignard D, Ziegelbauer K, et al. Signal transduction through homologs of the Ste20p and Ste7p protein kinases can trigger hyphal formation in the pathogenic fungus *Candida albicans*. *Proceedings of the National Academy of Sciences of the United States of America* 1996;93:13217-22.
- [145] San Jose C, Monge RA, Perez-Diaz R, Pla J, Nombela C. The mitogen-activated protein kinase homolog HOG1 gene controls glycerol accumulation in the pathogenic fungus *Candida albicans*. *Journal of bacteriology* 1996;178:5850-2.
- [146] Wesolowski J, Hassan RY, Hodde S, Bardroff C, Bilitewski U. Sensing of oxygen in microtiter plates: a novel tool for screening drugs against pathogenic yeasts. *Analytical and bioanalytical chemistry* 2008;391:1731-7.
- [147] Wu XZ, Cheng AX, Sun LM, Sun SJ, Lou HX. Plagiochin E, an antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reactive oxygen species accumulation in *Candida albicans*. *Biochimica et biophysica acta* 2009;1790:770-7.
- [148] Wesolowski J, Hassan RY, Reinhardt K, Hodde S, Bilitewski U. Antifungal

compounds redirect metabolic pathways in yeasts: metabolites as indicators of modes of action. *Journal of applied microbiology* 2009.

[149] Jouault T, El Abed-El Behi M, Martinez-Esparza M, Breuilh L, Trinel PA, Chamaillard M, et al. Specific recognition of *Candida albicans* by macrophages requires galectin-3 to discriminate *Saccharomyces cerevisiae* and needs association with TLR2 for signaling. *J Immunol* 2006;177:4679-87.

[150] Tkacz JS, Cybulska EB, Lampen JO. Specific staining of wall mannan in yeast cells with fluorescein-conjugated concanavalin A. *Journal of bacteriology* 1971;105:1-5.

[151] Klotz SA, Drutz DJ, Zajic JE. Factors governing adherence of *Candida* species to plastic surfaces. *Infection and immunity* 1985;50:97-101.

[152] Klippel N, Bilitewski U. Phagocytosis Assay Based on Living *Candida albicans* for the Detection of Effects of Chemicals on Macrophages Function. *Analytical Letters* 2007;40:1407-18.

[153] Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. *Oncogene* 1999;18:3166-72.

[154] Thasni KA, Rojini G, Rakesh SN, Ratheeshkumar T, Babu MS, Srinivas G, et al. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. *European journal of pharmacology* 2008;588:158-64.

[155] Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. *Japanese journal of clinical oncology* 1998;28:360-3.

[156] Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, et al. Genistein arrests cell cycle progression at G2-M. *Cancer research* 1993;53:1328-31.

[157] Constantinou AI, Kamath N, Murley JS. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. *Eur J Cancer* 1998;34:1927-34.

[158] Oki T, Sowa Y, Hirose T, Takagaki N, Horinaka M, Nakanishi R, et al. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. *FEBS letters* 2004;577:55-9.

[159] Ismail IA, Kang KS, Lee HA, Kim JW, Sohn YK. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. *European journal of pharmacology* 2007;575:12-20.

[160] MacLean-Fletcher S, Pollard TD. Mechanism of action of cytochalasin B on actin. *Cell* 1980;20:329-41.

[161] Cimini D, Fioravanti D, Tanzarella C, Degrossi F. Simultaneous inhibition of contractile ring and central spindle formation in mammalian cells treated with cytochalasin B. *Chromosoma* 1998;107:479-85.

[162] Chen CC, Wang JK. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. *Molecular pharmacology* 1999;55:481-8.

- [163] Bonini MG, Rota C, Tomasi A, Mason RP. The oxidation of 2',7'-dichlorofluorescein to reactive oxygen species: a self-fulfilling prophesy? *Free radical biology & medicine* 2006;40:968-75.
- [164] Antley PP, Hazen KC. Role of yeast cell growth temperature on *Candida albicans* virulence in mice. *Infection and immunity* 1988;56:2884-90.
- [165] de Repentigny L, Aumont F, Bernard K, Belhumeur P. Characterization of binding of *Candida albicans* to small intestinal mucin and its role in adherence to mucosal epithelial cells. *Infection and immunity* 2000;68:3172-9.
- [166] Schorey JS, Lawrence C. The pattern recognition receptor Dectin-1: from fungi to mycobacteria. *Current drug targets* 2008;9:123-9.
- [167] Monge RA, Roman E, Nombela C, Pla J. The MAP kinase signal transduction network in *Candida albicans*. *Microbiology (Reading, England)* 2006;152:905-12.
- [168] Klippel N. Interaction of human pathogen yeast *C. albicans* and phagocytes.
- [169] Kruppa M, Goins T, Cutler JE, Lowman D, Williams D, Chauhan N, et al. The role of the *Candida albicans* histidine kinase (CHK1) gene in the regulation of cell wall mannan and glucan biosynthesis. *FEMS Yeast Res* 2003;3:289-99.
- [170] Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. *PLoS Pathog* 2006;2:e35.
- [171] Roman E, Arana DM, Nombela C, Alonso-Monge R, Pla J. MAP kinase pathways as regulators of fungal virulence. *Trends in microbiology* 2007;15:181-90.
- [172] Buckley AR, Buckley DJ, Gout PW, Liang H, Rao YP, Blake MJ. Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. *Molecular and cellular endocrinology* 1993;98:17-25.
- [173] Peterson G, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. *Cell Growth Differ* 1996;7:1345-51.
- [174] Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. *The Prostate* 1993;22:335-45.
- [175] Constantinou A, Kiguchi K, Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. *Cancer research* 1990;50:2618-24.
- [176] Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. *Eur J Cancer* 1994;30A:1675-82.
- [177] Mukherjee S, Acharya BR, Bhattacharyya B, Chakrabarti G. Genistein arrests cell cycle progression of A549 cells at the G(2)/M phase and depolymerizes interphase microtubules through binding to a unique site of tubulin. *Biochemistry* 1994;33:1702-12.
- [178] Hasumuma R, Kawaguchi K, Kikuchi S, Sugiyama T, Kumazawa Y. Effects of isoflavones and soybeans fermented with *Bacillus subtilis* on

lipopolysaccharide-induced production of tumor necrosis factor- $\alpha$  and fibrinolysis in vivo. Immunopharmacology and immunotoxicology 2007;29:323-33.

[179] Lee YW, Lee WH. Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells. The Journal of nutritional biochemistry 2008;19:819-25.

[180] Schoenborn JR, Wilson CB. Regulation of interferon- $\gamma$  during innate and adaptive immune responses. Advances in immunology 2007;96:41-101.

[181] Blanchette J, Pouliot P, Olivier M. Role of protein tyrosine phosphatases in the regulation of interferon- $\gamma$ -induced macrophage nitric oxide generation: implication of ERK pathway and AP-1 activation. Journal of leukocyte biology 2007;81:835-44.

[182] Chu AJ, Wang ZG, Walton MA, Seto A. Involvement of MAPK activation in bacterial endotoxin-inducible tissue factor upregulation in human monocytic THP-1 cells. The Journal of surgical research 2001;101:85-90.

[183] Hooshmand S, Soung do Y, Lucas EA, Madihally SV, Levenson CW, Arjmandi BH. Genistein reduces the production of proinflammatory molecules in human chondrocytes. The Journal of nutritional biochemistry 2007;18:609-14.

[184] Dabaghi-Barbosa P, Mariante Rocha A, Franco da Cruz Lima A, Heleno de Oliveira B, Benigna Martinelli de Oliveira M, Gunilla Skare Carnieri E, et al. Hispidulin: antioxidant properties and effect on mitochondrial energy metabolism. Free radical research 2005;39:1305-15.

[185] Hirota A, Taki S, Kawaii S, Yano M, Abe N. 1,1-Diphenyl-2-picrylhydrazyl radical-scavenging compounds from soybean miso and antiproliferative activity of isoflavones from soybean miso toward the cancer cell lines. Bioscience, biotechnology, and biochemistry 2000;64:1038-40.

[186] Salvi M, Brunati AM, Clari G, Toninello A. Interaction of genistein with the mitochondrial electron transport chain results in opening of the membrane transition pore. Biochimica et biophysica acta 2002;1556:187-96.

[187] Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP. Effects of resveratrol on the rat brain respiratory chain. Drugs under experimental and clinical research 1999;25:87-97.

[188] Herrerias T, de Oliveira BH, Gomes MA, de Oliveira MB, Carnieri EG, Cadena SM, et al. Eupafolin: Effect on mitochondrial energetic metabolism. Bioorganic & medicinal chemistry 2008;16:854-61.

[189] Minagawa N, Koga S, Nakano M, Sakajo S, Yoshimoto A. Possible involvement of superoxide anion in the induction of cyanide-resistant respiration in *Hansenula anomala*. FEBS letters 1992;302:217-9.

[190] Wagner AM. A role for active oxygen species as second messengers in the induction of alternative oxidase gene expression in *Petunia hybrida* cells. FEBS letters 1995;368:339-42.

[191] Matsuno-Yagi A, Yagi T. Introduction: complex I--an L-shaped black box. Journal of bioenergetics and biomembranes 2001;33:155-7.

- [192] Fato R, Bergamini C, Bortolus M, Maniero AL, Leoni S, Ohnishi T, et al. Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species. *Biochimica et biophysica acta* 2009;1787:384-92.
- [193] Ohnishi T. Iron-sulfur clusters/semiquinones in complex I. *Biochimica et biophysica acta* 1998;1364:186-206.
- [194] Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. *Free radical biology & medicine* 1997;22:749-60.
- [195] Fang N, Casida JE. Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. *Proceedings of the National Academy of Sciences of the United States of America* 1998;95:3380-4.
- [196] Hutchinson MJ, Harrison PT, Floto RA, Allen JM. Fc gamma receptor-mediated phagocytosis requires tyrosine kinase activity and is ligand independent. *European journal of immunology* 1995;25:481-7.
- [197] Sulahian TH, Imrich A, Deloid G, Winkler AR, Kobzik L. Signaling pathways required for macrophage scavenger receptor-mediated phagocytosis: analysis by scanning cytometry. *Respiratory research* 2008;9:59.
- [198] Kusner DJ, Hall CF, Schlesinger LS. Activation of phospholipase D is tightly coupled to the phagocytosis of *Mycobacterium tuberculosis* or opsonized zymosan by human macrophages. *The Journal of experimental medicine* 1996;184:585-95.
- [199] Lloret S, Moreno JJ. Role of kinases and G-proteins on arachidonate release induced by zymosan in mouse peritoneal macrophages. *The international journal of biochemistry & cell biology* 1996;28:465-72.
- [200] Okazaki M, Chiba N, Adachi Y, Ohno N, Yadomae T. Signal transduction pathway on beta-glucans-triggered hydrogen peroxide production by murine peritoneal macrophages in vitro. *Biological & pharmaceutical bulletin* 1996;19:18-23.
- [201] Tanimura M, Kobuchi H, Utsumi T, Yoshioka T, Kataoka S, Fujita Y, et al. Neutrophil priming by granulocyte colony stimulating factor and its modulation by protein kinase inhibitors. *Biochemical pharmacology* 1992;44:1045-52.
- [202] Della Bianca V, Grzeskowiak M, Dusi S, Rossi F. Transmembrane signaling pathways involved in phagocytosis and associated activation of NADPH oxidase mediated by Fc gamma Rs in human neutrophils. *Journal of leukocyte biology* 1993;53:427-38.
- [203] Kobayashi K, Takahashi K, Nagasawa S. The role of tyrosine phosphorylation and  $Ca^{2+}$  accumulation in Fc gamma-receptor-mediated phagocytosis of human neutrophils. *Journal of biochemistry* 1995;117:1156-61.
- [204] Zalavary S, Grenegard M, Stendahl O, Bengtsson T. Platelets enhance Fc(gamma) receptor-mediated phagocytosis and respiratory burst in neutrophils: the role of purinergic modulation and actin polymerization. *Journal of leukocyte biology* 1996;60:58-68.
- [205] Yamaguchi S, Miyazaki Y, Oka S, Yano I. Stimulatory effect of

gangliosides on phagocytosis, phagosome-lysosome fusion, and intracellular signal transduction system by human polymorphonuclear leukocytes. *Glycoconjugate journal* 1997;14:707-14.

[206] Kogut MH, Genovese KJ, Lowry VK. Differential activation of signal transduction pathways mediating phagocytosis, oxidative burst, and degranulation by chicken heterophils in response to stimulation with opsonized *Salmonella enteritidis*. *Inflammation* 2001;25:7-15.

[207] Coxon PY, Summersgill JT, Ramirez JA, Miller RD. Signal transduction during *Legionella pneumophila* entry into human monocytes. *Infection and immunity* 1998;66:2905-13.

[208] Alsam S, Sissons J, Dudley R, Khan NA. Mechanisms associated with *Acanthamoeba castellanii* (T4) phagocytosis. *Parasitology research* 2005;96:402-9.

[209] Mead J, McNair N. Antiparasitic activity of flavonoids and isoflavones against *Cryptosporidium parvum* and *Encephalitozoon intestinalis*. *FEMS microbiology letters* 2006;259:153-7.

[210] Cui S, Jiang J, Ai H, Li J, Biltewski U, Niu J. Effect of genistein on the proliferation, morphology and cell cycle of Macrophage RAW264.7 *Beijing Journal of Traditional Chinese Medicine* 2010;39:40-3.

[211] Castellano F, Chavrier P, Caron E. Actin dynamics during phagocytosis. *Seminars in immunology* 2001;13:347-55.

[212] Murray RZ, Kay JG, Sangermani DG, Stow JL. A role for the phagosome in cytokine secretion. *Science (New York, NY)* 2005;310:1492-5.

[213] Hazen KC. Participation of yeast cell surface hydrophobicity in adherence of *Candida albicans* to human epithelial cells. *Infection and immunity* 1989;57:1894-900.

[214] Galan-Diez M, Arana DM, Serrano-Gomez D, Kremer L, Casasnovas JM, Ortega M, et al. *Candida albicans* {beta}-glucan exposure is controlled by the fungal CEK1-mediated MAPK pathway modulating immune responses triggered through Dectin-1. *Infection and immunity* 2010.

[215] Coleman JJ, Okoli I, Tegos GP, Holson EB, Wagner FF, Hamblin MR, et al. Characterization of plant-derived saponin natural products against *Candida albicans*. *ACS chemical biology* 5:321-32.

# 7 APPENDIX

Description of the genes included in the TLR pathway cluster

| Gene Symbol | Gene name  | Aliases                                    | Gene bank | Gene function                         | Average Ct |       |       |       |
|-------------|--|--|-----------|---------------------------------------|------------|-------|-------|-------|
|             |  |  |           |                                       | 1          | 2     | 3     | 4     |
| CCL2        | Chemokine (c-c motif) ligand 2   | MCP1,monocyte chemoattractant protein-1    | NM-011333 | C-C chemokine activity                | 25.9       | 21.04 | 20.75 | 24.93 |
| Ly96        | Lymphocyte antigen 96  | ESOP-1, MD-2, MD2, MGC151162               | NM-016923 | Adaptor protein                       | 28.74      | 28.31 | 24.98 | 27.7  |
| Ly86        | Lymphocyte antigen 86  | MD-1                                       | NM-010745 | Adaptor protein                       | 24.67      | 23.28 | 23.95 | 21.4  |
| Irak2       | Interleukin-1 receptor-associated kinase 2   | 6330415L08Rik, AI649099, IRAK-2, MGC102586 | NM-172161 | Adaptor protein                       | 26.28      | 25.62 | 22.97 | 26.87 |
| Nfkbib      | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta | IKB-beta, IKappaBbeta, Ikb, IkbB, MGC36057 | NM-010908 | Inhibitor of NF-κB                    | 33.05      | 32.56 | 28.45 | 32.69 |
| Rel         | Reticuloendotheliosis oncogene   | c-Rel                                      | NM-009044 | Transcription factor                  | 27.11      | 25    | 22.72 | 25.76 |
| Hmgb1       | high-mobility group box 1  |  | NM_002128 | Adaptor protein                       | 26.1       | 26.01 | 25.5  | 24.34 |
| TLR2        | Toll-like receptor 2   |  | NM-011905 | Receptor                              | 24.54      | 24.46 | 22.2  | 24.91 |
| TLR9        | Toll-like receptor 9   |  | NM-031178 | Receptor                              | 33.32      | 33.69 | 29.54 | 29.9  |
| fos         | FBJosteosarcoma oncogene   | c-fos                                      | NM-010234 | Transcription factor                  | 22.77      | 24.84 | 22.7  | 20.72 |
| CD80        | CD80 antigen   | Cd281,Ly-53                                | NM-009855 | TLR signalling                        | 28.3       | 29.05 | 28.01 | 30.6  |
| CD86        | Cluster of Differentiation 86  | CD28 antigen ligand                        | NM-006889 | TLR signalling                        | 35         | 32.19 | 32.73 | 34.98 |
| Rela        | V-rel reticuloendotheliosis viral oncogene homolog A (avian)                       | p65  | NM-009045 | Transcription factor                  | 23.97      | 25.57 | 23.01 | 25.31 |
| MEKK1       | Mitogen activated protein kinase kinase kinase 1                                   | MAPKKK1,Mekk,M FKK1                        | NM-011945 | Protein-kinase,Ser/Thr (non-receptor) | 29.65      | 30.71 | 28.26 | 27.52 |
| Ticam2      | Toll-like receptor adaptor molecule 1  | TICAM-1, TRIF                              | NM-174989 | Adaptor protein                       | 29.12      | 28.27 | 26.31 | 28.74 |
| Csf2        | Colony stimulating factor 2(granulocyte-macrophage)                                | GM-CSF                                     | NM-009969 | Secreted proteins-hematopoietins      | 35         | 27.39 | 32.08 | 35    |
| Csf3        | Colony stimulating factor 3 (granulocyte)  | G-CSF                                      | NM-009971 | Secreted proteins-cell proliferation  | 35         | 21.92 | 23.11 | 35    |
| Cxcl10      | Chemokine (C-X-C motif) ligand 10  | C7, CRG-2, INP10, IP-10, IP10, Ifi10,      | NM-021274 | C-C chemokine activity                | 32.25      | 25.28 | 24.95 | 29.01 |

|         |   |   |           |   |       |       |       |       |
|---------|---|---|-----------|---|-------|-------|-------|-------|
|         |   | Scyb10, gIP-10,<br>mob-1  |           |   |       |       |       |       |
| Ifnb1   | Interferon beta 1, fibroblast   | IFN-beta, IFNB, Ifb   | NM-010510 | Cytokine-inflammatory<br>response           | 35    | 30.17 | 30.17 | 35    |
| IL10    | Interleukin 10  | IL-10,cytokine<br>synthesis inhibitory<br>factor                    | NM-010548 | Cytokine-inflammatory<br>response           | 31.58 | 23.85 | 25.66 | 28.6  |
| IL1a    | Interleukin 1 alpha   | IL-1 $\alpha$   | NM-010554 | Cytokine-inflammatory<br>response           | 33.6  | 23.23 | 26.35 | 35    |
| IL1b    | Interleukin 1 beta  | IL-1 $\beta$  | NM-008361 | Cytokine-inflammatory<br>response           | 35    | 21.86 | 22.52 | 31.71 |
| IL6     | Interleukin 6   | IL-6  | NM-031168 | Cytokine-inflammatory<br>response           | 35    | 30.15 | 31.73 | 35    |
| Nfkb1   | Nuclear factor of kappa light<br>chain gene enhancer in B-cells<br>1, p105          | NF-kappaB1, p50<br>subunit of NF-<br>kappaB, p50/105                | NM-008689 | Transcription regulator                     | 26.2  | 22.63 | 23.23 | 24.83 |
| tnfaip3 | Tumor necrosis factor, alpha-<br>induced protein 3                                  | Zinc finger protein<br>A20  | NM-009397 | Ubiquitin-editing enzyme                    | 27.84 | 25.99 | 25.14 | 28.03 |
| nfkbia  | Nuclear factor of kappa light<br>chain gene enhancer in B-cells<br>inhibitor, alpha | I(Kappa)B(alpha)  | NM-010907 | Inhibitor of NF- $\kappa$ B                 | 26.76 | 26.36 | 25    | 25.92 |
| pel1    | Pellino 1   | --  | NM-023324 | Adaptor protein                             | 26.88 | 24.96 | 23.96 | 26.73 |
| ptgs2   | Prostaglandin-endoperoxide<br>synthase 2  | COX2,cyclooxygena<br>se 2   | NM-011198 | Prostaglandin and leukotriene<br>metabolism | 28.18 | 21.77 | 22    | 26.58 |
| TLR3    | Toll-like receptor 3  |   | NM-126166 | Receptor                                    | 28.88 | 26.48 | 26.2  | 28.68 |
| TLR7    | Toll-like receptor 7  |   | NM-133211 | Receptor                                    | 26.56 | 25.19 | 25.41 | 24.69 |
| TLR8    | Toll-like receptor 8  |   | NM-133212 | Receptor                                    | 30    | 29.28 | 30.52 | 30.96 |
| TNF     | Tumor necrosis factor   | DIF, MGC151434,<br>TNF-alpha, TNFSF2,<br>TNFalpha, Tnfa,<br>Tnfsf1a | NM-013693 | Cytokine-inflammatory<br>response           | 25.61 | 23.1  | 21.57 | 24.48 |

**Note: 1: Genistein- treated (50 $\mu$ M) macrophages RAW 264.7; 2: LPS -treated (100 ng/ml) macrophages RAW 264.7; 3: LPS+ Genistein treated macrophages RAW 264.7; 4 : control**